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Malignant catarrhal fever is a fatal lymphoproliferative disease of domestic and wild
ruminants. The disease is characterised by lymphocyte migration and proliferation with
degeneration of various tissues. This is thought to be responsible for the death of the
affected animal. There are two viral causal agents of the disease, Alcelaphine
herpesvirus-l (A1HV-1) and Ovine herpesvirus-2 (OvHV-2). A1HV-1 is found naturally
in Blue Wildebeest while OvHV-2 is found in sheep. Both cause no apparent disease in
the carrier species, however, when they infect a susceptible species, animals develop the
disease which is usually fatal. The virulent strain of A1HV-1 has been sequenced and
was found to encode eleven putative pathogenesis-associated herpesvirus genes. One of
these is contained within open reading frame A9. This encodes a protein that shares a
limited amino acid homology to the bcl-2 family of apoptosis regulatory proteins.
Apoptosis is a major form of cell death and is characterised by a series ofmorphological
and biochemical changes that take place in the cell. A number of bcl-2 family members
have been identified, that can be either anti- or pro-apoptotic. The proteins all possess at
least one bcl homology (BH) domain that determines the capacity of the bcl-2 proteins
to form homo- or hetero-dimers and/or to bind to proteins not in the bcl-2 family. ORF
A9 possesses only one of the BH domains, BH1, which in other proteins has anti-
apoptotic activity. The overall aim of this study was to characterise A1HV-1 A9. The
specific aims were to determine: if the A9 gene product is functional; when in the viral
life cycle A9 is expressed; where in the cell the protein is localised; whether any cellular
or viral binding partners can be defined; is the A9 gene expressed in large granular
lymphocyte (LGL) T cell lines? Northern blot analyses showed that A9 mRNA was
expressed as an early gene in the productive phase of the virus life cycle. The A9 gene
product was also shown to protect CHO cells from cis-platin induced apoptosis. The
protein encoded by the A9 gene was successfully expressed in E. coli and was used to
immunise mice and rabbits. Antibodies specific for the A9 protein were generated.
However, using these antibodies, the localisation ofA9 in CHO cells was inconclusive.
A9 mRNA was expressed in LGL T cells from MCF-affected rabbits. To determine
binding partners, an expression system involving a tandem affinity purification (TAP)
technique was used. Various cDNAs related to the bcl-2 family of proteins were
successfully transfected into CHO cells as shown by RT-PCR and immunofluorescence
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analysis. However, MADLI analysis of samples failed to identify specific binding
partners for A9. A9 vbcl-2 is anti-apoptotic and may function to allow viral replication
in infected cells in the productive phase of the life cycle.
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Malignant catarrhal fever (MCF) is an often fatal disease of domestic and wild
ruminants, which occurs worldwide (Plowright, 1960; Castro & Daley, 1982; Handley et
al., 1995). The disease is usually acute and is characterised by lymphocyte migration
and proliferation resulting in the degeneration of various tissues which is thought to be
responsible for the demise of affected animals (Reid & Buxton, 1989). MCF is caused
by either of two gammaherpesviruses Alcelaphine herpesvirus-l (A1FIV-1) or Ovine
herpesvirus-2 (OvFIV-2) although others have been implicated. A1FIV-1 MCF is
restricted to Africa and zoological collections, whereas OvHV-2 MCF is seen
worldwide. The current hypothesis is that the disease is caused by lymphocytes
dysregulated by virus infection that exhibit constitutive non MHC-restricted cytotoxic
activity and that destroy multiple tissues in vivo (Aiello, 1998; Swa et al., 2001).
1.2. Herpesviruses
The interaction between herpesviruses and their mammalian hosts has been
studied in detail (Roizman, 1990). Herpesviruses can infect the host with mild or no
apparent symptoms, however, they can also cause fatally incurable diseases. To date
there have been over one hundred different herpesvirus species identified. They all
share common biological features:
• They express enzymes and other factors that are involved in nucleic acid
metabolism (e.g. thymidylate kinase, thymidylate synthetase and dUTPase) as
well as a variable number of enzymes that are involved in nucleic acid synthesis
(e.g. DNA polymerase, helicase) and protein processing (e.g. protein kinases).
• The synthesis of viral DNA and capsids occurs in the nucleus. Herpesvirus
DNA circularises immediately upon the release from capsids into the nuclei of
infected cells.
• The production of infectious progeny virus is accompanied by the irreversible
destruction of the infected cell.
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• Herpesviruses have the ability to establish and remain in a latent phase in the
natural host. In cells harbouring latent virus the viral genome takes the form of
closed circular molecules, and only a small subset of viral genes are expressed
(Roizman et al., 1992).
A typical herpesvirion consists of a core containing linear double stranded DNA,
an icosohedral capsid of 100-1 lOnm in diameter and the tegument, which is surrounded
by a membrane envelope. Viral glycoproteins protrude from the envelope. The total
size of the herpesvirus particle varies between 120-300nm. This variation is thought to
be due to the variability in the thickness of the tegument. The double stranded DNA
genomes range from 120-230kb and with G+C DNA contents varying from 32-75%
(Roizman, 1990).
Herpesviruses are classified into families or subfamilies based on their natural
host (Roizman & Baines, 1991). The herpesvirus family Herpesviridae has been further
classified into three subfamilies Alphaherpesvirincie, Betaherpesvirinae and
Gammaherpesvirinae on the basis of the following biological properties.
Alphaherpesviruses have a variable host range, short reproductive cycle (i.e.
approximately 12-24 hours) and the ability to spread rapidly in culture. These viruses
establish a latent infection in neuronal cells (sensory ganglia). This subfamily contains
the genera Simplexvirus (e.g. Human simplex virus-1 (HSV-1) and bovine mamillitis
(BHV-2)) and Varicellovirus (e.g. Varicella zoster virus (VZV or HHV-3) and equine
herpesvirus 1 (EHV-1)).
Betaherpesviruses have a restricted host range, relatively long reproductive cycle
(i.e. 3-6 days) and spread slowly in culture. Infected cells frequently become enlarged,
forming cytomegalia. A latent infection can be maintained in lymphoreticular cells,
i
secretory glands, kidneys and other tissues. This subfamily contains the genera
Cytomegalovirus (e.g. human cytomegalovirus (HCMV or HHV-5)) and
Muromegalovirus (e.g. murine cytomegalovirus) and Roseolovirus (e.g. human
herpesvirus-6 (HHV-6) and human herpesvirus-7 (HHV-7)).
3
Gammaherpesviruses have a narrow host range. In vitro replication occurs in
lymphoblastoid cells as well as some types of epithelial and fibroblastic cells. The
viruses show specificity for either T or B-lymphocytes and have the ability to establish a
latent infection in lymphoid tissue. This family contain two genera Lymphocryptovirus
(e.g. Epstein-Barr virus (EBV)) and Rhadinovirus (e.g. herpesvirus saimiri (HVS))
(Roizman, 1990). Viruses belonging to the subfamilies of herpesviruses are summarised
in Table 1.1.
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Virus Natural reservoir Disease
Alphaherpesviruses
Herpes simplex vims 1 Human
(HSV-1)
Herpes simplex vims 2 Human
(HSV-2)





























































Malignant catarrhal fever in
cattle
Malignant catarrhal fever in
cattle
Table 1.1 Examples of herpesviruses in different subfamilies
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1.2.1. Replication of Herpesviruses
HSV-1 replication has been studied in detail (Roizman, 2001). Infection is
initiated when the virus attaches to the cell surface. It has been shown that the most
important viral proteins that are involved in this attachment are the envelope
glycoproteins gB and gC, these bind to cell surface glycosaminoglycans, preferentially
heparan sulphate (reviewed in Rajcani & Vojvodva, 1998). The fusion of the viral and
cellular membranes is triggered by the interaction of a third glycoprotein, gD with one of
several cellular co-receptors. These co-receptors include members of the tumour
necrosis factor receptor family, members of the immunoglobulin superfamily nectins (a
family of cell adhesion molecules) and 3-O-sulphated heparin sulphates (reviewed in
Spear et al., 2000). Fusion of the viral envelope with the host cell membrane requires
gB, gD and a gH-gL heterodimer. It has been demonstrated that gB, gD, gH, and gL and
the presence of one or more cellular gD receptors are indispensable for mediating fusion
(Turner et al., 1998). Fusion of the envelope with the plasma membrane results in the
capsid being transported to the nuclear pores to release the DNA into the nucleus.
Transcription and replication of the viral DNA and assembly of the new capsids occurs
in the nucleus. Viral DNA is transcribed by host RNA polymerase and mRNA is
translated in the cytoplasm (Roizman & Sears, 1990). Gene expression in the lytic
phase occurs in a chronological order that can be grouped into three categories;
immediate early, early and late.
Immediate early transcription of HSV-1 is activated by a virion protein, VP16,
which acts through the target sequence TAATGARAT (Sturm et al., 1988). The target
sequence is a binding site for the cellular octamer DNA-binding protein, Oct-1. VP 16
and host cell factor (HCF) bind to the Oct-1/TAATGARAT complex bringing it into
proximity with the preinitiation complex. The immediate early proteins transactivate
early gene expression and are required for the synthesis of all other viral-encoded
proteins (Roizman & Sears, 1990). The early proteins include enzymes that are required
for the replication of the viral genome: a DNA polymerase, a single stranded DNA
binding protein, a primosome (complex of proteins that are involved in DNA synthesis),
an origin-binding protein and a set of enzymes that are involved in DNA repair. The late
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genes are expressed finally and these encode the structural proteins of the virus (Lehman
& Bochmcr, 1999).
When the viral DNA enters the nucleus it adopts an "endless"' configuration,
which is consistent with circularisation. The origin of replication can be oris, of which
there are two copies in the "c' sequences (Irs, Trs) of the genome, or ohl of which there
is one copy in the Ul region of the genome (fig. 1.1). It has been suggested that HSV-1
DNA replication initiates by a theta mechanism, named after the appearance of the DNA
resembling the Greek letter 0. Studies have shown that at some stage theta replication
changes to the rolling circle mode, which is the principal mode of replication. In the
rolling circle mode, DNA replication produces long head to tail concatamers (Lehman &
Boehmer, 1999).
Recent studies of HSV genome configuration during early infection suggest this
model may need to be revised. A study carried out by Jackson and DeLuca (2003) failed
to observe circular genomes in wild type HSV-infected cells before the onset of DNA
synthesis, which would suggest that circular genomes may not be the initial replication
template. They also demonstrated that ICPO inhibited the formation of circular
genomes.
Fig 1.1. Schematic diagram of sequence arrangement of HSV-1. One
terminus contains N repeats of sequence A next to a longer sequence B. The
other terminus has one directly repeated sequence A next to a sequence C.
The terminal sequences are inserted in an inverted form internally (B' A'N, C').
Both the long and short regions can invert, forming four isomers.
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1.2.2. Latency in HSV
All herpesviruses are able to establish a latent infection. Latency is defined as a
persistent infection where the virus genome is present without the perseverance of
infectious virus particles (or viral antigens) (Engels & Ackermann, 1996). HSV has the
ability to remain in a latent phase in the human host for its lifetime. The vims remains
latent in the sensory nerves innervating the cells infected at the portal of entry, thus
avoiding the host immune response. During the latent stage of the virus life cycle the
viral DNA is in a circular episomal form and there is limited virus gene expression
(Roizman & Sears, 1990). In latently infected neurons, all of the lytic genes are
switched offwith only the latency-associated transcripts (LATs) detected. There are two
major products from these LATs, a 2kb and a 1.5kb RNA (Preston, 2000). LATs are
abundant in infected nuclei of the neurons in the host. The number of viral genomes per
latently-infected neuron ranges from 10 to 100 (Wagner & Bloom, 1997). Studies have
demonstrated that LATs are not essential in the establishment or maintenance of latency
or for vims reactivation from latency (Javier et al., 1988; Block et al., 1993; Pemg et al.,
1994). There are two proposed models describing the functions of LATs. The first is
that if present in the nucleus, LATs may inhibit translation of the immediate early gene
ICP0, which results in the reduction of lytic gene expression and reduces vims
replication and facilitates the establishment of latency (Mador et al., 1998). The second
proposes if LATs are in the cytoplasm they may be translated and this results in the
stimulation of replication to promote reactivation (Millhouse & Wigdahl, 2000).
LATs have also been shown to have an anti-apoptotic function. Pemg and co¬
workers (1999) were first to observe this and showed that there was an increase in
neurovirulence in LAT-mutated virus in rabbits. Since then, numerous studies have
identified a possible role of LATs in apoptosis (Pemg et al., 2000; Inman et al., 2001;
Kent et al., 2003). Fragments of the LAT region were tested for the ability to inhibit
apoptosis using an expression plasmid containing 2358bp of the LAT region. It was
shown that the region that was being expressed protected the cells from apoptosis
induced by various apoptotic agents and by the expression of Bax, a pro-apoptotic
protein (Pemg et al., 2000; Inman et al., 2001).
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1.3. Gammaherpesviruses
1.3.1. Epstein-Barr virus (EBV)
EBV was discovered by Epstein, Achong and Barr in 1964 (Epstein et al., 1964).
It is a human gammaherpesvirus that is present in more than 90% of the adult population
worldwide. The virus is a member of the genus Lymphocryptovirus and is present as a
life-long persistent infection in B-lymphocytes. EBV is associated with several diseases
such as infectious mononucleosis, X-linked lymphoproliferative syndrome, Burkitt's
lymphoma and Hodgkin's disease.
The EBV genome is 172Kb in length with a G+C DNA content of 60%. EBV
was the first herpesvirus to be completely cloned and sequenced (Bankier et al., 1983).
The viral genome encodes 100 viral proteins that play roles in viral replication, forming
structural components of the virion and modulating the host immune response. Two
types of EBV have been identified in the human population: type 1 and type 2. The
main differences between the two types can be found in the sequences of EBV nuclear
antigen-2 (EBNA-2), EBNA-3A, EBNA-3B and EBNA-3C (Sample et al., 1990). The
viral genome is co-linear with other herpesviruses such as VZV, HSV and
cytomegalovirus (CMV) (Kieff& Liebowitz, 1990). As with other
gammaherpesviruses, EBV possesses homologues to cellular proteins such as the two
Bcl-2 homologues encoded by BHRF1 and BALF1. EBV also possesses a homologue
of human IL-10, BCRF1, amongst other cytokine genes (Moore et al., 1990). Cellular
IL-10 has anti-inflammatory activities mediated by inhibition ofmacrophage and
monocyte synthesis ofpro-inflammatory cytokines such as IL-6 and IL-12 (Fiorentino et
al., 1991).
1.3.2. EBV lytic replication
The virus infects humans at the oropharyngeal epithelium, which is permissive
for virus replication (reviewed in Kieff& Liebowitz, 1990). EBV infects B cells but
does not replicate, establishing instead a latent infection. The major envelope
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glycoprotein, gp350, binds to the viral receptor CD21 on the surface of the B cell to
initiate viral entry (Fingeroth et al., 1984).
The lytic cycle can be induced in vitro by the addition of 12-O-tetradecanoyl
phorbol-13-acetate (TPA) or other methylation blockers. Following induction of the
lytic cycle, the cells exhibit morphological and biochemical changes. These changes
result from cytopathology, synthesis of viral DNA in the nucleus, assembly of
nucleocapsids, nucleation of the nucleocapsids and the envelopment of the virus, which
results in the budding of the vims through the inner nuclear membrane. Vims gene
expression occurs as with other herpesviruses in chronological order that can be
characterised into three phases; immediate early, early and late.
The immediate early genes products are BZLF1 or Z-transactivator (Zta) and
BRFL1 or replication and transcription activator (Rta). Both are key immediate-early
transactivators of early EBV lytic gene expression. The expression of these genes leads
to the activation of early genes (Takada & Ono, 1989). There are 30 early genes
expressed in the lytic phase of the EBV life cycle. Two early EBV genes, BSMF1 and
BMRF1, transactivate other early proteins (Cho et al., 1985). Many of the other early
genes that are expressed are involved in DNA replication, such as DNA polymerase
(BALF5), DNA-binding protein (BALF2), ribonucleotide reductase (BORF2) and
thymidine kinase (BXFL1) (Kieff & Liebowitz, 1990). Other early genes that are
expressed by EBV include BALF1 and BHRF1. These gene products are both involved
in apoptosis. The BHRF1 product has been shown to prevent apoptosis during the lytic
cycle (Henderson et al., 1993), whilst the BALF1 product has been shown to be an
antagonist to BHRF1. BALF1 acts by negatively regulating the anti-apoptotic activity
ofBHRF1 (Bellows et al., 2002).
Many of the late genes that are expressed encode stmctural proteins or proteins
that allow virus replication and establishment. Some of the viral glycoproteins are
expressed early in the lytic cycle and have a role in antibody-mediated immunity to viral
infection. Examples of viral glycoproteins that are expressed are BLLF1 (gp350/220),
BALF4 (gpl 10) and BXLF2 (gp85). Gpl 10 is an abundantly expressed late EBV
protein, that is present in the cell nucleus and in the endoplasmic reticulum, but it is not
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a major structural protein (Gong & Kieff, 1990). Gp85 and gp350/220 are found on the
virus and in the plasma membrane of lytically-infected cells (Gong & Kieff, 1990).
Gp85 is important in the fusion between the vims and the cell membrane, whereas
gp350/220 mediates viral binding to the CD21 B-cell receptor (Miller & Hutt-Fletcher,
1988).
1.3.3. EBV latency
As previously stated, EBV persists in B-lymphocytes in the latent state. The
vims alters the cell growth cycle so that the cell constantly proliferates. This results in
rapid and efficient cell growth and maintenance of the vims. The vims induces
immunoglobulin secretion, the expression of B-cell activation markers, DNA synthesis
and cell division. Four transcriptional forms of latency have been identified in EBV
(Cohen, 2000). These are known as latency I, II, III and IV. Latency I was first
identified in Burkitt's lymphoma cells and latency II is found in nasopharyngeal
carcinomas (Young et al., 1988). In latency I, only EBNA-1 and Epstein Barr encoded
small RNA (EBERs) are expressed. In latency II, EBERs, EBNA-I, latent membrane
protein-1 (LMP-1) and LMP-2 are expressed. During latency III, two non
polyadenylated RNAs (EBER-1 and EBER-2), six nuclear proteins (EBNA-1, 2, 3A, 3B,
3C and LP) and finally three latent membrane proteins (LMP-1, 2A and 2B) are
expressed. A fourth latency stage has been identified in the peripheral blood of healthy
individuals that had previously been infected with EBV. It was shown that only EBER
was present in all of the individuals tested and in several (but not all those tested) LMP-
2 and EBNA-1 was also detected (Tiemey et al., 1994).
EBNA-1 is the only protein that has been identified in all types of latency and
therefore is believed to have a critical role in maintaining latency. EBNA-1 binds the
EBV plasmid origin of latent DNA replication, oriP, to allow the EBV genome to persist
as a circular DNA episome (Yates et al., 1984). EBNA-2 is essential for B-lymphocyte
growth transformation and transactivates the expression ofEBNA1, EBNA3s and LMPs
(Abbot et al., 1990; Robertson et al., 1995). EBNA-2 up-regulates the expression of
LMP-1 and LMP-2 and other proteins that are involved in the growth and transformation
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of B cells (Johannsen et al., 1995). The EBNA 3 proteins also regulate the expression of
cellular genes. However, it has been shown that EBNA 3B is not essential for
lymphocyte infection in vitro (Wang et al., 1990). EBNA-LP has been shown to
enhance the ability ofEBNA-2 to up-regulate LMP-1 (Yokoyama et al., 2001).
LMP-1 localises in the plasma membrane of infected cells (Mann et al., 1985)
and binds several of the tumour necrosis factor receptor-associated factors. This results
in the activation of nuclear factor-xB (NF-kB) transcription factor, activation of c-jun,
up-regulation of cellular adhesion molecules, cytokine production and B-cell
proliferation. This protein is essential for B lymphocyte growth transformation by EBV
(Kaye et al., 1993). LMP-2 prevents the reactivation ofEBV from latently-infected
cells by blocking tyrosine kinase phosphorlyation (Miller et al., 1995). EBER (EBV
encoded small RNAs) do not encode proteins. It is thought that these RNAs play a role
in oncogenesis and the prevention of apoptosis (Komano et al., 1999).
1.3.4. Murine gammaherpesvirus 68 (MHV-68)
MHV-68 was first isolated from the bank vole (Clethrionomys glariolus) in
Slovakia (Blaskovic et al., 1980). The MHV-68 genome has been sequenced (Virgin et
al., 1997) and is co-linear with those ofHVS and KSHV. The genome contains
118,237bp of unique sequence flanked by multiple copies of a 1,213bp terminal repeat.
The unique region of the genome has a G+C content of 46% while the terminal repeat
sequence has a high G+C content of 78%. The MHV-68 genome is predicted to encode
80 gene products with at least 63 being co-linear with homologous genes in HVS and
KSHV. As with other gammaherpesviruses, MHV-68 encodes conserved herpesvirus
ORFs (Ml to M14). An example of this is ORF Ml. This shows sequence homology to
the poxvirus SPI-1 serpin family of proteins. The poxvirus SPI-1 protein regulates host
cell range by altering apoptosis, regulating inflammatory responses and altering
arachidonate metabolism (Brooks et al., 1995; Palumbo et al., 1997). MHV-68 encodes
cellular homologues that are involved in apoptosis regulation, cytokine signalling and
immune regulation. For example, MHV-68 encodes a cyclin homologue that shows
similarities to ORF72 (eclf2) in Herpesvirus saimiri (HVS). ORF72 has homology to
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cellular type D cyclins and is thought to associate and regulate cell proliferation (Jung et
al., 1994). An IL-8 receptor homologue is also present, which has a homologue in
KSHV that induces tumour formation and angiogenesis (Arvanitakis et al., 1997). ORF
Ml 1 shows homology with Bcl-2 and has been shown to protect cells against apoptosis
(Roy et al., 2000). ORF M3 was the first chemokine-binding protein to be identified in
MHV-68. The protein binds to chemokines of the CC, CXC, CX3C and C families and
prevents chemokine-induced signal transduction in vitro (Parry et al., 2000; van Berkel
et al., 2002).
The virus has the ability to establish a productive infection in fibroblast and
epithelial cells lines that have been derived from mammalian species including humans
(Svobodova et al., 1982). Mice that are infected intranasally with the virus, establish a
productive infection in alveolar epithelial cells and mononuclear cells of the lungs
causing interstitial pneumonia. The virus then spreads via the lymph nodes to the
spleen, where it establishes latency in germinal centre B cells (Sunil-Chandra et al.,
1992). Mice with an acute infection usually resolve this within 10-12 days but have a
life-long latent infection in lymphoid tissue. Latency in lymphoid tissue is characterised
by a transient phase of splenomegaly and lymph node enlargement, which peaks at
around 2-3 weeks post-inoculation. It is at this point that the maximum numbers of
splenocytes are latently-infected, the numbers of which subsequently decline (Nash &
Sunil-Chandra, 1994). One study demonstrated that over a period of three years, 9% of
the infected mice developed lymphoproliferative disease (LPD) and high-grade
lymphomas. This would suggest that long-term persistence in mice is associated with
the development of LPD and high-grade lymphomas (Sunil-Chandra et al., 1994).
The host response to MFIV-68 infection in the lungs is characterised by the
infiltration ofmonocytes/macrophages, which occurs during the first three days of
infection. However, by day five after infection the number of macrophages decreases
and the levels of T cells increase (Nash et al., 1994). It has been suggested that the large
number of CD8+ T cells that are found in the lungs have an anti-viral role (Ehtisham et
al., 1993). Deletion of CD8+ T cells before infection leads to uncontrolled virus
replication and death (Ehtisam et al., 1993). An antibody response to the virus develops
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slowly then rises considerably at two weeks after infection and remains high. However,
it has been shown that antibodies are not essential for the suppression of the acute
infection (Usherwood et al., 1996).
1.3.5. Kaposi's sarcoma-associated Herpesvirus (Human Herpesvirus-8)
Kaposi's sarcoma-associated Herpesvirus (KSHV) is a gammaherpesvirus that
belongs to the Rhadinovirus subfamily. The virus is associated with three neoplastic
disorders: Kaposi's sarcoma (KS), primary effusion lymphoma (PEL) and multicentric
Castleman's disease (MCD).
Early stage KS lesions are composed of small, irregular, endothelial-lined spaces
that surround normal blood vessels. They are accompanied by an infiltrate of
inflammatory cells. As the disease progresses, a spindle-celled vascular process expands
throughout the dermis and these spindle cells form slit-like, vascular channels which
contain red blood cells (Weninger et al., 1999). In early KS lesions, only 10% of
spindle and endothelial cells are KSHV positive. In late stage nodular lesions, around
90% of spindle cells contain KSHV suggesting that the virus provides a growth
advantage to infected cells (Boshoff et al., 1995).
Body cavity-based lymphoma or PEL (Cesarman et al., 1995) is normally found
as malignant effusions in the pleural, pericardial or peritoneal cavities without forming
significant tumour masses. The majority of PEL patients are HIV positive with
advanced immunosuppression. PEL is thought to originate from post-germinal centre B-
cells due to the presence of hypermutated immunoglobulin genes (Matolcsy et al.,
1998).
MCD is a lymphoproliferative disorder that is characterised by
lymphadenopathy, fever and splenic infiltration (Peterson & Frizzera, 1993). The disease
is common in HIV-infected individuals where it is often aggressive. KSHV positive
MCD cases form a distinct class of MCD, named plasmablastic MCD. A number of
patients with KSHV-associated plasmablastic MCD often progress to develop
plasmablastic lymphoma (Dupin et al., 2000).
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The organisation of the KSHV genome is very similar to other rhadinoviruses
such as HVS and MHV-68. The genome is 140.5kb long and is flanked by two terminal
repeat regions that have several 801bp repeat subunits of a high (85%) G+C content. As
with other herpesviruses, the genome contains genes that are conserved within all
herpesviruses and genes that are unique to KSHV. The latter genes have been
designated with a K prefix and are numbered sequentially (Schulz, 1998).
Some of the conserved herpesvirus genes that are seen in KSHV genome encode
homologues of cellular proteins that are involved in cell proliferation or cell survival.
For example, ORF K2 encodes a viral homologue of IL-6, a cytokine that is a functional
B cell growth factor and negatively regulates apoptosis; K13 encodes a viral Bcl-2
protein; ORF K9 is a viral interferon regulatory factor protein that blocks IFN and
interferon regulatory factor-mediated transcriptional activation. ORF 71 encodes a viral
FLICE (FADD homologous ICE) inhibitory protein (vFLIP) that inhibits Fas-mediated
apoptosis; ORF 72 encodes v-cyclin that forms a complex with cdk6 that results in the
prevention of normal G1 cell cycle arrest. ORF 74 encodes a viral G-coupled protein
receptor (GPCR) (Schulz, 1998). GPCR are a large family of receptors that play a
fundamental role in cellular communication. These receptors are thought to function in
cellular signalling pathways such as degranulation, lymphocyte homing and T-cell
activation. GCPR genes have been found in the genomes of poxviruses and
herpesviruses. It is thought that these viruses have evolved these genes through long co-
evolution with their hosts (Vink et al., 2001).
1.3.6. KSHV lytic replication
During latency, most of the KSHV genome is silent. This is thought to be due to
methylation of promoter sequences (Chen et al., 2001). For example, the promoter of
ORF 50 is heavily methylated in PEL cell lines. KSHV Rta, encoded by ORF 50, is
required to activate the lytic cycle (Lukac et al., 1999). The lytic cycle can be induced
in vitro using phorbol esters such as TPA either alone or with sodium butyrate. KSHV
gene expression has been investigated using DNA array expression profiling in PEL
cells stimulated by TPA (Paulose-Murphy et al., 2001). This study demonstrated that
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the first set of genes that are expressed after the induction of the lytic cycle are
regulators of gene expression such as ORJF 50, K8, ORF 57 and ORF 45. Genes that
control DNA replication such as DNA polymerase follow this. The genes that are
involved in virus structure and maturation are generally expressed later (Jenner et al.,
2001, Paulose-Murphy et al., 2001).
1.3.7. KSHV latency
KSHV can become latent in all of the cells that the virus infects, which are (pre-
and post-germinal centre) B-cells and endothelial cell precursors. These cell types all
have a high proliferative potential that is thought to help the vims propagate its genome
within the host. In the latent phase, the viral DNA exists as closed circular episomal
DNA. It has been demonstrated that all infected cells express the latent nuclear antigen,
viral cyclin (v-cyclin) and vFLIP (Jenner & Boshoff, 2002).
Latency-associated nuclear antigen-1 (LANA-1) possesses a number of
functions. Some of these include binding to cellular proteins such as RING3, one of five
human homologues of female sterile homeotic ifsh) ofDrosophila, a developmental
regulator and as a consequence of this interaction is phosphorylated (Piatt et al., 1999).
LANA-1 causes RING3 to relocate to nuclear heterochromatin regions, where it is
thought that LANA-1 and RING3 have a possible role in the regulation of chromatin
structure (Mattsson et al., 2002). LANA-1 has anti-apoptotic activity. When LANA-1
and p53 are over-expressed in p53-null cells, LANA-1 diminishes the apoptotic response
(Friborg et al., 1999).
KSHV also encodes a v-cyclin, a homologue of human cyclin D. v-Cyclin
phosphorylates the retinoblastoma protein in complex with cyclin-dependent kinase
(CDK) 6 and CDK4 (Godden-Kent et al., 1997) to allow the cell cycle to enter in S
phase and DNA synthesis. This abolishes cell cycle checkpoints and allows viral DNA
to be synthesised.
v-FLIP is a homologue of the cellular protein FLICE-inhibitory protein (FLIP).
v-FLIP proteins have been found in other gammaherpesviruses and protect the cells
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from many varieties of ligand-receptor-induced apoptosis. The KSHV v-FLIP protein
also has the ability to protect cells from Fas-mcdiatcd apoptosis (Djerbi et al., 1999).
1.3.8. Herpesvirus saimiri (HVS)
HVS is the prototype of the rhadinovirus subfamily. The virus occurs
naturally in squirrel monkeys {Saimiri sciureus), which inhabit Central and South
American rain forests. The virus was first isolated from primary squirrel monkey kidney
cells. However, it persists in peripheral blood lymphocytes. The virus replicates
productively in owl monkey kidney cells and induces cell lysis 3-20 days after infection
(Fickenscher & Fleckenstein, 1998). It is estimated that over 80% of squirrel monkeys
are persistently-infected with the virus (Jung et al., 1999). The virus causes no apparent
disease in the host animal. However, it infects New World primates such as tamarin
marmosets, owl monkeys, spider monkeys and howler monkeys (Melendz et al., 1969),
which develop lymphoproliferative syndromes and leukaemia. Experimentally, HVS
causes malignant lymphomas in New Zealand white rabbits (Ablahhi et al., 1985).
The virus has been classified into three subgroups A, B and C based on sequence
divergence at the left hand end of the unique L-DNA (Medveczky et al., 1984). The
variation has been linked with differences in the ability of the viruses to immortalise T
lymphocytes in vitro and to produce lymphoma in non-human primates. Viruses of both
subgroups A and C immortalise common marmoset T lymphocytes to IL-2 independent
proliferation (Szomolanyi et al., 1987). Subgroup C strains also immortalise rabbit and
rhesus monkey lymphocytes and can produce lymphoma in rhesus monkeys, as well as
in New World primates. The sequence variation is in open reading frames at the left
hand end of the genome, which are essential for HVS oncogenicity (Duboise et al.,
1998).
Lymphoid cell lines are established by the cultivation of tumour cell tissues from
marmosets and owl monkeys experimentally-infected with HVS (Johnson & Jondal,
1981). The cells lines have been cultured continuously for many years. Initially the cell
lines produced virus particles, however, this ability was lost after prolonged culture
(Marczynska et al., 1973). The cultured cells express many T cell markers and display
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cytotoxic activity (Johnson & Jondal, 1981). HVS subgroup C strains are able to
transform human T lymphocytes to stable growth in vitro. These transformed human T
cells do not produce viral particles (Fickenscher et al., 1997).
Albrecht and co-workers (1992) sequenced the genome of HVS. It contains 83
potential genes, with 60 being homologous to other herpesviruses. The genome ofHVS
encodes 75 ORFs (designated ORF1 to ORF75) and seven genes for small nuclear
RNAs. The viral genome consists of a low G+C (34.5%) content unique region that is
flanked by a high G+C (70.8%) repeat region (Albrecht et al., 1992). The viral genome
includes ORF 72 that encodes a cyclin homologue (Nicholas et al., 1992) and ORF 74, a
GPCR homologue (Ahuja & Murphy, 1993). The virus also encodes two potential
inhibitors of apoptosis: ORF16, that encodes a homologue of the Bcl-2 protein (Nava et
al., 1997); and ORF 71, that encodes a vFLIP. This is anti-apoptotic but is not essential
for viral replication, transformation or pathogenicity (Glykofrydes et al., 2000).
1.3.9. Other Gammaherpesviruses of veterinary importance
Equine herpesvirus 2 (EHV-2) is a gammaherpesvirus that is found in horses.
EHV-2 is common and can be isolated from leukocytes of "normal" (disease-free)
horses. The virus has been implicated in immunosuppression in foals, upper respiratory
tract disease, conjunctivitis, general malaise and poor performance (Telford et al., 1995).
The EHV-2 genome is most similar to EBV and HVS as the genome contains the
highest level of similarity to proteins specified by HVS and EBV. The viral genome is
linear double-stranded DNA and is 184kb in size comprising a unique region of 149kb
in size flanked by a 17.5kb direct repeat. The DNA G+C content is 58% in the unique
region and 55% in the repeat region (Telford et al., 1995). The genome is co-linear with
HVS and EBV and predicted to encode 70 ORFs. Unique genes with no counterparts in
HVS were designated with the letter E prefix (El to E10). Eight genes in the genome
have counterparts in HVS but not in EBV. Four of these have sequence homology
(ORFs 10, 11, 70 and 74) and four have positional homology (ORFs 12, 13 and 28)
(Telford et al., 1995).
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ORF E4 ofEHV-2 encodes a protein with 20% identity to the Bc1-xl protein.
Bc1-xl is an anti-apoptotic protein belonging to the Bcl-2 family of proteins (Bc1-xl will
be discussed in a later section). ORF E4 contains two Bel homology (BH) domains that
are thought to be responsible for anti-apoptotic function (Marshall et al, 1999). The
EHV-2 genome contains a gene encoding a homologue of the cytokine IL-10 (ORF E7)
and a GPCR encoded by ORF 74. This latter protein was located co-linearly to HVS
ORF 74 (Telford et al., 1995). A possible pathological role for EHV-2 is in the
reactivation ofEHV-1 and EHV-4 from latency (Welch et al., 1982). EHV-1 and EHV-
4 cause respiratory infections in young horses. EHV-2 transactivates the immediate-
early gene promoter ofEHV-1 in vitro (Purewal et al., 1992).
Bovine herpesvirus 4 (BHV-4) has been isolated from cattle that show various
clinical symptoms such as skin lesions, genital and respiratory diseases, but it has also
been isolated from apparently normal healthy cattle (Zimmerman et al., 2001). BHV-4
has been classified as a gammaherpesvirus and has sequence homology to KSHV and
HVS (Broil et al., 1999). As with other gammaherpesviruses, BHV-4 possesses
apoptosis regulators, vBcl-2 (ORF 16) and a v-FLIP protein (ORF 71) (Wang et al.,
1997). However, the genome does not possess a known cytokine or cytokine receptor,
GPCR or interleukin receptor within the long unique genome region, in contrast to other
gammaherpesviruses such as HHV-8 and EHV-2 (Zimmermann et al., 2001).
Due to the shortage of human organs for transplantation, xenotransplantation is
considered as an alternative, particularly using pig organs. However, this has brought
into question the possible risk of porcine pathogens transferring to human recipients. A
search for porcine herpesviruses identified two gammaherpesviruses ofpigs, porcine
lymphotropic herpesvirus 1 and 2 (PLHV-1 and PLHV-2). These viruses are widely
distributed with a high prevalence in domestic and feral pigs (Ehlers et al., 1999). No
disease has been identified in PLHV infection in pigs under natural conditions, however,
a porcine gammaherpesvirus has been associated with experimental posttransplant
lymphoproliferative disease (PTLD) in miniature swine following allogeneic
hematopoietic stem cell transplantation (Huang et al., 2001). The PTLD that was
observed was similar to that seen in some humans after tissue transplantation.
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Through amino acid comparisons and phylogenic analysis of a partial PLHV-1
region of the genome, it appears to have a very similar gene content and arrangement to
that ofAlcelaphine herpesvirus-\ (A1HV-1). The genome possesses homologues of
genes found in other gammaherpesviruses that may have a role in the pathogenesis of
disease. One gene that was identified was E4/BALFlh. Homologues of this gene are
present in EBV and EHV-2. ORF A5/BILFlh encodes a GPCR. This gene is similar to
ORF A5 ofA1HV-1, ORF E6 ofEHV-2 and ORF BILF1 ofEBV all ofwhich encode
GPCRs. ORF A8/BLLFlh is closely related to ORF A8 of A1HV-1 and ORF BLLF1 of
EBV (Goltz et al., 2002). BLLF1 mediates the attachment ofEBV to B cells via the
CD21/CR2 (Tanner et al., 1987) receptor and induces T cell apoptosis (Tanner &
Alfieri, 1999).
Fig 1.2 compares the genomic arrangement of a selection of
gammaherpesviruses.
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Fig. 1.2. Comparison of the genetic organisation among some of the
gammaherpesviruses
The genomes of (a) herpesvirus saimiri (HSV) (b) murine gammaherpesvirus 68 (MHV-
68), (c) Kaposi sarcoma associated herpesvirus (KSHV), (d) Alcelaphine herpesvirus-1
(AIHV-1), (e) equine herpesvirus 2 (EHV-2), (f) Epstein-Barr virus (EBV) are shown.
The genome of EBV has been inverted relative to its conventional orientation.
Abbreviations CCPH, complement control protein homologue; DHFR, dihydrofolate
reductase; GPCR, G protein-coupled receptor; STP-A, saimiri transformation protein;
TS, thymidylate synthetase; vll_-6 viral interleukin 6; vlL-10, viral interleukin 10; vlL17,
viral interleukin 17; vlL-8R, viral IL-8 receptor; vIRF, viral interferon-responsive factor;
vFLIP, viral FLICE inhibitory protein; vMIP-1a/p, viral macrophage inflammatory protein
1a/p. // denotes non-coding regions in the genomes of AIHV-1 and EHV-2. The
conserved gene blocks I (blue), II (turquoise), III (red) and IV (green) are shown and the
open reading frame designations within these boxes relate to the HVS numbering
system. Interspersed between these gene blocks are ORFs that are largely unique to
each individual family member and contain several homologues to cellular genes
(Adapted from Simas & Efstathiou, 1998).
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1.4. Malignant catarrhal fever
MCF is a systemic disease of cattle and wild ruminants (Castro & Daley, 1982;
Plowright, 1990; Handley et al., 1995). To date there are two viruses found to be causal
agents of the disease, Alcelaphine herpesvirus-1 (A1HV-1) and Ovine herpesvirus-2
(OvHV-2). A1HV-1 is found naturally in Blue Wildebeest (Connochaetes taurinus)
while OvHV-2 is found in sheep. Both cause no apparent disease in their carrier species.
However, when the viruses are transmitted to susceptible species disease can occur,
which is often fatal. Experimentally-infected rabbits exhibit similar clinical symptoms
and pathology to cattle infected with A1HV-1 and OvHV-2. This provides a very useful
experimental model for MCF.
1.4.1. Epidemiology
Mettam (1923) first investigated the association between wildebeest and MCF.
Wildebeest could transmit MCF to cattle of all ages by being in close proximity
(Plowright et al., 1960; Mushi & Rurangirwa, 1981a). Wildebeest calves are probably
the principal source of excreted A1HV-1 that can be contracted by susceptible species.
Most adult wildebeest are persistently infected with A1HV-1 (Plowright, 1967).
However, it is thought that they may only excrete the virus under certain circumstances,
for example severe stress, malnutrition and exposure to high environmental
temperatures. The virus can be isolated from the blood of adult wildebeest in late
pregnancy (Rweyemamu et al., 1974). Viremia has been demonstrated in pregnant blue
wildebeest that were near full-term. This would suggest that some calves are born with
infection obtained, in utero, while others may acquire the infection shortly after birth
(Plowright et al., 1972; Rurangirwa et al., 1982; Barnard et al., 1994). The natural route
of infection in cattle is probably through close contact with wildebeest calves. It has
been shown that intranasal instillation of cell-free viral suspensions can produce
infection in both cattle and rabbits (Mushi & Wafula, 1983). However, natural aerosol
infection would realistically take place only over short distances. Viral loads of nasal
secretions in wildebeest calves tend to be low (103 or 102 TCIDso/ml) (Mushi &
Rurangirwa, 1981a). The virus is thought to replicate in the corneal epithelium and pass
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down the nasal duct to the nasal cavity (Mushi & Rurangirwa, 1981a; Kurangirwa et al.,
1982). Wildebeest calves over three months old express virus neutralising antibody
detectable in their nasal secretions that may affect virus excretion (Mushi et al., 1981).
Wildebeest calves can acquire neutralising antibody from colostrum (Reid & Buxton,
1989). Neutralising antibodies in nasal secretions belong to the IgA class and are
thought to be induced locally by the virus in the nasal cavity (Mushi and Rurangirwa,
1981a). The production of the IgA antibodies in nasal secretions coincides with the
cessation of virus shedding (Rurangirwa et al., 1982).
1.4.2. Clinical Symptoms
The clinical signs ofMCF vary between individual animals. However, they can
be characterised into three main forms of the disease. These are (1) head and eye, (2)
intestinal and (3) neurological forms, which can have a peracute, acute, subacute or
chronic course (Reid & Buxton, 1989). The head and eye form of the disease is more
commonly seen in cattle, whereas deer develop a chronic form with fatal, haemorrhagic
enteritis (Thanr, 1997). The incubation period for the disease also varies between
animals and can last from a few weeks to several months (Reid & Buxton, 1989).
In all cases ofMCF the rectal temperature and pulse rate rises. There is a nasal
and ocular discharge that may start as clear and watery but then progresses to muco¬
purulent (brown coloured secretion) (Reid and Buxton, 1989). This discharge can
accumulate and encrust around the nostrils and muzzle and can lead to the nasal
passages becoming obstructed, which in turn leads to laboured breathing. In most cases
there is congestion, erosion and necrosis of the nasal and oral mucosa and the muzzle
(Barnard et al., 1994). Symptoms can also include dullness, inappetance and a decline
in milk yield of lactating animals.
Many MCF-affected animals develop ocular lesions that in turn leads to bilateral
corneal opacity that can progress to impaired vision or total blindness. The affected
animals are often photophobic. Nervous signs such as twitching of the ears, muscle
tremors, loss of coordination and aggressive behaviour can be seen in affected animals.
Constipation is common in infected cattle and can be persistent. This eventually gives
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way to diarrhoea, which can be blood-tinged. In deer with MCF, it is common for the
affected animals to have acute diarrhoea from the onset of the disease (Reid and Buxton,
1989). Within four to five days of developing the clinical symptoms of MCF, affected
cattle will often die (Barnard et al., 1994).
1.4.3. MCF Pathology
There are various tissues and organs affected by AlHV-l and OvFIV-2 MCF.
The most commonly affected are the upper respiratory and digestive tracts, lymph
nodes, brain, liver, kidneys and the urinary bladder (Barnard et al., 1994). Lymph node
enlargement is seen at the onset of fever. In rabbits infected with AlHV-l, popliteal and
submandibular lymph nodes are significantly larger compared to rabbits infected with
OvHV-2. In OvHV-2-infected rabbits, severe lesions are seen more commonly in
mesenteric lymph nodes. The affected lymph nodes exhibit lymphoid hyperplasia,
which is accompanied by an alteration of shape, haemorrhage, oedema and focal
necrosis (Reid & Buxton, 1989; Schock, 1996).
In the respiratory tract, lesions can be found in the mouth, pharynx, soft palate
and tongue. These may show signs of haemorrhage and focal necrosis of the epithelium,
erosions and ulcerations (Reid & Buxton, 1989). Ulceration and haemorrhage of the
mucous membranes that cover the nasal septum, turbinates, sinuses and the horn cores
can also be seen. In infected rabbits, lesions that are seen in the respiratory tract are
more severe in AlHV-l induced MCF than OvHV-2 MCF (Reid & Buxton, 1989).
The small intestine exhibits a reddened mucosa and small haemorrhages can be
seen while the large intestine possesses more obvious mucosal haemorrhaging and
erosions (Reid & Buxton, 1989). In A1F1V-1 MCF, the spleen and the liver can enlarge
to twice the normal size. However, this is not as obvious in OvHV-2 MCF (Reid &
Buxton, 1989). The kidneys can also be swollen and contain foci of lesions, which in
some cases may be small haemorrhagic foci (Barnard et al., 1994). As shown in fig 1.3
lymphocytes accumulate in the cortex of the kidney. The mucosa of the urinary bladder
can exhibit oedema, small haemorrhages, erosions and ulcerations. These lesions are
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often associated with the presence of blood in the urine. In the genital tract there can be
erosion of the vaginal mucosa (Denholm & Westbury, 1982; Reid & Buxton, 1989).
Fig 1.3 MCF, kidney and liver histology. (A) H&E staining showing interstitial
accumulation of lymphocytes in the cortex of a bovine kidney (infected with OvHv-2).
(B) H&E staining of a section of deer liver (infected with OvHV-2). Arrow 1 shows
lymphocyte accumulation without tissue damage. Arrow 2 shows area of necrosis. (C)
& (D) Vasculitis in deer infected with OvHV-2 MCF. (C) Shows a healthy, normal artery
with pronounced lumen (L), endothelial lining cells (E), muscle layer (M) and connective
tissue (C). (D) MCF: Arteritis showing lymphoid cells infiltrating the endothelial lining
cells, muscle layer and connective tissue. All pictures taken with magnification x 220.
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1.4.4. MCF Histopathology
MCF microscopic lesions can be characterised into four groups: hyperplasia and
necrosis in lymphoid organs, interstitial accumulation of lymphocytes in non-lymphoid
organs, vasculitis and epithelial degeneration.
Lymphoid hyperplasia exhibits as an increase in the numbers of lymphoblastoid
cells in the paracortex of lymph nodes. Focal necrosis also occurs, often follicular in
origin. Vasculitis affects the arteries, arterioles, veins and venules (fig 1.3 C&D). This
is accompanied by an infiltration of lymphocytes and macrophages (Liggitt &
DeMartini, 1980). The blood vessels can become blocked by the increase in numbers of
lymphoid cells and the multiplication of endothelial cells (Reid et al., 1979).
1.4.5. Transmission to susceptible species
When cattle and wildebeest are in close proximity, cattle can develop MCF. In
most cases the seasonal occurrence of the A1HV-1 MCF disease in cattle is related to the
calving season of the wildebeest. In Kenya, MCF usually occurs between April and July
following the wildebeest calving season in February to April (Plowright, 1964).
However in South Africa, MCF occurs twice, firstly during January to May which
coincides with the wildebeest calving season and subsequently between September and
November when the wildebeest calves are nine to eleven months old (Barnard et al.,
1988). It has been reported that there is a higher incidence of A1HV-1-MCF in East
Africa during the months of January through to July, which encompasses the time when
the wildebeest calves are bom and up until they are 2-3 months old (Plowright, 1990).
MCF has also been reported in South Africa between January and May when cattle and
wildebeest share grazing and watering places (Barnard et al., 1989). Wildebeest calves
younger than three months of age excrete virus into the nasal cavity (Heuschele et al.,
1985). It is believed that close contact could facilitate infection transmitted via aerosol
droplets, and also that aggressive snorting could produce such aerosols, which would
infect cattle (at least over a short distance). The Masai people believe that cattle become
infected from either the placenta of the wildebeest or the hair that the wildebeest calves
shed (Barnard et al., 1994). However, vims has not been isolated from the placenta
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(Rossiter, 1983). A vector (e.g. flies) has been suggested in virus transmission (Barnard
& Pypekamp, 1988). However, there is no evidence to support this. It has been
demonstrated that African face flies (Musca xanthomelas) were able to carry A1HV-1
infected material after feeding on wildebeest tears. They would have to regurgitate into
the eyes of cattle within 30 mins for it to be effective. This would appear to be unlikely,
and furthermore the amount of virus they carry would be very low (Barnard et al.,
1990).
All breeds of cattle (Bos taurus) are susceptible to MCF (Plowright, 1990).
Other animals such as kudus (Tragelaphus strepsiceros), sitatunga (Tragelaphus spekei),
eland (Taurotragus oryx) and roan antelope (Hippotragus equines) found in zoological
collections are also susceptible to MCF (Wothington & Bigalke, 2001). However, in
free-living animals in the wild, MCF has not been reported in these species even when
wildebeest and these species come into close contact (Barnard et al., 1994).
The mechanism through which OvHV-2 MCF is passed to susceptible species
from sheep still remains unclear. It is known that close contact between sheep and the
susceptible species (e.g. cattle) can result in MCF (Plowright, 1990). Shared
accommodation with common food and water troughs can result in transmission. As
with A1HV-1-MCF, the incidence ofOvHV-2-MCF is seasonal and has been associated
with the lambing season (Selman et al., 1978).
1.4.6. Experimental transmission of MCF
Rabbits can be easily infected with A1HV-1 or OvHV-2 intraperitoneally or
intravenously by inoculation of cells from lymphoid tissues of infected cattle or other
rabbits. The incubation period for the disease in rabbits varies from 12 days to several
weeks (Reid & Buxton, 1989). The clinical signs and pathology of the disease are
similar to that that found in A1HV-1-MCF or OvHV-2-MCF in cattle (Schock, 1996).
Once infected, IgG and IgM antibodies against the virus appear simultaneously
approximately two to six days before the onset of clinical disease. An IgG2 antibody
response is detected 2-4 days later (Rossiter, 1982). Hamsters, guinea pigs, rats and deer
are also susceptible to MCF, producing similar symptoms as seen in cattle. However,
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inoculated mice produce no symptoms ofMCF (Jacoby et al., 1988). MCF is a problem
in deer. Members of the Cervidae such as red deer (Cervus elaphus), axis deer (C. axis),
Siku deer (C. Nippon), Russa deer (C. timorensis), Roe deer (Capreolus capreolus), Pere
David deer (.Elaphus davidianus), white-tailed deer (Odocoileus virginianus) and black-
tailed deer (O. hemionus columbianus) are more susceptible than cattle to both A1HV-1
and OvHV-2 MCF (Huck et al., 1961; Reid & Buxton, 1984; Jessup, 1985). When the
farming of red deer was first established in Europe and New Zealand, major outbreaks of
MCF occurred affecting up to 50% of the herd (Reid et al., 1979). Plowever, it is not
now such a severe problem and outbreaks generally occur sporadically affecting
individual animals.
1.4.7. Alcelaphine herpesvirus-1 (AIHV-1)
Alcelaphine herpesvirus-1 was first characterized as Bovine herpesvirus-3
(BHV-3) by the World Health Organisation (WHO, 1976). However, this name was
altered to Alcelaphine herpesvirus-1 to reflect the carrier (or reservoir) species in which
the virus is found. Using electron microscopy and morphological characterisation, the
virus was identified as a herpesvirus (Plowright et al., 1963; Castro and Daley, 1982).
Plowright and co-workers were able to isolate the virus and demonstrated that it was
present in the blood of blue wildebeest (Connochaetes taurinus) (.Plowright et al., 1960).
Since then AIHV-1 has been characterised as a gammaherpesvirus belonging to the
subfamily Rhadinovirus (Roizman & Sears, 1990). The genome sequence ofAIHV-1
was resolved confirming this categorisation (fig. 1.4.) (Ensser et al., 1997).
The two most commonly described isolates ofAIHV-1 are WC11 and C500.
WC11 was first isolated from blue wildebeest and is cell-free and attenuated (Plowright
et al., 1960). The cell-associated and virulent C500 was first isolated from infected
cattle (Plowright et al., 1975). After extensive passage of the cells in culture, the virus
becomes cell free and attenuated (Wright et al., 2001). As with HVS, the DNA is
arranged in blocks separated by non-conserved ORFs. The non-conserved regions, as in
other Rhadinoviruses, contain homologues of cellular genes. The viral genes were
numbered according to their homologues in HVS. The genome consists of 130,608bp of
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low G+C content (46.17%) DNA (L-DNA), flanked by 20-25bp repeats of a sequence
with a high G+C content (71.83%) (H-DNA) 1113bp-2229bp. The L-DNA contains of
approximately 60 conserved herpesvirus ORFs that were arranged co-linearly to HVS.
There were eleven conserved herpesvirus ORFs identified which were not present in
HVS and have been designated with the letter A prefix (Ensser et al., 1997).
ORF Al possesses a TATA box-like sequence upstream and a polyadenylation
site downstream. ORF A2 has a predicted amino acid sequence with similarity to the
transcription factor ATF3 (Ensser et al., 1997). ATF3 is a member of the ATF/CREB
family and is a transcriptional repressor (Chen et al., 1996). ORF A3 was found to
encode a semaphorin-like protein. Semaphorins are a family of transmembrane and
secreted proteins that regulate axonal guidance in the developing nervous system
(reviewed in Goshima et al., 2002). It has also been reported that semaphorins have a
role in immunoregulation. A human semaphorin has been identified in lymphoid tissues
such as lymph nodes, thymus and spleen. The human semaphorin protein exhibits 46%
amino acid identity to the A1HV-1 semaphorin (Lange et al., 1998). ORF A4 does not
display homology to any sequence in the databases and no function is known, although it
contains a putative signal peptide cleavage site and so may be secreted (Coulter et al.,
2001). ORF A5 is a homologue of EBV BILF1 and EHV-2 E6. These encode GPCR
with seven transmembrane domains. ORF A6 is predicted to encode a protein of 220
amino acids and has a 19.5% amino acid identity to BZLF1 of EBV (Ensser et al.,
1997). EBV BZLF1 encodes Zta, a DNA-binding transcriptional activator (Takada &
Ono, 1989. ORF A7 shows a weak sequence homology of 17.1% to BZLF2 (Coulter et
al., 2001). In EBV this protein encodes a glycoprotein, gp42, which interacts with the
pi domain of the MHC class II protein (Li et al., 1997). ORF A8 is a positional
equivalent of the EBV gene that encodes the glycoprotein gp350/220, however, A8
shows only a limited sequence homology of 16.5% to this protein. The protein is
predicted to encode a glycoprotein. ORF A9 encodes a Bcl-2-like protein that may
regulate apoptosis. It shares sequence homology in the Bcl-2 homology (BH) 1 domain
only (Ensser et al., 1997). ORF A9 will be discussed in more detail in a later section.
ORF A10 is predicted to encode a glycoprotein that is 472 amino acids in size (Ensser et
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al., 1997). The protein is specific to A1HV-1 and may be involved in the attachment and
entry of the virus into the cell (Coulter et al., 2001). Virus that has become attenuated
by extended passage in cell culture undergoes a variety of genome rearrangements. In
some cases the 5'end of the A10 gene is lost and a block ofDNA from the middle of the
genome is inserted into a position between the 3' end ofA10 and the terminal repeat.
Therefore, the product ofA10 is not expressed in these cells (Handley et al., 1995;
Wright et al., 2003). A1HV-1 and OvHV-2 conserved herpsvirus genes and their
possible function are listed in table 1.2.
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Table 1.2 AIHV-1 and OvHV-2 ORFs
AIHV-1 gene OvHV-2 gene Possible function
A1 Unknown
A2 02 Leucine zipper protein,
transcriptional regulator
02.5 IL-10 homologue




A4.5 04.5 Bcl-2 homologue: cell
death regulator
A5 05 G-protein coupled receptor;
intracellular signalling
A6 06 EBV BZLF1 homologue;
transcriptional activator
A7 07 Viral glycoprotein
A8 08 Viral glycoprotein
08.5 Unknown
A9 09 Bcl-2 homologue; cell
death regulator
A10 010 Unknown
Table 1.2. AIHV-1 and OvHV-2 ORFs and possible functions (based on sequence
homologues).
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1.4.8. Ovine Herpesvirus-2 (OvHV-2)
Sheep-associated-MCF (SA-MCF) caused by OvFIV-2 was first recognised in
Europe (Colson, 1930). Since then it has been recorded worldwide. As yet no free virus
has been isolated from domestic sheep. Infection of susceptible cattle and rabbits with
virus-infected cells induces MCF, and from various tissues large granular lymphocytes
(LGLs) of T-cell (or possibly natural killer (NK) cell) phenotype can be developed and
grown in culture (Plowright, 1990; Schock et al., 1998). DNA from these cell lines
hybridises to unique regions of A1HV-1 (Reid, 2000), indicating that A1HV-1 and
OvHV-2 are related. To determine whether the LGL cell lines supported productive or
latent phases of the virus life cycle, an electrophoretic technique was used (Gardella et
al., 1984). Gardella gel analysis works on the basis that latent virus is in closed circular
episomal form and lytic cycle virus is in linear form. Lysis of infected cells by detergent
protease, followed by long electrophoresis times and southern blotting with viral probes,
can resolve the linear and circular viral genomes. Such analysis of LGL cell lines has
shown that bovine LGL cell lines were predominantly latently-infected (Rosbottom et
al., 2002). Rabbit cell lines on the other hand had predominantly linear DNA present in
Gardella gels, which would indicate that most of the cells were undergoing productive
replication (Rosbottom et al., 2002). LGL cell lines can be used to infect susceptible
species (Reid et al., 1983; Swa et al., 2001). The L-DNA genome sequence ofOvHV-2
has recently been determined (Rosbottom, 2003) (figl .5). The predicted amino acid
identities ofORF products in comparison to A1HV-1 ranges from 28% (in ORF 06) to
83% (comparing the capsid protein vp23 encoded by ORF 26). The genomic
arrangement ofOvFIV-2 is very similar to that of A1HV-1 (Ensser et al., 1997). Many
of the conserved herpesvirus genes that were originally described in A1HV-1 appear to
be present in OvHV-2. These include 02, 03, 05, 06, 07, 08 and 09. However, there
are also differences, such as the presence of an ORF 49 in OvHV-2, which is not present
in A1HV-1. This ORF is not unique to OvHV-2 as it is present in HVS and most other
gammaherpesviruses. Other OvHV-2-specific ORFs include 03.5, which is predicted to
encode a secreted protein and is in the same position as A4 of A1HV-1. However, their
predicted amino acid sequences are very different. OvHV-2 also possesses ORF 02.5,
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which is not seen in A1HV-1. This encodes a 182aa protein with homology to IL-10.
IL-10 homologues are present in other gammaherpesviruses such as EBV and EHV-2
(Rosbottom, 2003) as well as other viruses such as the betaherpesvirus CMV and
parapoxvirus orf virus (Lyttle et ah, 1994; Kotenko et ah, 2000; Haig et ah, 2002).
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1.4.9. Other viruses implicated in MCF
In serological studies, antibodies to A1HV-1 or antigenically related viruses have
been detected in species belonging to four subfamilies ofBovidae: Alcelphinae,
Hippotroginae, Caprinae and Ovibovinae (Reid, 2000). Using techniques including
serology, DNA alignment and phenylogenic analysis a gammaherpesvirus similar to
A1HV-1 was found in goats, and named caprine herpesvirus-2 (CpHV-2). This virus is
found worldwide, endemic in goats and is possibly associated with malignant catarrhal
fever in Sika deer (Crawford et al., 2002).
A herpesvirus was recovered from cells of a roan antelope (Hippotragus
equinus) and found to be antigenically related to A1HV-1 and OvHV-2. This
gammaherpesvirus was designated hippotragine herpesvirus-1 (HipHV-1). On
inoculation into rabbits the virus caused MCF (Reid and Bridgen, 1991).
A virus isolated from Jimela topi and Cape hartebeest was designated
Alcelaphine herpesvirus-2 (A1HV-2) (Seal et al., 1989). A study carried out by Flach
and co-workers (2002) showed that scimitar-homed oryx and gemsbok carry their own
gammaherpesviruses. Antibodies were present that cross-reacted with A1HV-1 and
gammaherpesvirus DNA was detected using primers against herpesvirus DNA
polymerase. A herpesvirus was isolated from scimitar-homed oryx and caused MCF
when inoculated into rabbits.
1.4.10. Diagnosis and prevention of MCF
There are several methods available to diagnose MCF. Customarily, this has
been achieved using post mortem histopathology, history of the herd and the clinical
signs that the animal presented with. At present, the laboratory diagnostic tests for vims
that are used include vims isolation (A1HV-1) from infected cells, indirect
immunofluorescence (using A1HV-1), virus neutralisation and PCR.
The most effective method to isolate the vims is by infecting monoloayers of
bovine turbinate (BT) cells with either vims-infected cells or free vims. Typical
syncytial (multinucleate cell) CPE will develop within 10 to 20 days (Reid & Buxton,
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1989) however specificity still needs to be confirmed by indirect immunofluorescence or
immunoperoxidase assays (Ferris et al., 1976; Rossiter, 1981).
An indirect immunofluorescence assay is carried out using sera from diseased
animals. This can be used in the diagnosis of clinical cases or in identifying latently-
infected carriers. A1HV-1 virus is grown in BT cells on a coverslip until 50-70% CPE is
reached. A fluorescence test is carried out using serum from the infected animal, BHV-
4 is used as a negative control. However, this test is used post mortem and is not
particularly sensitive it cross-reacts with other herpesviruses (Rossiter, 1981).
The virus neutralisation test measures serum A1HV-1 and OvHV-2 neutralising
antibodies. The test is carried out in 96-well plates using a virus stock of 100 TCID50.
The virus is incubated in BT cells for 6 - 9 days and is checked for CPE (Seal et al.,
1988). The median virus-neutralising titers of the sera are determined using the method
of Karber (1931). Animals considered to have been exposed to the virus usually have
serum titres above 1:4. One advantage of this assay is that the antibodies do not cross
react with other known bovine herpesviruses. However, the disadvantage is the results
take between 12-14 days to get.
A competitive inhibition enzyme-linked immunosorbent assay (CI-ELISA) was
produced using a monoclonal antibody that is specific for a glycoprotein that is
conserved between A1HV-1 and OvHV-2 (Li et al., 1994; Li et al., 2001). The assay
measures antibody to the virus and is used to determine OvHV-2 in samples.
MCF virus-specific PCR is the preferred method to diagnose MCF (by detecting
viral DNA) in a clinical case as it can be used on material obtained antemortem or post
mortem (Tham, 1997). It has a high sensitivity and specificity in sheep, goats,
wildebeest and all susceptible animals identified so far. PCR is much quicker than virus
isolation. The portion ofDNA that is amplified for A1HV-1 is ORF 21. This ORF has
homology to EBV ORF BXLF1 that encodes for thymidine kinase. A study comparing
PCR and CI-ELISA showed a 95% agreement. However, this study concluded that PCR
was the most reliable method for detecting OvHV-2 MCF in susceptible species (Li et
al., 1995).
38
1.4.11. Vaccines for MCF viruses
Various vaccine strategies have been tried and tested (Plowright, 1968;
Rweyemamum et al., 1976; Hamdy et al., 1978; Rossiter 1982) without positive results.
In one study virus isolated from hartebeest and passaged in a BT cell monolayer
did not induce MCF in six inoculated cattle (Reid & Rowe, 1973). All developed
serum-neutralizing antibody to WC11. Three of the animals were challenged with cell-
associated virulent virus isolated from wildebeest and the remaining three were
challenged with cell-associated virus that had been passaged in BT cells. The three
animals challenged with wildebeest cell-associated virus developed MCF and died,
while of the three challenged with BT cell-associated virus only one developed MCF
and died. The remaining two animals were then challenged with wildebeest cell-
associated virus became viraemic and developed the disease (Reid & Rowe, 1973).
There have been a number of studies carried out with virulent A1HV-1 virus that
had been formalin-inactivated or combined with an adjuvant and administered
intraperitoneally. These studies produced high levels of neutralising antibodies.
However, they provided no resistance to parenteral challenge by cell-associated virulent
virus (Plowright et al., 1975). In rabbits vaccinated with inactivated antigens
administered intravenously resistance was not produced against the virulent cell
associated strain of the virus (Edington & Plowright, 1980).
Keeping reservoir species and susceptible species apart is the current best
method of control of MCF. This is particularly important in animals that are kept in
captivity. Susceptible species should be segregated from wildebeest, especially during
the breeding season and up until the wildebeest calves are at least six months old. If an
animal does develop MCF then it should be kept in isolation (Hinchcliff, 2000).
1.5. The host antiviral immune response
The first barrier to virus infection is a host epithelial cell layer. Upon infection
of epithelial cells an inflammatory response is initiated. These cells produce cytokines
and chemokines involved in inflammation, which is characterised by an increase in
blood flow, vascular permeability and leukocyte recruitment to the site of infection
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(Roitt et al., 1998). The early response to a virus infection is antigen non-specific and
forms part of the innate immune response. Interferon (IFN, type 1 IFN-a/p or type 2
IFNy) is an important part of host response to virus infection. IFNs stimulate an "anti¬
viral state" in target cells, to block or impair viral replication, slow the growth of target
cells and make them more susceptible to apoptosis (reviewed in Goodbourn et al.,
2000). IFNs induce anti-viral mechanisms after binding to their specific receptors on
infected cells. This leads to a signal transduction cascade involving Janus kinases (JAK)
and signal transducer and activation of transcription (STAT) factors that leads to the
transcription of IFN-inducible genes (Goodbourn et al., 2000). The best characterised
IFN-inducible components of the antiviral response are protein kinase R (PKR) and the
2'-5' oligoadenylate synthetases. A 67kDa cytosolic PKR protein, binds dsRNA of
virus antigen and inhibits the phosphorlyation of the a subunit of elF-2 (a translation
initiation factor) after binding vims dsRNA to inhibit viral and cell protein translation
thereby inhibiting viral replication (Clemens & Elia, 1997). The 2'5'-oligoadenylate
synthetase activates a latent endonuclease RNase L that degrades viral RNA preventing
viral infection (Roitt et al., 1996) and also promotes NFkB. NFkB plays an important
role in the induction ofmany immunomodulatory genes, including other cytokines,
MHC class I and cell adhesion molecules (Goodboum et al., 2000). Apoptosis, or
programmed cell death, is an innate mechanism that the host uses to eliminate vims-
infected cells. It can be induced by a variety of stimuli such as radiation, drug treatment,
cytokine withdrawal and infection. Apoptosis will be discussed in detail in a later
section.
As well as interferons (IFNa/(3/y), tumour necrosis factor (TNF), natural killer
(NK) cells and macrophages are also produced in response to a vims infection. TNF
promotes the production of other cytokines and enhances the activation of T and B cells.
It can increase the expression ofMHC class I and II molecules thereby improving vims
antigen presentation (Banyer et al., 2000). Active NK cells can be detected within two
days of viral infection (Roitt et al., 1996). IFN activates NK cell cytotoxicity and lysis
of vims-infected cells (Biron, 1997).
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Complement activation also plays a role in antibody mediated viral immunity by
coating the virus, promoting phagocytosis or by directly lysing viruses with lipid
membranes (Barber, 2001).
The adaptive immune response is initiated when viral peptides (antigens) are
presented by antigen-presenting dendritic cells to antigen-specific T-lymphocytes in a
MHC-restricted manner. The adaptive immune response is characterised by virus-
antigen specificity and immunological memory. Antigen-specific B-lymphocytes
develop into plasma cells that secrete antibodies, whereas T-lymphocytes either assist B-
lymphocytes to produce virus-specific antibodies or directly attack and kill virus-
infected cells (e.g. cytotoxic T-cells (CTL)). Antigen-presenting dendritic cells present
antigens on the surface of the cell in association with the major histocompatibility
complex gene derived proteins (MHC class I and II). The MHC class I molecule
consists of a polymorphic transmembrane heavy chain associated with a non-
polymorphic light chain and a peptide derived from proteolysis of cytoplasmic proteins.
By transferring these peptides from the cytoplasm to the cell surface, the MHC class I
antigen presentation system provides CTL's with a means of inspecting the intracellular
environment (Heemels & Ploegh, 1995; York & Rock, 1996). These protein complexes
bind antigen less specifically than the antigen receptors on T-and B-lymphocytes but
ensure that T-and B-lymphocytes recognise the antigen efficiently in order that foreign
as opposed to self-antigens are preferentially recognised. Memory exhibited as a
vigorous immune response involving large numbers of antigen-specific lymphocytes is
produced rapidly after subsequent infection (Haig, 2001).
CTL's use perforin and granzymes or/as well as FAS-FASL mediated
mechanisms to induce death in virus-infected cells. Natural killer cells also secrete
processed granzymes that can enter the target cells through repair endocytosis. These
processes lead to activation of pathways that eventually lead to apoptosis of infected
target cells (Barber, 2001).
41
1.5.1. Immune evasion mechanisms adopted by herpesviruses
As the host animal has evolved mechanisms to attempt to prevent the virus from
establishing, the virus has itself evolved mechanisms to evade the immune system. Such
strategies include interference with/or avoidance of the innate and adaptive immune
responses (Haig, 2001). For example, by interfering with the host apoptosis response
(Vossen et al., 2002), interferon response (Goodboum et al., 2000) and aspects of the
adaptive immune response.
One way in which the virus overcomes the immune system to interfere with
antigen processing and presentation. This is the mechanism by which the host
recognises foreign peptides and activates CD8+ T cells or CD4+ T cells to establish an
anti-viral immune response. For example, EBV encodes a nuclear antigen (EBNA)-l
that is able to avoid CTL detection and encodes a mechanism to inhibit the generation of
epitopes (Levitskaya et al., 1995), HSV encodes a cellular protein 47(ICP47) that binds
to the transporter associated with antigen presentation and inhibits transporter associated
with antigen presentation-mediated peptide translocation across the ER membrane (Fruh
et al., 1995). HCMV possess pp65 that modulates the processing of another HMCV
protein. These proteins prevent peptide generation and transport (Alcami &
Koszinowski, 2000).
Viruses have also evolved strategies to counteract the complement system. It has
been shown that herpesviruses such as HSV and VZV can inhibit the classical
complement activation pathway by avoiding complement binding to antibody-antigen
complexes. This removes the antibody-antigen complexes from the cell surface of the
infected cell or by expressing Fc receptors (Dowler & Veltri, 1984). Another way in
which they can bypass the complement pathway is by expressing proteins with
functional similarities to regulators of complement activation (RCA) proteins and other
complement regulators in order to protect their lipid envelopes and the membranes of the
infected cells (Favoreel et al., 2003). An example of this can be seen with HVS, which
encodes two proteins that share amino acid homology with complement regulators.
ORF4 encodes a protein with homology to decay-accelerating factor (CD55) and has
been found to inhibit C3 convertase activity. ORF15 encodes a protein with homology
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to CD59, the terminal product of the complement cascade, the membrane attack
complex. Finally the viruses can incorporate the host complement control proteins into
their viral envelope and so can upregulate the expression of these proteins in the infected
cells (Favoreel et al., 2003). HCMV has been found to upregulate CD55 (a protein that
can protect cells from complement mediated lysis) and CD46 (protein that is involved in
the regulation of complement activation). Functional studies revealed that the
upregulation of CD55 resulted in the suppression of the alternative complement pathway
and an increase in resistance to complement-mediated lysis.
Herpesviruses can also interfere with the interferon response by blocking IFN-
induced transcriptional responses and the janus kinase/signal transducers and activators
of transcription factors. This can be achieved by inhibiting PKR activation and the
phosphorylation of eIF-2a.
Herpesviruses can reduce the inflammatory response. This is demonstrated in
EBV and CMV, which possess homologues of mammalian IL-10, a cytokine with anti¬
inflammatory activity (Zdanov et al., 1997).
Herpesviruses can modulate the activity of chemoattractant cytokines that
regulate leukocytes trafficking to sites of infection. They can also encode cytokine
receptors (vCKR). For example, HCMV and HHV-6 encode vCKR's. However, their
function is unknown. The viral envelope protein, gp350, in EBV induces the expression
of the IL-1 receptor antagonist, which inhibits the activity of IL-1. IL-1 is important in
inflammatory responses (Roberge et al., 1996).
1.5.2. Viral initiation and prevention of apoptosis
Multicellular organisms have a variety of strategies to defend themselves from
viral infection. On infection ofmany cell types, cytokines such as IL-1 and TNF are
produced, which in turn activate and recruit macrophages, NK cells and neutrophils.
These cells can induce phagocytosis and help to clear the viral infection. Apoptosis is
another anti-viral strategy. If the cell can commit suicide before the virus has replicated
or before large amounts of vims are produced this will protect surrounding cells. The
second line of defence, adaptive immunity, is mediated through humoral and cell
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mediated immune responses. This line of defence involves cytotoxic T cells, antibodies
and cytokines.
Virus replication can trigger apoptosis directly or provoke the recognition by
CTLs and NK cells. CTLs can trigger receptor-mediated apoptosis either by the release
of soluble factors such as TNF or by direct cell-cell contact via membrane-bound Fas
ligand (FasL). Engagement of both of these factors leads to the recruitment of
cytoplasmic components, which can eventually lead to caspase activation (this will be
discussed later in the chapter). The attachment and entry of the host cell can trigger
apoptosis. For example, even non-infectious virus particles ofHSV-1 can induce
apoptosis in HeLa cells (Galvan & Roizman, 1998). Therefore, it would appear that
viral entry can trigger apoptosis in susceptible cells unless anti-apoptotic proteins are
expressed to prevent the apoptotic pathway.
The lytic granule-mediated mechanisms are the major pathway by which CTL
eliminate virus-infected cells (Kagi et al., 1995). The major factors of this pathway
include perforin and granzymes A and B. Perforins function by allowing granzymes to
redistribute from the endosomal compartment to the cytoplasm and nucleus. Both
granzyme A and B can induce apoptosis in the target cell however, they can do this in
different ways (Russell & Ley, 2002). Granzyme B-mediated apoptosis involves the
cleavage of Bid by granzyme B to activate the mitochondria pathway (which will be
discussed later in this chapter) (Sutton et al., 2000).
When viruses infect cells their proteins disturb normal cell physiology and
provide upstream signals that trigger a death response. There are a number of
checkpoints that trigger apoptosis in host cells such as the attachment and entry of
viruses in the host cell, IFN production, mitochondrial sensors, activation of p53 and the
inundation of viral proteins in the ER (reviewed in Everett & McFadden, 1999).
Initiation of the Fas and TNF pathway occurs by the binding of the receptor and
ligand on the cell surface this results in the stimulation of the Fas induced apoptosis
pathway, which is described in section 1.5.2. Therefore many viruses have evolved
proteins that prevent this pathway from being initiated, for example Adenoviruses
express protein E3-10.4K and E3-14.5K these proteins reduce the presentation of Fas
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molecules on the surface of the cell. This reduction results in the resistance to Fas-
mediated cell death. These proteins also confer some resistance to TNF-mediated
apoptosis (Dimitrov et al., 1997; Shisler et al., 1997).
PKR is one activator of IFN and PKR gene expression is in turn upregulated by
IFN. The enzyme becomes activated by dsRNA binding two dsRNA binding motifs in
its amino terminus, to promote dimerisation, this stimulates trans-autophosphorylation.
The phosphorylated dimeric PKR recognises the eukaryotic translation initiation factor-2
(eIF-2). Therefore for a virus to overcome this pathway and produce a successful
infection it has to evolve mechanisms to inhibit PKR function. KSHV expresses a
protein vIRF2 (ORF K11.1) that binds and inactivates PKR thereby preventing the initial
activation of IFN, by this particular pathway (Burysek & Pitha, 2001). It has also been
demonstrated in other viruses, for example, the hepatitis C virus expresses a protein
NS5A, this protein binds and inhibits PKR (Gale et al., 1997). Hepatitis C virus also
expresses an envelope protein, E2, this has been shown to inhibit kinase activity thereby
blocking the inhibitory effect that PKR has on protein synthesis (Polak et al., 1997).
Activation of p53 is a mechanism that the host cell uses to induce apoptosis upon
viral infection. p53 can be activated by many different types ofDNA damage such as
double-stranded breaks in DNA by y-irradiation, the presence ofDNA repair
intermediates and chemical damages to DNA. Unscheduled DNA replication and viral
gene expression can lead to the activation of transcription factor p53. In the cell cycle
p53 activation leads to the transcription of p21. p21 binds to a number of cyclin and
Cdk complexes to stop DNA replication (El-Deiry et al., 1993). The mechanism by
which p53 induces apoptosis still remains unclear. It is known that p53 targets genes
that are involved in apoptosis such as Bax, Fas and NFkB (Bennet et al., 1998; Gottlieb
& Oren, 1998; Ryan et al., 2000). Many viruses have evolved proteins to counter the
effects of p53, for example adenoviruses express proteins, E1B-55K that act as p53
antagonists. E1B-55K binds and inactivates p53 (Alcami & Koszinowski, 2000).
HHV-8 also encodes a p53 inhibitor, LANA. Human papilloma virus encodes a protein
E7 that induces p53-induced apoptosis, however, it also encodes a protein, E6, which
binds p53 and proteolytically degrades it (Tortorella et al., 2000).
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1.5.4. Apoptosis
Apoptosis can be triggered by a variety of stimuli. It is a major form of cell
death and one way in which the host can limit viral proliferation. Therefore,
herpesviruses have developed strategies to prevent apoptosis by expressing proteins that
block cell death. This can be carried out by encoding homologues of cellular anti-
apoptotic Bcl-2 proteins, blocking signals triggered by activation of TNFR family
members and inactivating IFN-induced PKR and the tumour suppressor p53. One
example of this can be seen in FIHV-8, K13 protein, which encodes a vFLIP protein.
This protein interacts with Fas associated death domain (FADD) or FLICE and inhibits
the recruitment of FLICE, which initiates the caspase cascade.
Some of the gammaherpesviruses that have been sequenced encode a vFLIP and
at least one Bcl-2 homologue, suggesting that these are important proteins in the viral
life cycle and/or in pathogenesis. The cellular Bcl-2 family and FLIP are key regulators
of apoptosis suggesting that it is an important anti-viral defence mechanism.
There are two major forms of cell death: apoptosis and necrosis. The features
that are normally seen in cells that are undergoing necrosis are clumping of the nuclear
chromatin, dilation of the endoplasmic reticulum and dispersal of ribosomes. These
factors are followed by the swelling of the mitochondria, and progress to the rupturing of
nuclear, organelle and the plasma membranes. The eventual result is that phagocytic
cells ingest and degrade the debris (Wyllie et al., 1980).
The onset of apoptosis is characterised by the shrinking of the cell and the
condensation of nuclear chromatin into sharply defined masses that marginate against
the shrinking nuclear membranes. The cellular phospholipid bilayer is disrupted and
leads to the phospholipid, phosphatidylserine, being exposed on the outer leaf of the
plasma membrane and the activation of an endonuclease, which cleaves genomic DNA.
The precise endonuclease is still unknown. Work carried out by Enari and co-workers
(1998) showed that a caspase-activated deoxyribonuclease (CAD) and its inhibitor
(ICAD) exist as a complex. After apoptotic stimuli, ICAD is cleaved from the complex
allowing CAD to enter the nucleus and degrade chromosomal DNA. However, others
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have found various other nucleases that could also be considered as candidates (Zhang et
al., 1998; Sakahira et al., 1998, Wyllie, 1998) it would therefore appear that the
apoptosis-associated nuclease is not sequence specific and no one nuclease is involved
entirely (Wyllie, 1998). The nucleus condenses further and breaks up, with double
membranes surrounding the nuclear fragments. The whole cell breaks down into
membrane bound apoptotic bodies, which are spherical or ovoid in shape. The apoptotic
bodies are rapidly phagocytosed by healthy neighbouring cells such as macrophages
(Wyllie etal., 1980).
Apoptosis can be broadly categorised into three stages: activation, execution and
disposal. Activation can be caused by an external stimulus delivered through surface
receptors or an internal stimulus such as the action of a drug, toxin or radiation. The
execution phase is a regulatory cascade which when initiated leads to the biochemical
and morphological changes characteristic of apoptosis. It is during this phase that the
cell is committed to apoptosis. The final phase, disposal, involves the removal of the
resulting apoptotic bodies by phagocytic cells such as macrophages.
There are two main pathways that initiate apoptosis; firstly through ligand
binding and secondly by loss of suppressor activity. Death receptors can play a role in
initiating apoptosis when a cell loses contact with its surroundings or incurs irreparable
internal damage. These receptors belong to the tumour necrosis factor (TNF) receptor
gene superfamily. One of the most studied and well-characterised death receptors is Fas
(also known as CD95 or Apo 1) (Ashkenazi & Dixit, 1998). Fas is a cell surface protein
and is a receptor for Fas ligand (FasL). Fas L is a homotrimeric molecule that binds to
three Fas molecules. Fas ligation leads to the clustering of the receptor death domains.
An adaptor protein called FADD (Fas-associated death domain) binds through its own
death domain. FADD also contains a death effector domain that binds to an analogous
domain repeated in tandem within the pro-enzyme form of caspase-8 (also known as
FLICE). Caspase-8 is self-cleaved after binding to FADD and activates downstream










Fig 1.6. Apoptosis can be initiated by ligand binding. Fas binds to FasL which in turn
binds to Fas associated death domain (FADD). This results in the self-cleavage of pro-
caspase-8 to caspase-8, which activates the series of caspase cascades.
The second pathway for initiation of apoptosis involves the loss of suppressor activity in
response to a variety of cellular stresses such as DNA damage, protein kinase inhibition
or loss of survival signalling, e.g. when cytokines are not available. This pathway is
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often called the mitochondrial-dependent pathway and involves members of the Bcl-2
family of proteins. The mechanism of how apoptosis is initiated in this pathway still
remains unclear. Possible mechanisms will be discussed in detail in a later section.
Apoptosis is accomplished by specialised cellular machinery which is highly
conserved in different species (Thornberry & Lazebnik, 1998). Cytosolic Aspartate-
Specific Proteases, also known as caspases, are responsible for the deliberate
disassembly of a cell into apoptotic bodies. Caspases exist as an inactive form in the
cytosol as a single polypeptide chain (Green & Kroemer, 1998). They all share
similarities in amino acid sequence, structure and substrate specificity. All procaspases
contain a highly homologous protease domain that can be divided into two subunits, a
large subunit of 20kDa and a small subunit of approximately lOkDa. Each procaspase
also contains a prodomain or NH2-terminal peptide of variable length (Chang & Yang,
2000). It is believed that oligomerisation of procaspases is the mechanism of initiating
caspase activation. However, effector procaspases are activated most commonly by
initiator caspases and also by other proteases (Chang & Yang, 2000). Caspases cleave
after aspartic acid residues with recognition of at least four amino acids essential for
efficient catalysis. Caspases-6, 7 and 3 are directly implicated with the execution of
apoptotic cells, while caspases-8, 10, 9 and 2 are initiator caspases which function as
signalling molecules. Caspases are also involved in the cleavage of pro-apoptotic Bcl-2
proteins to produce a fragment that promotes apoptosis (Thornberry & Lazebnik, 1998).
Bid, a pro-apoptotic Bcl-2 family member is cleaved by the initiator caspase-8 following
death receptor activation (Li et al., 1998).
The final stage in apoptosis is the disposal of the apoptotic body that is formed in
apoptosis. During apoptosis the plasma membrane is disrupted leading to the exposure
of phosphatidylserine on the plasma membrane. Phosphatidylserine is one receptor that
phagocytic cells use as a signal of an apoptotic cell (Eadok & Chimini, 2001). The
apoplolic cells are enveloped by pseudopodia that are extended by the phagocyte.
Binding and engulfment is achieved by one or more membrane receptors such as CD 14
(Devitt et al., 1998), SR-A (Piatt et al., 1996) and CD36/vitronectin receptor.
Internalisation of the apoptotic cell involves the reorganisation of some of the
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cytoskeleton through adaptor molecules. The internalised apoptotic material is
phagocytosed by dendritic cells, taken into the MHC class I pathway and presented to
CTLs (Piatt etal1998).
1.5.5. Measuring Apoptosis
The process of apoptosis involves many changes in cell morphology as discussed
previously. The process of cell shrinkage, increased cytoplasmic density, chromatin
condensation and the segregation into sharply circumscribed masses to produce
apoptotic bodies can be detected by electron microscopy (Kerr et al., 1972). Confocal
laser-scanning microscopy can also be used to analyse the morphological changes that
take place (Smith et al., 1992). By using DNA dyes such as propidium iodide and
Hoechst 33342, the condensed chromatin and nuclear fragmentation that takes place can
be examined.
During apoptosis, the DNA is cleaved by an endonuclease as described
previously. This results in multiple fragments of 185bp being produced (Wyllie, 1980).
These fragments can be analysed by agarose gel electrophoresis to show the typical
"DNA-ladder" configuration (Compton & Cidlowski, 1986). The sensitivity of this
assay can be increased by labelling free 3' OH ends of the nicked DNA with "P-dATP
or "P-dCTP before agarose gel electrophoresis (Rosl, 1992).
Flow cytometric analysis, based on the morphological and cell phenotypic
changes that take place (e.g. DNA fragmentation, DNA loss and membrane changes) can
be used to make quantitative measurements of apoptosis. Apoptotic cells exhibit lower
forward scatter and higher side scatter values than viable cells due to changes in size and
granularity of the cells (Sgonc & Wick, 1994).
During apoptosis, the plasma membrane undergoes several changes. The
phospholipid bilayer is disrupted which leads to the exposure of phosphatidylserine from
the inner to the outer leaflet of the plasma membrane. This can be detected by annexin
V, which binds to phosphatidylserine in the presence of calcium. To discriminate
apoptotic cells from necrotic cells, propidium iodide is used in conjunction with annexin
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V. This assay gives an early detection of apoptosis, but the disadvantage of this assay is
the inability to distinguish between late apoptotic cells and necrotic cells.
A major event in apoptosis is the loss of mitochondrial membrane potential.
This can be measured by staining the mitochondria with cationic, lipophilic
fluorochromes such as 5,5',6,6'-tetrachloro-l,1',3,3'-
tetraethylbenzimidazolcarbocyanine (JC-1), 3,3'-dihexyloxacarbocyanine iodide
(DiOC(,(3)) or rhodamine 123. In apoptotic cells the incorporation of these dyes is
reduced (Zamzami et al., 1995).
1.6. Bcl-2 family of proteins
The Bcl-2 family is one of the most important families of regulatory proteins
involved in apoptosis. The prototype of the family, the Bcl-2 proto-oncogene, was
discovered at the chromosomal breakpoint of t( 14:18) in human B-cell lymphomas
(Bakhshi et al., 1985). It was found to inhibit cell death rather than promote cell
proliferation. Since this discovery, a number of Bcl-2 family members have been
discovered that act as both anti- and pro-apoptotic proteins. The proteins all contain at
least one of four domains known as Bel homology (BH) domains as well as a
transmembrane domain at the carboxy terminus. BH domains are important as they
determine the capacity for the Bcl-2 proteins to form homo- or hetero-dimers or to bind
proteins outside the Bcl-2 family (Tsujimoto & Shimizu, 2000). The Bcl-2 proteins can
be roughly divided into three categories (fig 1.7):
• Anti-apoptotic members such as Bcl-2, Bc1-xl, and Bcl-w share sequence
homology within all four domains BH1, BH2, BH3 and BH4.
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• Pro-apoptotic members such as Bax, Bad and Bak share sequence
homology in BH1, BH2 and BH3, but do not possess the BH4 domain.
• 'BH3 only proteins' such as Bik, Bid and Bim are pro-apoptotic and as
the name suggests, share sequence homology only in the BH3 domain
(Adams & Cory, 1998; Tsujimoto & Shimizu, 2000). These proteins
cannot homodimerise, but can form heterodimers with anti-apoptotic
members (Kelekar & Thompson, 1998).
11BH41 IBH31 iBHll IBH21 : M Bcl-2, Bcl-X|
I IBH31 IBHll IBH21 BM Bax, Bak
I IBH3 I Bik, Bim
I IBH3 I | Bad, Bid
Fig 1.7. Comparisons of Bcl-2 protein domains. Anti-apoptotic proteins such as Bcl-2
and Bcl-xL share sequence homology with all four domains. Pro-apoptotic members
such as Bax and Bak share sequence homology in BH1, BH2 and BH3. Other pro-
apoptotic members called the BH-3 only members contain only the BH3 domain. Pro-
apoptotic members such as Bik and Bim possess the transmembrane domain while
others such as Bad and Bid do not.
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The BH1 and BH2 domains are important for Bcl-2 and Bcl-X[. to interact with
pro-apoptotic proteins in order to prevent apoptosis (Borner et al., 1994). The BH1
domain possesses a conserved "NWGR" sequence motif has a vital role in preventing
apoptosis and facilitates the heterodimerisation of other Bcl-2 family members.
However, mutational studies have shown that this sequence is not essential in
homodimerisation (Yin et al., 1994).
The BH3 domain appears to play a fundamental role in the induction of
apoptosis. Through a series of mutagenic studies, this domain was shown to be key for
pro-apoptotic proteins (Reed, 1998). It allows the pro-apoptotic proteins to interact with
and antagonize anti-apoptotic proteins (Yang et al., 1995). The introduction of the BH3
domain from Bax into Bcl-2 (anti-apoptotic) converts the protein to a pro-apoptotic
protein (Hunter & Parslow, 1996). Mutations in the BH3 domain that affect
heterodimerisation and apoptotic activity have been shown to occur at leucine at position
1 and aspartic acid at position 6 of the BH3 domain (Kelekar & Thompson, 1998).
The BH4 domain is highly conserved throughout the anti-apoptotic proteins. If
this domain is deleted from Bcl-x^ it loses its apoptotic function, suggesting that the
BH4 domain is vital for apoptotic behaviour. This domain binds to proteins not in the
Bcl-2 family, but have a role in apoptosis involving mediators such as Rafl, ced4 and
calcineurin (Huang et al., 1998; Shibasaki et al., 1997; Wang et al., 1994). The BH4
domain may be essential for Bcl-2/Bcl-xL prevention of apoptotic mitochondrial
changes (Shimizu et al, 2000). The BH4 domain interacts with the voltage-dependent
anion channel (VDAC) (Buya et ul., 2001).
1.6.1. BcI-Xl structure
The structure of BcI-xl has been examined in detail by X-ray crystallography and
nuclear magnetic resonance (NMR). The protein consists of seven amphipathic a-
helices which are joined by flexible loops (Reed, 1998). There are two main a-helices
(a5 and a6). Studies have demonstrated that lying upstream of a.5 is the BH1 domain.
The BH2 domain can be found in the distal region of a6. These two central helices are
predominantly hydrophobic. The BH3 domain has been shown to be on al (Reed,
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1998). A hydrophobic cleft is formed at the surface of the Bc1-xl protein by the BH1,
BH2 and BH3 domains (Muchmore et al., 1996; Reed, 1998). This is the binding site
for the BH3 domain of Bak (Muchmore et al., 1996). The Bc1-xl protein shares
structural similarity with the pore-forming diphtheria toxin. These toxins form pores
which act as channels for ions and small proteins (Motyl, 1999; Antonsson & Martinou,
2000). This suggests that Bc1-xl proteins may form pores in the endoplasmic and
mitochondrial membranes and may be regulated by signals dependent on voltage and pH
(Motyl, 1999).
1.6.2. Bid structure
The structure of the pro-apoptotic protein Bid was determined by heteronuclear
NMR spectroscopy. The structure of this protein was very similar to that of Bc1-xl. It
consists of eight helices that are arranged into three layers. As with Bc1-xl there are two
central helices (aF and aG) that are surrounded by amphipathic helices on either side.
This protein, however, does not form the cleft that allows the BH3 domain to bind
(McDonnell et al., 1999).
1.6.3. Possible mechanisms of cytochrome c release
The anti-apoptotic proteins are found within the cytoplasmic region of the
mitochondrial membrane, endoplasmic reticulum and nuclear envelope (Adams and
Cory, 1998; Gross et al., 1999). Most pro-apoptotic family members are found in the
cytosol or cytoskeleton before the induction of apoptosis. An exception is Bak, which is
an integral protein of the mitochondrial membrane (Gottlieb, 2000). After the induction
of apoptosis, the BH3-only proteins undergo post-translational changes, which allow
them to target membranes, especially the mitochondrial membrane (Gross et al., 1999).
Mitochondria play an essential role in the regulation of apoptosis by releasing
apoptogenic factors such as cytochrome c and apoptosis inducing factor (AIF) (Liu et
al., 1996; Yang et al., 1997; Kluck et al., 1997). The actual mechanism by which
cytochrome c is released is the subject of a long-standing debate and remains unresolved
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(Skulachev, 1996; Vander Heiden et al., 1997). Bax and other pro-apoptotic proteins
promote the release of cytochrome c.
One theory behind the release of cytochrome c is that Bcl-2 family members
aggregate to form a pore that is large enough to allow the passage of cytochrome c. This
was suggested by structural similarity between Bc1-xl and a bacterial pore-forming toxin
(diphtheria toxin). In vitro, Bcl-2 family members are able to form ion-conducting pores
in artificial bilayers (Schendel et al., 1997). Bid is proteolysed by caspase 8 and the C-
terminal portion (tBid) interacts with the mitochondria membrane (Li et al., 1998;
Desagher et al., 1999; Gilmore et al., 2000). Bax and Bak are thought to undergo a
conformational change after they have interacted with tBid. In the cytosol, where Bax is
normally found, the protein exists as a monomer. However, upon activation by tBid,
Bim or by BH3 domains of BH3-only proteins, Bax changes conformation, translocates
and inserts itself into the outer mitochondrial membrane. After induction by similar
proteins, Bax can homo-oligomerise to form a complex that creates a large pore-forming
channel (Fig 1.8). A model that has been proposed is that BcI-xl may bind to Bax in
order to prevent Bax proteins from entering the mitochondrial membrane and thereby











Fig 1.8. Possible mechanism of cytochrome c release during apoptosis. The pro-
apoptotic Bcl-2 member, Bid is cleaved to, tBid. tBid can interact with Bax and Bak to
change their conformation. Bax translocates from the cytosol to the mitochondrial
membrane where it oligomerises and inserts into the membrane to form a pore to allow
the release of cytochrome c. Anti-apoptotic members such as Bc!-xL can prevent this
translocation by binding to the BH3 domain of pro-apoptotic proteins.
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A second theory is that the opening of the permeability transition pore (PTP)
allows the release of cytochrome c. The PTP is a large multi-protein complex that can
form a large channel between the cytosol and the mitochondrial matrix. The PTP is
comprised of the voltage dependent anion channel (VDAC) (found in the outer
membrane), the adenine nucleotide translocator (ANT) (found in the inner membrane),
creatine kinase, hexokinase and cyclophilin D. Voltage, matrix pH, oxidative stress,
electron flow, cylophilin D and ANT can regulate the opening of the pore (Gottlieb,
2000). The outer membrane is permeable to solutes of up to 5kDa, allowing the
exchange of respiratory chain substrates between the intermembrane space and the
cytosol. Inner membrane impermeability is essential for the maintenance of the
electrochemical potential (Van Loo et al, 2002). This model proposes that Bax can
interact with the VDAC and the ANT to form a large hybrid channel (fig 1.9). Using
isolated mitochondria and recombinant Bcl-2 family members it was also shown that the
VDAC channel is a target for the Bcl-2 family members. Bcl-xL closes the VDAC
channel in liposomes while pro-apoptotic proteins such as Bax and Bak can open the
VDAC channel to allow the passage of cytochrome c (Tsujimoto & Shimizu, 2000).
Recent experiments using co-immunopreciptation have shown that Bcl-xi. and VDAC
interact. Other work showed that the BH4 domain of both Bcl-2 and BcI-xl was able to
inhibit VDAC-dependent cytochrome c release (Harris & Thompson, 2000).
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Fig 1.9. Possible mechanisms of cytochrome c release during apoptosis. The pro-
apoptotic Bcl-2 member Bax can translocate to the mitochondria where it can open the
voltage dependent anion channel to allow the release of cytochrome c by binding the
voltage dependent anion channel. Bcl-xL can also bind to the voltage dependent anion
channel and prevent it from opening.
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1.6.4. After the release of cytochrome c
Once cytochrome c has been released it exerts its effects by acting as a co-factor
for the assembly of a large caspase-activating complex in the cytosol called the
apoptosome. The apoptosome was discovered by Wang and colleagues through a cell-
free system that was based on cytosolic extracts in HeLa cells (Liu et al., 1996).
Once cytochrome c has been released from the mitochondria it binds to Apaf-1.
Apaf-1 is a cytosolic protein that contains a caspase-recruitment domain (CARD), a
nucleotide-binding domain (a similar domain that is found in the C. elegans protein
CED-4) andmultiple WD-40 repeats (Zou et al., 1997). Apaf-1 binds to dATP, which
triggers oligomerisation to form the apoptosome. The apoptosome complex is a wheel¬
like structure consisting of a central hub, connected to seven radial spokes. It is
predicted to be composed of seven Apaf-1 CARD domains. The nucleotide-binding
domain promotes oligomerisation and also forms spokes projecting outwards from the
hub, connecting the core of the apoptosome to the Y-shaped tail formed by a bundle of
WD-40 repeats (Acehan et al., 2002).
The CARD domain ofApaf-1 becomes exposed in the apoptosome, this results
in the recruitment of procaspase-9 to the complex. The recruitment of procaspase-9
initiates the auto activation of pro-caspase 9 to caspase 9. Only activated caspase-9 has
the ability to efficiently cleave and activate downstream executioner caspases such as
caspase-3 and -7 (Slee et al., 1999). Upon activation caspase-3 then processes and
activates caspases-2 and -6 followed by the activation of caspases-8 and 10 (by caspase-
6) (Braton et al., 2001).
Simultaneous with cytochrome c release Smac/Diablo, a 25kDa mitochondrial
protein is also released from mitochondria into the cytosol during apoptosis. Upon
import into the mitochondria a 55 amino acid mitochondrial targeting sequence is
removed to produce a mature Smac molecule. The first four amino acid of the mature
Smac molecule binds to BIR (baculovirus IAP (inhibitor of apoptosis protein)) (Du et
al., 2000). The IAP family are a group of intracellular proteins that contain BIR
domains that inhibit active caspases (Chai et al., 2000). Therefore when cytochrome c
and Smac are released from the mitochondria, cytochrome c binds to Apaf-1, however,
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this pathway can be terminated when IAPs bind and inhibit activated caspases.
Therefore, Smac binds IAPs preventing this pathway from occurring (Braton et al.,
2001).
1.6.5. Viral bcl-2 homologues
The Bcl-2 family of proteins play an important role in apoptosis. Viruses have
evolved Bcl-2 homologues to help evade the host immune response. The first viral Bcl-
2 homologue was identified in cells which had been infected with adenovirus. The viral
protein E1B 19K was required to prevent the destruction of the host cell and viral DNA
and also enhanced the cytopathic effects during productive virus infection (Pilder et al.,
1984). Since this discovery, a number of viruses that have been sequenced have been
found to possess at least one Bcl-2 homologue. In all of the gammaherpesvimses that
have been sequenced a Bcl-2 homologue is present.
From the sequences of the viral Bcl-2 homologues it would appear that none of
these possess the unstructured loop that is present in both cellular Bcl-2 and Bc1-xl.
However, they do contain a hydrophobic region within the carboxy terminus of the
protein. It is thought that intracellular membrane localisation is mediated by this
hydrophobic region (Cheng et al., 1997). It would appear that the gammaherpesviruses
have hijacked cellular Bcl-2 homologues in order to play an important role in the virus
life cycle.
HHV-8 possesses a Bcl-2 homologue which protects against Sindbis virus-
induced apoptosis. The gene product was found to possess amino acid sequence
homology within two BH domains BH1 and BH2, but overall it only shares around 15-
20% sequence similarity with other Bcl-2 family members (Cheng et al., 1997). The
gene contains the "NGWR" sequence that has been shown to be important for the
prevention of apoptosis and heterodimerisation with other Bcl-2 family members (Yin et
al., 1994). The conserved caspase cleavage site present in human Bcl-2 is absent in the
viral protein. The protein also lacks the unstructured loop that can be seen in cellular
Bcl-2 proteins (Huang et al., 2002). The KSHV Bcl-2 protein localises to organelle
membranes in the same way as human Bcl-2, i.e. mainly the mitochondrial membrane,
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but it can also be found in the ER and golgi apparatus (Sarid et al., 1997). This protein
can prevent early apoptotic cell death in cells that are infected with the virus and may
also be involved in the development and growth of transformed cells in concert with the
human Bcl-2 protein (Widmer et al., 2002).
The MHV-68 Bcl-2 homologue, encoded by ORF Ml 1, protects cells such as
murine epithelial, HeLa and BHK cells from TNF-a induced apoptosis (Wang et al.,
1999; Bellows et al., 2000; Roy et al., 2000). Investigations carried out by Gangappa
and co-workers (2002) demonstrated that theMil gene was required for reactivation
from latency. Using a Ml 1 deficient vims establishment of latency did not require the
vims Bcl-2 homologue, nor was it required for replication during an acute infection
(Gangappa et al., 2002).
EBV possesses two bcl-2 homologues, BHRF1 (BamHl rightward reading
frame) and BALF1 (BamHl 'A' fragment leftward reading frame 1). The first to be
described was BHRF1 (Khanim et al., 1997). It was found to contain both BH1 and
BH2 domains, which as previously stated bind to pro-apoptotic proteins to inhibit
apoptosis. The BHRF1 product encodes a 17kDa protein that protects against
chemotherapeutic dmgs- and gamma radiation-induced apoptosis (McCarthy et al.,
1996; Khanim et al., 1997; Dawson et al., 1998) and is also expressed as an early lytic
gene (Bellows et al., 2002). It has been suggested that BHRF1 may function to increase
the life span of the cells undergoing viral replication (Marshall et al., 1999). The
second Bcl-2 homologue found in EBV was BALF1, which has the BH1 and BH2
domains and is expressed early during the lytic phase of the viral life cycle. However,
Bellows and co-workers (2002) showed that BALF1 failed to protect cells against
Sindbis vims-induced apoptosis. Using co-immunoprecipitation studies it was found
that the BALF1 product directly bound to the BHRF1 product and KSHV Bcl-2 to
inactivate their anti-apoptotic function (Bellows et al., 2002). The protein has been
found to localise at the mitochondria membrane, as with cellular Bcl-2 proteins (Hickish
et al., 1994). Both BHRF1 and BALF1 were dispensable for efficient B-cell
immortalization when deleted from the vims genome as individual knockouts.
However, when deleted as a double knockout the EBV mutants are unable to
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immortalize B-cells. The conclusion was that the viral Bcl-2 proteins protected infected
cells until latency was established (Altmann & Hammerschmidt, 2003).
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1.7. Thesis Objectives and strategies
A1HV-1 expresses eleven conserved herpesvirus genes that are not seen in other
herpesviruses. Some may be homologues of cellular proteins that the virus has
'adopted' to allow itself to establish a life cycle and remain persistent in the host. The
detailed mechanism underlying the pathogenesis ofA1HV-1 still remains unknown and
it is thought that these conserved genes that are found in A1HV-1 are involved in the
unique pathogenesis of the disease. The overall aim of this study was to characterise the
A9 gene that is present in A1HV-1 to determine if it functions as an anti-apoptotic
effector, and if so, determine the mechanism the virus uses to evade the host apoptotic
response.
Specific objectives:
The main objectives of this study were:
• To determine if the Bcl-2 protein present in A1HV-1 was anti-apoptotic.
• To determine where in the cell viral Bcl-2 localised.
• To determine when in the virus life cycle the A9 gene was expressed.
• To detect and characterise cellular or viral binding partners for the viral
A9 Bcl-2 protein.





2.1 Animals and viruses
2.1.1 Animals
2.1.1.1 Mice
Female BALB/c mice, 2-3 months of age were used for the preparation of
monoclonal antibodies. Mice were group-housed and supplied with proprietary food
and water ad libitum.
2.1.1.2 Rabbits
Specific pathogen-free 3-12 month old New Zealand white rabbits (Harlan, UK)
of either sex were used for the preparation of polyclonal antibodies and in the production
of large granular lymphocytes (LGL). Rabbits were housed in individual cages and
supplied with proprietary food and water ad libitum.
2.1.2 Viruses
The WC11 strain ofA1HV-1, first isolated from a blue wildebeest, has been
extensively passaged in culture and is a cell-free, attenuated virus (Plowright et al.,
1960; Plowright, 1968; Wright et al., 2003). The C500 strain of A1HV-1 was first
isolated from an infected ox (Plowright et al., 1975; Wright et al., 2003). The virus is
mainly cell-associated and virulent when cultured in bovine turbinate (BT) cells for a
short time (i.e. up to passage number 5) thereafter becoming cell-free and attenuated (i.e.
does not cause disease when inoculated into rabbits or cattle).
2.1.3 Inoculation of rabbits with AIHV-1 virus
Rabbits were inoculated intravenously with the virulent C500 low passage cell-
associated strain of AIHV-1. Approximately 3 x 106 (in 1ml) of C500 low passage
AIHV-1-infected BT cells were used to inoculate rabbits. The rectal temperature was
recorded each day and the animals euthanased after 2 days of febrile response (>40°C).
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Rabbit spleen, mesenteric and popliteal lymph nodes were removed aseptically from
infected rabbits for further study. LGL cell lines were established from these tissues as
described in section 2.2.1.
2.2 Cell Culture
2.2.1 Preparation of large granular lymphocyte (LGL) cell lines
Rabbit spleen, mesenteric and popliteal lymph nodes were removed aseptically
from infected rabbits after 2 days of febrile response. The tissue was chopped finely
with scissors in the presence of Iscove's modification of Dulbecco's medium (IMDM)
(Gibco, BRL) supplemented with 10% (v/v) foetal bovine serum (FBS), 200U/ml
penicillin, 200pl/ml streptomycin and 350U/ml recombinant human interleukin-2 (hrlL-
2) (Chiron UK Ltd). Cell suspensions were passed through stainless steel sieves and set
up in 25cm2 flasks (Costar UK Ltd) and maintained as described in section 2.2.2. The
LGL cell line used in this study was BJ2590.
2.2.2 Cell maintenance
Maintenance ofMCF LGL cell lines was based on methods previously
determined by Reid et al., 1989. Briefly, all MCF LGL cell lines were grown in 25cm2
flasks and maintained in IMDM containing 350U/ml ofhrIL-2 for optimum growth.
Half of the medium was replaced with fresh medium containing fresh IL-2 once a week.
Chinese hamster ovary (CHO) fibroblast cells were maintained in Glasgow's
modified Eagles medium (GMEM) (Sigma) containing ImM sodium pyruvate (Gibco
BRL), lOOpM non-essential amino acids (Gibco BRL), G + A (0.74pM 1-glutamic acid
and 0.9pM 1-asparagine) and nucleosides (26pM adenosine, 24pM guanosine, 28pM
cytidine, 28pM uridine, lOpM thymidine) supplemented with 7.5% (v/v) heat-
inactivated foetal bovine serum (FBS). CHO cells that had been transfected with the
pEE14 constructs (see section 3.2.16) were maintained in glutamine-free GMEM
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supplemented with 7.5% (v/v) heat inactivated dialysed FBS (dFBS) and 25pM
methionine sulfoxamine (MSX).
pEE14 contains a glutamine synthetase gene that confers on transfected CHO
cells resistance to MSX. CHO cells transfected with pEE14 were maintained in GMEM
containing no glutamine and MSX selection was applied to select for pEE14-transfected
CHO cells.
CHO cells that had been transfected with pZome-C or pZome-PGK-C constructs
(see section 2.6.1.2) were maintained in GMEM supplemented with 7.5% (v/v) FBS, 2%
(v/v) glutamine and puromycin. These vectors contain a puromycin resistance gene that
is only expressed in transfected cells. Therefore, maintaining these cells with puromycin
pressure selects for puromycin-resistant transfected cells. After carrying out titration
experiments, the optimum concentration of puromycin was 6p.g/ml. Cells were
incubated in 25cm2, 75cm2 or 225cm2 flasks (Costar UK Ltd) in a humidified
atmosphere of 5% CO2 in air at 37°C.
Bovine turbinate (BT) cells were maintained in IMDM supplemented with 10%
heat-inactivated FBS. Cells were passaged twice a week.
2.2.3 Cell passage
For adherent cell lines, medium was removed from the flask and cells washed
twice with warm (37°C) PBS. Cells were removed from the flasks using trypsin
(0.25%)/versene (0.02%) incubated at 37°C, in a humidified atmosphere of 5% CO2 in
air for 2 mins. The flask was gently tapped to remove any bound cells and a small
volume of medium containing FBS was added to neutralise the trypsin. Cells were
passaged twice a week and maintained with the selective pressure where appropriate
(see section 2.2.2).
2.2.4 Cryopreservation
Cells were grown in 225cm cell culture flasks until near confluent. They were
pelleted by centrifugation at 254 x g for 5 mins. Cell pellets were resuspended in growth
medium, supplemented with 50% (v/v) FBS and 10% (v/v) dimethyl sulphoxide
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(DMSO) to give a concentration of 5 x 106 cells/ml. The suspension was transferred
into a cryotube (Nunc Inc.) and then placed in a Cryo freezing container (Nalge Nunc
International) to provide reproducible, slow cooling. The container was stored at -70°C
for 24 hrs and tubes were transferred to a liquid nitrogen tank for storage until required.
Cells removed from frozen storage were thawed rapidly in a 37°C water bath and
the suspension diluted in 10ml ofwarm culture medium. Cells were washed and
centrifuged at 254 x g for 5 mins. The cell pellet was resuspended in 20ml of culture
medium and set up in a 162cm2 flask (Costar Ltd, UK).
2.2.5 Determination of cell morphology by Leishman's staining
Cell suspensions, 200pl, at a density of 1 x 106 cells/ml, were centrifuged, using
a cytospin 3 machine (Shandon), onto slides and the cell morphology was revealed using
Leishman's stain (BDH Laboratory Supplies, UK). Slides were incubated in undiluted
Leishman's stain for 2 mins followed by an incubation of 10 mins with Leishman's stain
diluted 1:2 with tap water. Cells were rinsed with water, allowed to dry and mounted
with Shandon mounting media (Thermo Shandon Ltd). Cells were then examined by
light microscopy using a BH-2 Olympus microscope (Olympus).
2.2.6 Determination of cell growth and viability
A 50pl sample of cells was mixed with an equal volume of 0.1% (w/v) nigrosine
(Merck Ltd), 2% (v/v) FBS in water. Dead cells were identified by the entry of
nigrosine into the cells, whereas live cells excluded the dye. Live and dead cells were
counted in a haemocytometer. The density of live cells and percentage viability (i.e.
[number of live cells / (number of live + dead cells)] x 100) were calculated.
2.2.7 Stable and transient transfection of genes and cDNAs into cells
DNA-mediated gene/cDNA transfer (transfections) into cells was carried out
using lipofectamine (Invitrogen). This allows for functional and protein analyses to be
carried out on the transfected cells expressing recombinant protein. Stable transfections
were carried out to create long-term selected cell lines, whereas transient transfections
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were carried out to provide a rapid expression system. Lipofectamine™ 2000 reagent is
a cationic lipid that provides high transfection efficiency and protein expression levels.
The protocol used was as described by the manufacturer (Invitrogen). The day before a
stable transfection, CHO cells were seeded in a 6 well plate (Costar UK Ltd) at a
concentration of 2 x 105 cells/ml with 2ml of cell suspension added to each well. In the
case of transient transfections cells were set up in 8 well chamber slides (Lab-Tek) at a
concentration of 1 x 105 cells/ml with 200pl of cell suspension added into each well.
Cells were incubated at 37°C, in a 5% CCL in air atmosphere and allowed to grow to
approximately 90% confluency. Purified plasmid DNA (2jag for stable transfections and
0.2pg for transient transfections), containing the gene to be expressed, was diluted in
250pl or 50pl ofGMEM (Sigma) (containing no serum or antibiotics) for stable and
transient transfections respectively. This was mixed briefly by pipetting. Lipofectamine
(4pl or 0.4pl of stock suspension) was diluted in 250j.fi or 50pl GMEM containing
neither serum nor antibiotics. Both mixtures were incubated separately at room
temperature for 5 mins. The diluted lipofectamine and diluted DNA were then mixed
together and incubated at room temperature for 20 mins. The lipofectamine-DNA
complex (500pl or lOOpl total volume) was then added to CHO cells and mixed by
gently rocking the plate. Cells were incubated at 37°C, in a humidified atmosphere of
5% CO2 in air for 24 hr. Thereafter, for stable transfections CHO cells were passaged
1:10 and were continuously maintained in medium with the appropriate selective
pressure to maintain expression of the gene of interest. Transient transfected CHO cells
were incubated at 37°C and 5% CO2 for 24-72 hrs to allow for gene expression without
selection.
2.2.8 Preparation of cell lysates
CHO cells (approximately 107) were washed in situ twice with warm PBS and
then removed from the flasks by scraping with a cell-scraper (Costar UK Ltd). Cells
were removed from the flasks and pelleted by centrifugation at 254 x g for 5 mins.
Supemates were removed, and 1ml cold lysis buffer (1% (v/v) Triton X-100 or 1% (v/v)
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NP-40, 20mM Tris pH7.2, 150mM NaCl) containing protease inhibitors (0.02mg/ml
pancreas-extract inhibitor, 0.02mg/ml chymotrypsin inhibitor, 0.0005mg/ml
metalloprotease inhibitor, 0.002mg/ml trypsin inhibitor, 0.33mg/ml papain inhibitor
were used in the form of a Complete™ protease inhibitor tablet, (Roche)) was added to
cell pellets and mixed by vortexing for 10 sees. Lysates were incubated on ice for 20
mins, passed through a 26G needle and returned to ice for a further 20 mins. Cellular
debris was removed from lysates by centrifugation at 17,900 x g for 15 mins.
2.2.9 Immunostaining of cells
Cells were seeded at a density of 1 x 105 cells/ml in 8 well chamber slides (Lab-
Tek) with 200pl of the cell suspension into each well and incubated at 37°C, 5% CO2 in
air for 48 hrs. Cells were washed with warm PBS and fixed by immersion in ice cold
acetone or 1% (w/v) paraformaldehyde in PBS for 10 mins. Cells were washed in PBS
then placed into a moist box and blocked with 50pl of normal goat serum (DAKO)
(1:40), donkey serum (1:10) or normal swine serum (1:10) (the serum used was from the
species of animal that the secondary antibody was raised in) for 1 hr at 37°C to prevent
non-specific binding. Cells were then washed twice with PBS for 5 mins each time and
then incubated with the primary antibody in PBS for 1 hr at 37°C (antibodies used and
concentrations are shown in table 2.1). Controls were incubated for 1 hr at 37°C in PBS
with normal serum (DAKO) (1:1000). Cells were washed twice in PBS for 5 mins
before incubation with a secondary conjugate (see table 2.1) for lhr at 37°C. Cells were
washed twice with PBS for 5 mins each time and if necessary were incubated in tertiary
conjugate (see table 2.1) at 37°C for lhr. Cells were washed with PBS, air dried and
mounted using Mowiol (Mowiol 4-88 (Sigma), 30% (v/v) Glycerol, 0.2M Tris pH8.5,
2.5% (w/v) DABCO (Sigma)) mounting media. After labelling, the cells were examined
using an Olympus BX50 microscope (Olympus) using a blue (NB) filter (to examine
FITC conjugates) at 470-490nm or using a green (NG) filter (to examine TRITC
conjugates) at 530-550nm.
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Antigen Primary* Secondary Tertiary




























Table 2.1 Antibodies and conjugates used in immunostaining. Dilutions used and
suppliers are shown. FITC= Fluorescine isothiocyanate. TRITC= tetramethyl
rhodamine isothiocyanate. * See section 2.7 for description of the preparation of the
different antibodies.
2.2.10 Confocal Microscopy
Confocal microscopy was used to analyse the cellular location of the A9 protein.
Cells were prepared and fluorescently stained as described in section 2.2.9. Fluorescent
images were acquired using an MRC-600 confocal laser scanning microscope (CLSM:
Bio-Rad Laboratories) mounted on an Axiovert 100 inverted microscope equipped with
Plan-Apochromat® objective lenses (Carl Zeiss). Fluorophores were excited
sequentially using the 488 nm (FITC) and 568 nm (Rhodamine) lines from a 15 mW
Kr/Ar laser (Bio-Rad Laboratories).
71
2.3 Molecular Biology Techniques
2.3.1 Digestion of DNA with Restriction Enzymes
Restriction enzymes were obtained from Invitrogen, New England Biolabs,
Promega or Roche and were used with the supplied buffers according to the
manufacturer's instructions. Restriction enzyme digests were typically carried out for 2
hrs at 37°C in a 20-200pl volume, using 10 units enzyme per 1-1Opg ofDNA. Digestion
was analysed using agarose gel electrophoresis (as described in section 2.3.13).
2.3.2 Ligation of DNA
Ligation ofDNA was performed using T4 DNA ligase (Roche). Ligation
reactions were set up in a total volume of 20pl containing lOOng of linearised plasmid
DNA and varying amounts of insert DNA depending on size, such that the molar ratio of
plasmid to insert DNA was 1:4. The reactions contained 2pl of 10 x DNA ligase buffer
(660mM Tris/HCl, 50mM MgCE, lOmM ATP, pH 7.5) and 2 units ofT4 ligase. All
ligation experiments included negative controls whereby insert DNA was omitted from
the reaction in order to check for self-ligation of the plasmid. Ligation reactions were
performed overnight at 4°C.
2.3.3 TA Cloning using pGEM-T Easy Vector
PGR products were cloned into pGEM-T Easy TA cloning vector (Promega) according
to the manufacturer's instructions. A ligation reaction was set up in a total volume of
lOpl to contain; 1 x Rapid Ligation Buffer, 50ng pGEM-T Easy Vector, 3pl PCR
product and 6 Weiss units T4 DNA ligase. The reaction was incubated at room
temperature for 1 hr and a 2pl aliquot used to transform E. coli JM109 strain. After
transformation, bacteria were plated out onto LB-Amp plates to which lOOpl per plate
(0.1M stock) isopropyl-p-D-thiogalactopyranoside (IPTG) and 20pl per plate (50mg/ml
stock) 5-bromo-4-chloro-3-indolyl-P-D-galactopyranoside (X-Gal) had been added.
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2.3.4 Preparation of competent E. coli
JM109 competent cells were used for the transformation of plasmid DNA by
heat shock. The bacteria were grown in sterilised Luria-Bertani (LB) medium
(Sambrook et al., 1989) with the addition of appropriate antibiotics. Agar plates were
made with 15g/l bacteriological agar (ICN Biochemicals) in LB medium.
An aliquot, 1Opl, of frozen E. coli cells stocks were streaked onto LB plates
containing 50pg/ml ampicillin and incubated at 37°C overnight. A bacterial colony was
picked with an inoculating loop and grown in 10ml of LB broth containing 50pg/ml
ampicillin in an orbital shaker (HT, Infors, AG) at 37°C overnight. An aliquot, 2.5ml, of
overnight culture was added to 500ml of LB broth containing 50pg/ml ampicillin and
incubated in an orbital shaker at 37°C until the O.Deoo was 0.2. Bacteria were pelleted
by centrifugation at 4000 x g for 10 mins at 4°C. The bacterial pellet was resuspended
in 250ml of ice-cold sterile 0.1M calcium chloride (CaCl2) and left on ice for 20 mins.
The mixture was centrifuged at 4000 x g for 10 mins at 4°C, and the pellet was
resuspended in 5-20ml of CaCl2. Sterile glycerol was added to a final concentration of
10% and the cells were split into 0.5ml aliquots and stored at -70°C until required.
2.3.5 Transformation of competent E. coli with plasmid DNA
E. coli strain JM109 was used as a standard strain for the expression of high
yields of recombinant proteins except that strain GI724 was used for vector pTRXFUS
(Invitrogen). A 50pl aliquot of competent bacterial cells GI724 or JM109 as required
was thawed on ice. The ligation reaction or purified plasmid DNA (approximately 50ng
total DNA) was added and the mixture was held on ice for 30 mins, after which it was
heat-shocked at 42°C for 2 mins. Transformed GI724 cells were spread on low
tryptophan RMG-agar (16.7mM Na2HP04, 22mM KH2P04, 8.5mM NaCl, 18.7mM
NH4C1, ImM MgCl2, 2.0 % (w/v) Casamino acids, 1.5% (w/v) agar) (Invitrogen) plates
containing 100pg/ml ampicillin and 0.5% (w/v) glucose then incubated at 30°C
overnight to inhibit tryptophan-induced protein expression. Transformed JM109 cells
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were spread on LB plates containing 100p.g/ml ampicillin and incubated at 37°C
overnight.
2.3.6 Selection and growth of ampicillin resistant colonies
Single ampicillin-resistant colonies were inoculated into 1ml RM medium
(16.7mM Na2HP04, 22mM KH2P04, 8.5mM NaCl, 18.7mM NH4C1, ImM MgCl2, 0.2%
(w/v) Casamino acids) (Invitrogen) for GI724 cells, or LB-broth (1% (w/v) Tryptone,
1% (w/v) yeast extract, 0.5% (w/v) NaCl) for JM109 cells containing lOOpg/ml or
50p,g/ml ampicillin respectively. GI724 cells were incubated at 30°C, while JM109 cells
were grown at 37°C. Cells were incubated overnight with constant agitation in an
orbital shaker.
2.3.7 Storing bacterial cultures as glycerol stocks
Glycerol stocks were made by growing E. coli bacterial cultures in LB broth
containing 50pg/ml ampicillin to log phase and adding glycerol to 30% (v/v), before
mixing and storing at -70°C.
2.3.8 Quantification of nucleic acids
DNA and RNA were quantified by spectrometry. Nucleic acid samples were
diluted in distilled water or TE buffer. Using distilled water or TE (lOmM Tris-Cl, pH
7.5, ImM EDTA) buffer as a reference, the OD26o and OD28o were determined using a
Cecil CE 2041, 2000 series spectrophotometer. The nucleic acid concentration was
determined by using the following formula:
OD260 reading x dilution factor x A = pg/ml nucleic acid
(where A = 50 for double stranded DNA and 40 for single stranded RNA)
The purity of the test sample was estimated using the OD 260.280 ratio which gives an
indication of contamination by protein (with peak absorbance at 280nm).
Pure preparations ofDNA and RNA have ratios of 1.8 and 2.0 respectively.
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2.3.9 Small scale preparation of plasmid DNA (mini-preps)
Small scale preparations of plasmid DNA were used for initial characterisation of
cloned DNA fragments. The method used is as described by the manufacturer's
protocol (QIAprep plasmid minipreps, Qiagen). A single bacterial colony was picked
and grown in 10ml of LB broth containing 50pg/ml ampicillin in an orbital shaker at
37°C overnight. Bacterial cells were pelleted by centrifugation at 4000 x g for 10 mins
at room temperature. The pellet was resuspended in 250pl of buffer PI (resuspension
buffer containing RNase) and transferred to a microcentrifuge tube. This was followed
by the addition of 250pl of buffer P2 (lysis buffer) and mixing by inversion of the tube.
Genomic DNA and proteins were precipitated by the addition of 350pl of buffer N3
(neutralising buffer) mixed by inversion and then centrifuged in a microcentrifuge at
17900 x g for 10 mins. The supernatant was transferred into a QIAprep spin column
(Qiagen) and centrifuged at 17900 x g for 30-60 sees. Unbound material was discarded,
the column was washed with 0.5ml ofbuffer PB (to remove trace nuclease activity) and
centrifuged at 17900 x g for 30-60 sees. The column was washed with 0.75ml of buffer
PE (containing ethanol) and centrifuged at 17900 x g for 30-60 sees (to remove residual
wash buffer), unbound material was discarded and the column centrifuged for a further 1
min at 17900 x g. The QIAprep column was placed into a fresh Micro-centrifuge tube
and DNA was eluted by the addition of 50pl of buffer EB (lOmM Tris-Cl pH7.5, ImM
EDTA) and centrifuged for 1 min. DNA was stored at -20°C until required.
2.3.10 Large scale preparation of DNA (Maxi-preps)
The method used was as described by the manufacturer's protocol (Qiagen) an
alkaline lysis followed by ion-exchange chromatography. A single colony of bacteria
was picked using an inoculating loop and grown in 10ml of LB broth containing
50pg/ml or lOOpg/ml ampicillin in an orbital shaker at 37°C overnight. 5ml of the
overnight culture was incubated in 500ml of LB broth overnight. E. coli cells were
pelleted by centrifugation at 6000 x g for 15 mins at 4°C. The pellet was resuspended in
10ml of buffer PI (50mM Tris-Cl, pH 8, lOmM EDTA, lOOg/ml RNase A), 10ml of
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buffer P2 (200mM NaOH, 1% (w/v) SDS) was added and incubated at room
temperature for 5 mins. Chilled buffer P3 (3M potassium acetate pH 5.5), 10ml, was
added, mix by inverting tube and incubated on ice for 20 mins. The solution was
centrifuged at 1380 x g for 10 mins and the supernatant was filtered through 3M filter
paper (Whatman). The QIAgen tip-500 (Qiagen) was equilibrated by applying 10ml of
buffer QBT (750mM NaCl, 50mM 3-N-morpholino propanesulphonic acid (MOPS)
(20mM MOPS, 5mM Sodium acetate pH8.0, ImM EDTA pH8.0) pH7, 15% (v/v)
isopropanol, 0.15% (v/v) Triton X-100) and allowed to empty under gravity flow.
Supernatant was applied to the QIAgen tip and allowed to enter the resin by gravity.
The QIAgen tip was washed twice with 30ml of buffer QC (1M NaCl, 50mM MOPS
pH7, 15% (v/v) isopropanol). DNA was eluted with 15ml of buffer QF (1.25M NaCl,
50mM Tris-Cl pH8.5, 15% (v/v) isopropanol). DNA was precipitated by adding 10.5ml
of isopropanol, mixing and centrifuging at 15300 x g for 30 mins at 4°C. The DNA
pellet was washed with 5ml of 70% (v/v) ethanol and centrifuged at 15000 x g for 10
mins. The supernatant was removed and the DNA pellet was dried gently at room
temperature before resuspending in lOOpl of TE buffer. The DNA was stored at -20°C
until required.
2.3.11 QIAquick Gel Extraction
QIAquick gel extraction was used to purify PCR products prior to cloning. The
protocol used was as described in the manufacturers instructions (QIAquick gel
extraction kit, Qiagen). DNA fragments were excised in the minimum volume from
agarose gels using clean, sharp scalpels. Gel slices were weighed and three volumes of
buffer QG were added to every one volume of gel. The mixture was incubated at 50°C
for 10 mins in order to dissolve the gel pieces. One gel volume of isopropanol was
added to the samples and mixed, the samples were transferred to QIAquick spin columns
(Qiagen). The columns were centrifuged at 17900 x g for 1 min to bind DNA to the
column. Unbound material was discarded and 0.5ml of buffer QG was applied to the
column. The column was centrifuged at 17900 x g for 1 min to remove all traces of
agarose solution. The column was washed using 0.75ml of buffer PE and centrifuged at
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17900 x g for 1 min. Unbound material was discarded and the column was further
centrifuged at 17900 x g for 1 min to remove any residual ethanol from buffer PE. The
column was placed into a fresh microfuge tube and DNA was eluted from the column
with 50pi of buffer EB by centrifugation at 17900 x g for 1 min. Purified DNA was
stored at -20°C until required.
2.3.12 Polymerase chain reaction (PCR)
PCR was used for two purposes in this study: either in the production ofDNA
fragments for cloning or in conjunction with reverse transcription to examine the
expression of A1HV-1 genes. Both procedures were carried out in the same way. PCR
amplification was performed using the Expand™ long template PCR system (Roche).
The reaction was set up in a total volume of 50pl as follows, 0.75pl of Taq DNA
polymerase, 5pl 10 X PCR buffer (Roche buffer 3 containing 22.5mM MgC^, and
detergents, pH 9.2), 0.5pl of each primer at 0.2pmol, 2-4pl of template DNA, 2pl of
lOmM dNTP's and distilled water. A negative control was prepared that included all
components, except that template DNA was replaced with water. The reaction was
gently mixed and a layer ofmineral oil was added to the top of the reaction mixture to
prevent evaporation. PCR was carried out in thin walled 0.5ml Micro-centrifuge tubes
in a Hybaid Omingene thermal cycler (Hybaid Ltd). All primers used in this study are
shown in appendix 2.1.
PCR reactions involved one cycle of denaturation at 93°C for 2 mins. A further
10 cycles consisting of denaturation at 93°C for 20 sees, annealing temperature for 30
sees and elongation stage at 68°C for 2 mins. The next 25 cycles involved the same
conditions for denaturation and annealing and an elongation step of 5 mins. A final
cycle involved the same conditions for denaturation and annealing followed by an
elongation step of 7 mins.
Annealing temperatures varied depending on the PCR primers used. All primers
were obtained from MWG-Biotech. Annealing temperatures were calculated using the
following formula:
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[(Number of Gs + Cs) x 4] + [(Number ofAs + Ts) x 2] = annealing temperature (Suggs
et al., 1981), (where G = guanine; C = cytosine; A = adenine; T = thymine). If a
restriction endonuclease recognition site was incorporated in the oligonucleotide primer,
its sequence was not used in the above equation.
2.3.13 Agarose gel electrophoresis of DNA
DNA fragments were analysed using conventional agarose gel electrophoresis.
Agarose concentration varied between 0.5-2% (w/v) depending on size ofDNA
fragment, electrophoresis buffer used was 1 X TBE (45mM Tris/borate, ImM EDTA
pH7.3). Electrophoresis was generally carried out at 100V for 30-45 mins. Ethidium
bromide was added to a final concentration of 0.5pg/ml and DNA was visualised by
fluorescence under UV illumination. A record was obtained by photographing the gels
using the Imagemaster® VDS (Pharmacia Biotech). The sizes ofDNA fragments were
determined by comparison with known standards (lkb DNA markers, Promega).
2.3.14 Agarose gel electrophoresis including crystal violet
Crystal violet allows the viewing ofDNA fragments by white light instead of
UV, reducing DNA damage thus increasing the chances of successful cloning (Hartman,
1991). Agarose (1% w/v) was dissolved in 1 x TAE (40mM Tris acetate, ImM EDTA
pH 7.2). Before pouring the gel, crystal violet (Sigma) was added to a final
concentration of 0.8pg/ml. The same concentration was also used in the TAE running
buffer. Electrophoresis was carried out at 100V for 30-45 mins. DNA fragments were
viewed on a white light box (Artwork Light box 2418), DNA bands were extracted from




RNA analysis was used to determine when in the productive phase of the virus life cycle
various genes were expressed or to determine if the gene was being expressed.
2.4.1 Extraction of total cellular RNA
Control (non-infected) and A1HV-1-infected BT cells were pelleted and media
removed. Cells (approximately 1 x 107 cells) were homogenised in 10ml ofRNA
extraction buffer (4M guanidinium isothiocyanate, 25mM sodium citrate pH 7.0, 0.5%
(w/v) sarcosyl, 0.72% (v/v) P-ME). The lysates were incubated at room temperature
with agitation on a Rotatest shaker (Luckham) for 20 mins and then stored at -20°C until
required. The lysates were transferred to a 50ml tube (Falcon) and 0.1 volumes of 3M
sodium acetate pH 4.8, was added followed by 1 volume of water-saturated phenol and
0.2 volumes of chloroform. The mixture was vortexed, incubated for 5 mins at room
temperature and then incubated on ice for 10 mins. The solution was centrifuged at
9800 x g for 30 mins. The upper phase (aqueous layer) was transferred to a fresh tube
and 1 volume of isopropanol was added, the mixture was stored at -20°C overnight.
RNA was pelleted by centrifugation at 7700 x g for 30 mins. The RNA pellet was
resuspended in 0.5ml ofRNA extraction buffer, 0.5ml of isopropanol was added and the
samples were centrifuged at 17900 x g (Microcentrifuge 113, Sigma) for 10 mins. The
pellet was washed with 0.5ml of 70% (v/v) ethanol, vortexed, centrifuged at 17900 x g
for 10 mins. Samples were resuspended in lOOpl of sterile distilled water and stored at
-20°C until required.
2.4.2 Northern blotting
RNA was analysed using agarose gel electrophoresis. Gels contained agarose
(1% (w/v)) and 5% (v/v) formaldehyde in MOPS (electrophoresis buffer).
Electrophoresis was carried out at 100V for 30-60 mins. RNA was visualised by
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ethidium bromide fluorescence under UV illumination. A record was obtained by
photographing gels using the ImageMaster® VDS (Amersham Pharmacia).
The MOPS/formaldehyde gel was washed twice for 20 mins in 10 x standard
saline citrate (SSC) (1.5 NaCl, 0.15M tri-Sodium citrate) with agitation on a Rotatest
shaker (Luckham). RNA was transferred to a nylon membrane (Hybond N, Amersham
Pharmacia) by capillary transfer. The gel and membrane were sandwiched between
several sheets of 3mm filter paper (Whatman) and topped with a paper towel stack with
a weight on top which was placed on a bridge of three sheets of 3mm filter paper
(Whatman) with 10 x SSC and incubated overnight. RNA was fixed to the membrane
after drying at room temperature by UV cross-linking using a Hybaid cross-linker
(Hybaid) for 1 min according to manufacturers instructions. Membranes were stored at
room temperature wrapped in Saran wrap and stored in dark until required or used in
hybridisation.
For probe labelling, DNA was diluted to a concentration of 2.5-25ng in 45pl of
TE buffer. DNA was denatured by heating to 95-100°C for 5 mins in a boiling water
bath, cooled on ice for 5 mins and centrifuged at 17900 x g for 30 sees. Denatured DNA
was transferred to a Rediprime reaction tube (Amersham Bioscience) and 5j.il of
'X')
Redivue [ PjdCTP (Amersham Pharmacia) was added to the Rediprime reaction tube
and thoroughly mixed by pipetting until a colour change was observed. The labelling
reaction was incubated at 37°C for 2 hrs, heated to 95-100°C for 5 mins and then cooled
immediately on ice for 5 mins. The northern blot membrane was washed in 2 x SSC for
5 mins at room temperature. The probe was then added to sufficient 'rapid-hyb' buffer
(10-20ml)(Amersham Biosciences) to cover the northern blot membrane and hybridised
overnight in a hybridisation oven at 65°C.
After hybridisation, unbound probed and non-specifically bound probe were
removed by washing the membrane twice in 2 x SSC containing 0.2% (v/v) SDS for 5
mins at room temperature, then a further wash at 65°C for 2 hrs. The membrane was
then wrapped in Saran wrap and exposed to X-ray film (Kodak X-Omat AR, Sigma) at
-70°C overnight.
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2.4.3 Reverse transcription polymerase chain reaction (RT-PCR)
RT-PCR was used to produce cDNA to examine the expression of genes. RT-
PCR was carried out as described by the manufacturers protocol (RETROscript Kit,
Ambion). A reaction containing lpg total cellular RNA and 2pl (1.25pM) Random
decamers was made up to 12pl with sterile nuclease-free water and mixed briefly,
centrifuged at 17900 x g for 30 sees and heated at 75°C for 3 mins. Samples were
'pulse-centrifuged' and placed on ice and the following components were added; lOpl
10 X RT Buffer (500mM Tris-HCl, pH 8.3, 750mM KC1, 30mM MgCl2, 50mM
dithiotreitol (DTT)), 4pl dNTP (2.5mM each dNTP) mix, lpl RNase inhibitor, lpl
reverse transcriptase (RETROscript Kit, Ambion). The components were mixed,
centrifuged at 17900 x g for 30 sees, incubated at 42°C for 1 hr, and then at 92°C for 10
mins. Samples were then ready to be used for PCR amplification (as described in
section 2.3.12) or stored at -20°C until required.
2.5 Protein Analysis
2.5.1 Sodium dodecylsulphate - polyacrylamide gel electrophoresis (SDS-
PAGE)
The separation of proteins was performed by discontinuous polyacrylamide gel
electrophoresis under reducing conditions using the method described by Laemmli
(1970) in the Mini Protean II system (Biorad). Samples were boiled in an equal volume
of reducing Laemmli sample buffer (lOOmM Tris pH6.8, 200mM DTT, 4% (w/v) SDS,
0.2% (v/v) bromophenol blue, 20% (v/v) glycerol) prior to loading onto gels. Proteins
were separated on 10%, 12%, or 15% (depending on the molecular weight range to be
separated) acrylamide gels made up in separating gel buffer (0.375M Tris-HCl pH 8.8,
1% (w/v) SDS, 0.1% (v/v) tetramethylethylenediamine (TEMED), 0.1% (w/v)
ammonium persulphate (APS)), overlaid with 4% acrylamide made up in stacking buffer
(0.15M Tris-HCl pH 6.8, 0.5% (w/v) SDS, 0.2% (v/v) TEMED, 0.2% (w/v) APS).
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Electrophoresis was carried out at 200V for 45-60 mins in tank buffer (25mM Tris,
192mM Glycine, 0.1% (w/v) SDS).
2.5.2 Protein detection in SDS-PAGE gels
Separated proteins were detected by Coomassie brilliant blue R concentrate
(Sigma Aldrich) or by silver staining.
For Coomassie staining of proteins, gels were incubated in the Coomassie
brilliant blue R concentrate for 1 hr with agitation followed by three washes in destain
(10% (v/v) methanol, 10% (v/v) Glacial acetic acid in water) for 30 mins each wash.
For more sensitive detection, silver staining was used. Firstly, the gels were
fixed in 50% (v/v) methanol, 10% (v/v) glacial acetic acid in water for 20 mins followed
by two washes in 5% (v/v) methanol, 7% (v/v) glacial acetic acid in water for 10 mins
each. After a 10 mins wash in distilled water, proteins were reduced in DTT (5pg/ml in
water) for 15 mins with agitation on a Rotatest shaker (Luckham) and gels were washed
again in distilled water for 10 mins. Gels were stained in 0.1% (w/v) silver nitrate in
water for 20 mins followed by a quick rinse with distilled water. Protein bands were
visualised by incubation with 0.3M sodium carbonate, 0.02% (v/v) formaldehyde in
water for 5-10 mins. The reaction was stopped by the addition an equal volume of 0.1%
(w/v) citric acid in water.
2.5.3 Western blot analysis (immuno-detection of gel-separated proteins)
Gel-separated proteins were electrophoretically-transferred from gels to nitro¬
cellulose membranes (Amersham Pharmacia). The gel and membrane were sandwiched
between several sheets of 3mm filter paper (Whatman) soaked in transfer buffer (25mM
Tris, 200mM Glycine, 5mM SDS) and then placed in a semi-dry blotting apparatus
(Sigma). A tube was rolled over the surface of the filter paper to exclude all air bubbles
from between layers. The transfer of proteins was carried out at 70mA per gel
(2mA/cm of gel) for 1 hr. After transfer, the membrane was blocked with 4% (w/v)
non-fat milk (Marvel) in wash buffer (0.5M NaCl, 0.5% (v/v) Tween 80 in PBS) for 45-
90 mins. The membrane was incubated in primary antibody in wash buffer for 1 hr then
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HRP-conjugated secondary antibody (Dako) in wash buffer for 1 hr at room
temperature. Between blocking, primary and secondary antibody stages, the membrane
was thoroughly washed in wash buffer for at least 20 mins with constant agitation on a
Rotatest shaker (Luckham). After a final wash, bound HRP-antibody-antigen complexes
were detected by treating blots with the enhanced chemiluminescence (ECL) reagent
(Amersham International) according to manufacturer's instructions, and exposure to
Hyperfilm ECL (Amersham International) for 10-60 sec before development.
2.5.4 Measurement of protein concentration
Protein concentrations in samples were determined using the Bicinchoninic acid
(BCA) Protein Assay Reagent Kit (PIERCE) according to the manufacturer's protocol.
The BCA Protein assay reagent kit includes: BCA Reagent A; 500ml, containing sodium
carbonate, sodium bicarbonate, bicinchoninic acid and sodium tartate in 0.1M sodium
hydroxide, BCA reagent B, 25ml containing 4% (w/v) cupric sulphate and albumin
standard, 2mg/ml.
A standard curve was generated using a range of bovine serum albumin (BSA)
concentrations, 0.05-2.0mg/ml, made up in PBS. Each test sample, lOpl in PBS, was
pipetted into duplicate wells of a 96-well flat-bottomed plate (Costar UK Ltd). To each
well 200pl of the working reagent (50 parts BCA reagent A with 1 part BCA reagent B)
was added and the plate was incubated at 37°C for 30 mins. A colour change was
detected by the absorbance at 562nm on a DYNEX MRXII microplate reader (DYNEX).
The protein concentration was calculated using the standard curve of BSA concentration
against O.D.562.
83
2.6 Detecting protein-protein interactions
2.6.1 Tandem affinity purification (TAP)
2.6.1.1 Construction of AIHV-1 and EBV fusion proteins in E. coli
TAP-tagged fusions were made in the pZome-C retroviral vector (Cellzome) (Fig
2.1). An A9 fragment was amplified by PCR (see section 2.3.12) fromAlHV-1 DNA
using PCR primers bclahvF and bclahvR (appendix 2.1). The PCR product was then
cloned into pGEM-T Easy (Promega) (see section 2.3.2). After sequencing to verify
accurate amplification the A9 gene fragment was prepared by digestion with Ncol.
Digested fragments were purified by agarose gel electrophoresis in the presence of
crystal violet (see section 2.3.14) and the Qiaquick gel extraction kit (as described in
section 2.3.11). The purified A9 fragment and Ncol cut pZome-C plasmid DNA were
ligated (as described in section 2.3.2). Clones carrying the A9 fragment in the correct
orientation were digested with BamHl to remove 30bp of residual DNA carried over
from the pGEM-T vector. DNA was sequenced to check that the vector-insert junctions
were correct.
The PGK promoter sequence was amplified by PCR from another vector, pSuper
(Oligoengine), to contain an EcoBl site at the 5' end and a Hindlll site at the 3' end (as
described in section 2.2.12) and was ligated into the pGEM-T Easy vector as described
above. The original SV40 promoter was removed from the pZome vector by digesting
with EcoRl and Hindlll (as described in section 2.3.1) and replaced with the PGK
promoter excised from pGEM-T Easy. The A9 fragment was recloned into the pZome-
PGK-C vector, as described above (Fig 2.2).
Epstein Barr virus Bcl-2 homologue BHRF1 was used as a control in this study.
This Bcl-2 homologue was chosen as it has been shown to bind to Bax and Bak
(Marshall et al., 1999). BHRF1 was amplified by PCR (see section 2.3.12) from EBV
DNA using PCR primers BHRF1F and BHRF1R (appendix 2.1). The PCR product was
cloned into the pGEM-T Easy vector (section 2.3.6). After sequencing to verify
accurate amplification, the BHRF1 gene fragment was prepared by digestion with Ncol.
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The digested fragment was purified as described above and ligated into the pZome-
PGK-C retroviral vector.
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Fig 2.1. Vector pZome-1-C was obtained from Cellzome.
The plasmid directs the synthesis of the TAP-tag protein under the control of the
retroviral LTR promoter. It also contains the ampicillin resistance gene for the selection
of plasmid containing bacterial colonies and the puromycin resistance gene for the
selection of plasmid containing transfected mammalian cells, which is transcribed from
the SV40 promoter. CBP denotes the calmodulin binding protein and TEV denotes the
tobacco etch virus cleavage site.
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Fig 2.2. Vector pZome-PGK-C.
The plasmid directs the synthesis of the TAP-tag protein under the control of the
retroviral LTR promoter. It also contains the ampicillin resistance gene for the
selection of plasmid containing bacterial colonies and the puromycin resistance gene
for the selection of plasmid containing transfected mammalian cells, which is
transcribed from the murine PGK promoter. CBP denotes the calmodulin binding
protein and TEV denotes the tobacco etch virus cleavage site
Has to be used for insertion of cDNA
I





2.6.1.2 Transfection of TAP-tagged fusion DNA into CHO cells
Purified p-Zome-PGK-C vector DNA containing the required insert (2pg) was
stably-transfected into CHO cells using the lipofectamine™ 2000 reagent (as described
in section 2.2.7). The following day, transfected CHO cells were passaged 1:10 and
selected in the presence of puromycin (6pg/ml). In order to purify the TAP-tagged
proteins, transfected CHO cells were grown to high cell density in triple-layer flasks
(TPP) with 6p.g/ml of puromycin added.
2.6.1.3 Harvesting transfected CHO cells
For TAP-tag analysis, 109 to 1010 cells were harvested from triple-layer flasks.
Transfected CHO cells were washed twice with warm (37°C) PBS to remove excess
serum, removed from the flasks using trypsin/versene and incubated at 37°C, 5% CO2 in
air for 2 mins. The flasks were gently tapped to remove any bound cells and the trypsin
was neutralised in 20ml GMEM supplemented with 7.5% (v/v) FBS and 2% (v/v)
glutamine. Cells were pelleted by centrifugation at 1500 x g for 5 mins at 4°C. The
remaining steps were carried out at 4°C unless stated. Pelleted cells were resuspended in
5ml of PBS and centrifuged at 1500 x g for 5 mins. Cells were lysed in 0.5ml of lysis
buffer per 107 cells, (20mM Tris pH 7.5, 0.15M NaCl, Complete® protease inhibitor
tablet (Roche)) frozen, and thawed three times using dry ice. The lysate was centrifuged
at 16000 x g for 10 mins. The supernatant was transferred to a fresh tube and NP-40
added to give a final concentration of 0.1% (v/v). The pellet was resuspended in 1.5ml
of lysis buffer containing 0.1% (v/v) NP-40. This protein pellet was further solubilised
by three freeze- thaw cycles, centrifuged at 17900 x g for 10 mins and both soluble and
pellet-derived fractions were stored at -20°C until required.
2.6.1.4 Purification of TAP-tagged proteins
The protocol was adapted from Cox et al., 2002. IgG sepharose (Amersham
International), 200pl, was transferred to a 0.8 X 4cm disposable Poly-Prep column (Bio-
Rad). The sepharose was washed with 10ml of IPP150 buffer (lOmM Tris-Cl pH 8.0,
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150mM NaCl, 0.1% (v/v) NP-40) and protein lysates were transferred to the column
containing washed beads and rotated for 2 hrs to allow proteins to bind via the Protein A
domains. Unbound proteins were eluted under gravity and the Sepharose washed three
times with 10ml IPP150. The column was then washed with 10ml TEV cleavage buffer
(lOmM Tris-Cl pH 8.0, 150mM NaCl, 0.1% (v/v) NP-40, 0.5mM EDTA, ImM DTT)
and bound TAP-tagged proteins were released from the IgG column by incubation with
lml TEV cleavage buffer containing lOunits of TEV protease (Invitrogen) and rotated
for 2 hrs at room temperature. Proteins were eluted under gravity and mixed with 3ml of
IPP150 calmodulin-binding buffer (lOmM Tris-Cl pH 8.0, lOmM P-mercaptoethanol,
150mM NaCl, ImM magnesium acetate, ImM imidazole, 2mM CaCl2, 0.1% (v/v) NP-
40) with a final CaCE concentration of 3mM. The mixture was added to 200pl of
calmodulin beads (Stratagene) that had been washed with 10ml of IPP150 calmodulin
binding buffer. Protein and calmodulin beads were mixed by rotating at 4°C for 1 hr.
Unbound material was eluted under gravity and the column was washed with 30ml of
IPP150 calmodulin-binding buffer. Bound proteins were eluted in 1ml of IPP150
calmodulin elution buffer (lOmM Tris-Cl pH 8.0, lOmM P-mercaptoethanol, 150mM
NaCl. ImM magnesium acetate, ImM imidazole, 2mM EGTA, 0.1% (v/v) NP-40).
The eluted proteins were concentrated using microcons (Millipore) at 17900 x g
until the samples occupied a total volume of 50pl The concentrated eluted fractions
were stored at -20°C until further analysed (see below).
2.6.2 Identification of protein interactions by immunoprecipitation
Cell lysates (lml) were prepared as described in section 2.2.8, pre-cleared with
0.25pg of normal rabbit serum and 20pl of protein A/G-agarose (Santa-Cruz) to remove
the binding of non-specific proteins and incubated at 4°C for 30 mins. The suspension
was pelleted by centrifugation at 1000 x g for 30 sec, and the supernatant was
transferred to a fresh micro-centrifuge tube. The cell lysate was then incubated with an
appropriate primary antibody for 2 hr at 4°C by rotating. Protein A/G-agarose (20pi)
was added to the suspension and incubated at 4°C overnight. The pellet was collected
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by centrifugation at 1000 x g for 5 mins at 4°C, the supernatant was discarded, and the
pellet washed 3 times with 1ml PBS. The pellet was finally resuspended in 40pl of 2 x
reducing sample buffer and analysed by electrophoresis.
2.7 Anti-A9 Antibody Production
For the production of anti-A9 Bcl-2, a thioredoxin fusion protein was used as an antigen.
E. coli strain GI724 was used to properly regulate expression of the fusion protein. The
bacterial cells were grown in RM medium, then transferred to induction medium.
Protein expression was induced by the addition of tryptophan.
2.7.1 Production of recombinant AIHV-1 A9 protein
2.7.1.1 Expression of recombinant AIHV-1 A9 protein in E. coli
Thioredoxin fusion proteins were prepared in the ThioFusion™ Expression
System (Invitrogen). The vector pTrxFus (Invitrogen) contained the following
restriction sites - Kpnl, Smal, BamRl, Xbal, AccI, SalI, Pstl that could be used to place
the thioredoxin open reading frame upstream of a cloned gene (fig 2.3).
An DNA fragment encoding the A9 gene excluding the transmembrane domain
was amplified by PGR (see section 2.3.12) from AIHV-1 DNA using primers Y4233 and
Y4234 (appendix 2.1). The PCR product and pTrxFus DNA was digested with Kpnl
and Xbal and ligated together (as described in section 2.3.2).
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Fig 2.3. pTrxFus vector was obtained from Invitrogen.
This vector uses the PL promoter from bacteriophage X to drive expression. Expression
is induced by the addition of tryptophan, which shuts down cl repressor synthesis to
allow the transcription from the PL promoter. The vector also contains an ampicillin
resistance gene to aid selection of transformed E. coli.
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2.7.1.2 Induction of protein synthesis
E. coli GI724 transformed with thioredoxin fusion constructs were inoculated
into 10ml RM medium (Invitrogen thiofusion expression system) containing 100pg/ml
ampicillin. An aliquot, 5ml, of overnight culture was added to 100ml of induction
medium (42mM Na2HP04, 22mM KH2PO4, 8.6mM NaCl, 18.7mM NH4CI, 2 % (w/v)
Casamino acids, 8% (w/v) dextrose, lOOpg/ml ampicillin) and incubated in an orbital
shaker for 2/i hrs at 30°C. Thioredoxin fusion protein expression was induced by the
addition of tryptophan to ImM (Sigma) and incubated at 37°C for 2/4 hrs in an orbital
mixer. Cells were centrifuged at 1080 x g for 10 mins and the bacterial pellet stored at
-20°C until required.
2.7.1.3 Harvesting recombinant thioredoxin fusion protein
E. coli cell pellets were resuspended in 15ml of PBS containing a protease
inhibitor cocktail tablet (Complete®, Roche) and 100pl of lysozyme (Sigma)
(lOmg/ml). Cells were lysed by sonication using a sonication probe (Jenson) for 1 min.
Soluble and insoluble proteins were separated by centrifugation at 13000 x g for 30
mins. Insoluble pellets were solubilised in 45pl reducing Laemmli sample buffer (see
section 2.5.1) and heated in a boiling water bath for 5 mins. An equal volume of 2 x
reducing Laemmli sample buffer was added to lOpl of supernatant and 20pl of pellet.
The proteins were analysed by SDS-PAGE electrophoresis (see section 2.5.1) and the
gel was stained by Coomassie blue to detect the presence of recombinant protein.
2.7.2 Affinity Purification of recombinant thioredoxin-A9 fusion protein
using ThioBond™ columns
The ThioBond™ resin was used in the affinity purification of thioredoxin fusion
proteins. All fusions expressed from the pTrxFus plasmid contain vicinal dithiols while
other proteins are washed away. The purified thioredoxin fusion proteins were eluted
using P-mercaptoethanol (P-ME).
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The method used was as described in the manufacturer's instructions
(Invitrogen). ThioBond™ resin (Invitrogen) was equilibrated using equal volumes of
running buffer (PBS, ImM EDTA) containing 20mM p-ME. Fresh running buffer
containing 20mM p-ME was added and incubated for 30-60 mins. The resin was
allowed to settle and supernatant removed. The resin was then washed three times with
running buffer (without P-ME), before incubating for lhr with the cell lysate. The
complex was then applied to a column and unbound protein collected. The resin was
washed in running buffer containing ImM P-ME. Recombinant thioredoxin-A9 fusion
protein was eluted using running buffer containing 200mM P-ME. Samples were
collected in 1ml fractions and stored at -20°C for future use. The column was
regenerated using running buffer and stored at 4°C until required.
2.7.3 Purification of thioredoxin recombinant protein by electroelution
Crude E. coli lysate, 200pl, was prepared in the same volume of 2 x Laemmli
sample buffer. Proteins were visualised during separation by Coomassie blue staining of
SDS-PAGE gels (see section 2.5.2.). Recombinant thioredoxin-A9 proteins were
excised from gels using a clean scalpel.
Gels containing the excised protein bands were roughly chopped and placed in
the cathode (-ve/upper) chamber of a Biorad electroelution unit. Both chambers and the
tank unit were filled with tank buffer (25mM Tris, 200mM Glycine, 5mM SDS). A
current of 50mA was applied for approximately 30 mins or until all the blue dye
(protein) had moved from the upper to the lower chamber. Electroeluted material was
collected, washed in Vivaspin concentrators (with a lOkDa cut-off membrane)
(Vivascience) with PBS and stored at 4°C until required.
2.7.4 Immunisation of animals
Mice were immunised subcutaneously with an emulsion of complete Freunds'
adjuvant (Difco Laboratories), 200pl, mixed with an equal volume of antigen (purified
recombinant thioredoxin-A9 protein, 26pg). Four weeks later, mice were re-immunised
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intraperitoneally using an emulsion of Freunds' incomplete adjuvant, 50pl, with an
equal volume of antigen (31 pg). Serum was tested after the second immunisation for
the presence of specific antibody by Western blot (see section 2.5.3). The mice were re-
immunised intraperitoneally four weeks later with 50pl of Freunds' incomplete adjuvant
with an equal volume of antigen (31pg). Animals were euthanased by cervical
dislocation and the spleen was collected for hybridoma production.
For the production of polyclonal antibodies, rabbits were immunised
intramuscularly with an emulsion of complete Freund's adjuvant mixed with an equal
volume of antigen (electroeluted recombinant thioredoxin-A9 protein) (containing
75pg). Fours weeks later, animals were re-immunised subcutaneously with an emulsion
of Freunds' incomplete adjuvant with an equal volume of antigen (containing 75pg).
Animals were ex-sanguinated under halothane anaesthesia and the serum was collected
for antibody.
2.7.5 Production of A9 protein specific monoclonal mouse antibodies
NSO mouse myeloma cells were removed from liquid nitrogen (see section
2.2.4) and cultured one week prior to fusion. NSO mouse myeloma cells (ECCAC, UK)
were recovered from cell culture by gently tapping the cell culture flask. Cells were
transferred into 50ml tubes and centrifuged at 238 x g for 5 mins with the pellet being
resuspended in 20ml ofNSO growth medium (Rosewell Park Memorial Institute
(RPMI) medium with L-glutamine (Gibco), 5mM N'-[2-hydroxyethyl] piperazine-N'-
[2-ethanesulphonic acid] (HEPES, Sigma), 1.5% (w/v) L-Glutamine, (10000U)
Penicillin/Streptomycin) containing 10% (v/v) FBS.
Mouse macrophages from non-immunised Balb/c mice were used as feeder cells.
Ice-cold PBS containing penicillin (200U/ml) and streptomycin (200pl/ml) was injected
into the peritoneal cavity. The body was massaged and the PBS was withdrawn using a
syringe. The suspension was centrifuged at 500 x g for 10 mins, washed twice with PBS
and a cell count was carried out. The cell pellet was resuspended to a concentration of
2-5 x 104 cells/ml in plating out medium (NSO medium containing 20% (v/v) FBS, OPI
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media supplement (0.15g/l oxaloacetate, 0.05g/l pyruvate, 0.0082g/l bovine insulin)
(1:50, Sigma) and hypoxanthine aminopterin thymidine (HAT) (1:50, Sigma)) and
plated out at 75pl/well in 96 well plates. The plates were incubated overnight at 37°C in
a humid 5% CO2 in air atmosphere.
Immunised spleen was recovered and rinsed well with medium containing
streptomycin (200pl/ml) and penicillin (200U/ml). The spleen was placed in a 90mm
petri dish (Bibby Sterilin Ltd) and cells were flushed out by using syringes with 26G
needles. RPMI containing 10% (v/v) FBS (10ml) was injected into the spleen to
displace cells into the surrounding medium. The spleen was teased apart by the action
of the needles to completely release spleen cells. The medium was transferred to a
universal and the debris allowed to settle. The supernatant was removed and the cells
pelleted at 254 x g for 5 mins. The cell pellet was resuspended in ice cold 0.17M NH4CI
(5ml) and placed on to ice for 10 mins. The cells were washed twice with medium
without serum and resuspended in serum-free medium.
NSO cells were added to the spleen cells to give a fusion ratio of 1:5
(NSO:spleen). The cell suspension was centrifuged at 254 x g for 5 mins. The
supernatant was removed and the cell pellet was resuspended in 1ml ofwarm
polyethylene glycol (PEG) solution (Sigma). Serum-free medium (10ml) was slowly
added to the fusion mixture and the cells centrifuged at 185 x g for 5 mins. The cell
pellet was resuspended in 10ml of plating-out medium and the cell suspension was
added to 80ml of plating-out medium. Cells were dispensed (125pl/well) to plates
containing macrophage feeder cells and incubated at 37°C in a humid 5% CO2 in air
atmosphere. Supernatant material was tested for reactivity to the thioredoxin-A9 fusion
protein by ELISA (see section 2.7.6).
2.7.6 Enzyme linked immuno-sorbent assay (ELISA)
ELISA's were used to measure the antibody from hybridoma clones specific for
the A9 protein.
96 well ELISA plates (M129B, Greiner Laborotechnik) were coated with
50pl/well of either thioredoxin protein (control) or recombinant thioredoxin-A9 fusion
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protein (0.5pg/ml) in 0.1M carbonate buffer pH 9.6 at 4°C overnight. Plates were
washed three times with wash buffer (PBS containing 0.05% (v/v) Tween 20® (Sigma)),
then non-specific binding sites were blocked for 1 hr at room temperature with lOOpl per
well 4% (v/v) FBS and washed again three times in wash buffer. Plates were incubated
with 50pl per well of hybridoma supernatant at neat, 1:5, 1:10 and 1:20 dilutions for 1 hr
and then washed three times with wash buffer. Secondary antibody, goat anti-mouse-
HRP conjugate (DAKO) was added at a dilution of 1:2000 for 1 hr. All dilutions were
in wash buffer. The plates were washed three times with wash buffer and the colour
reaction was allowed to develop with the addition of 50pl per well of SureBlue™ TMB
Microwell Peroxidase (KPL) for 10-15 mins. The reaction was terminated by the
addition of 50pl of 2.5M TFSC^per well. The optical density of the reaction mixture




Apoptosis assays were carried out with A9-transfected CHO cells. BHRF1
cDNA from EBV was used as a positive Bcl-2 control and an ovine interferon (IFN)
transfected CHO cell line that was resistant to MSX selective pressure but did not
produce IFN was used as a transfection control (Graham et al., 1995). Untransfected
(UTF) cells were used as a negative control. Cells were set up in GMEM supplemented
with 2% (v/v) dialysed FBS.
2.8.2 Induction of apoptosis
CHO cells were seeded 24hrs before incubation with (25pM) Cis-platinum
dichloroamine II (cis-platin) (Sigma). This dose was based on a dose-response
experiment. Cis-platin has been shown to induce apoptosis by binding to the purine
bases on DNA and causing the DNA helix to kink (Jamieson & Lippard, 1999). This
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results in slower DNA replication which induces apoptosis. Cells were incubated with
cis-platin for 3 hrs at 37°C, 5% CO2 in air in an incubator. Media was removed from
cells and fresh medium was added. Samples were analysed using the appropriate
apoptosis assay (see below) at 24, 48 and 72hrs after incubation with cis-platin.
2.8.3 Extraction of DNA
DNA was extracted from CHO cells to analyse the DNA and identify if the
typical "DNA laddering" that is observed in apoptotic cells was produced in cells treated
with cis-platin.
CHO cells were cultured in 35mm2 petri dishes (Nalgene) at a concentration of 3
x 105cells/ml with 1.5ml of cell suspension added to each dish. After 24 hrs, apoptosis
was induced using cis-platin.
At 24, 48, and 72 hrs after treatment with cis-platin, the media was removed
from cells. The cells were washed with warm (37°C) PBS and removed from the petri
dish by incubating for 2 mins at 37°C with trypsin (0.25%) /versene (0.02%). Trypsin
was neutralised with the addition 200pl ofGMEM containing 7.5% (v/v) FBS. Cells
were pelleted by centrifugation at 100 x g for 10 mins and washed with 500pl of PBS to
remove residual serum. Cells were pelleted by centrifugation at 100 x g for 10 mins and
resuspended in 200pl of PBS. DNA was extracted from the cells using Easy-DNA kit
(Invitrogen) according to the manufacturers protocol. Cells were lysed using 350pl of
solution A (lysis buffer), vortexed and incubated at 65°C for 10 mins. 150pl of solution
B (precipitation solution) was added to the lysate (to precipitate proteins and lipids).
This was vortexed, and 500pl of chloroform was added to the samples, which were
vortexed again and centrifuged at 17900 x g for 20 mins. The upper phase of the
solution was transferred into a fresh micro-centrifuge tube (1.5ml) and 1ml of 80% (v/v)
ice-cold ethanol was added, vortexed and incubated on ice for 30 mins. The samples
were centrifuged at 17900 x g for 10 mins, the ethanol removed and replaced with 500pl
of ice-cold 80% (v/v) ethanol. The tubes were inverted five times and centrifuged at
17900 x g for 5 mins. The DNA pellet was resuspended in 20pl of TE buffer containing
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0.5pl of 2mg/ml RNase. DNA was incubated at 37°C for 30 mins. Loading buffer (30%
(v/v) glycerol: TE, 0.25% (w/v) bromophenol blue) (6pl) was added to a sample ofDNA
for analysis by agarose gel electrophoresis (section 2.3.13).
2.8.4 Caspase-3 assay
Cells were cultured at a concentration of 5 x 104 cells/ml in GMEM
supplemented in 2% (v/v) FBS. The cell suspension, 1ml (5 x 104 cells) was added to a
24 well plate (Costar). After 24 hrs, apoptosis was induced using cis-platin as described
in section 2.8.2.
The assay was carried out 24, 48 and 72 hrs after incubation with cis-platin. The
media was removed from the cells and retained. The cells were washed with 1ml of
warm (37°C) PBS and removed from the 24 well plate. The PBS was retained and the
cells were removed from the plate by incubating for 2 mins at 37°C with trypsin
(0.25%)/ versene (0.02%). Trypsin was neutralised with the addition of 500pl of
GMEM containing 7.5% (v/v) FBS. Cells were pelleted by centrifugation at 100 x g for
5 mins and resuspended in 500pl of PBS. Cells pelleted by centrifugation at 100 x g for
4 mins. The supernatant was removed and the cells were resuspended in 50pl of ice-
cold lysis buffer (lOmM Hepes pH 7.4 (Sigma), 42mM potassium chloride, 5mM
magnesium chloride, ImM DTT, lpg/ml Pepstatin A (Sigma), lpg/ml Leupeptin
(Sigma), 5pg/ml Aprotinin (Sigma), 0.1% Triton X-100). Cells were incubated on ice
for 10 mins, vortexed and pelleted by centrifugation at 17900 x g for 4 mins. The
supernatant was removed and stored at -20°C until required.
1OjliI of lysate was added in triplicate to a 96 well flat bottom plate (Costar). To
this 150pl of caspase assay buffer (20mM Hepes pH 7.4, ImM EDTA, 10% sucrose,
5mM DTT, 0.1% CHAPS, 13.3pM N-Acetyl-Asp-Glu-Val-Asp-7-ami-do-4-
methylcoumarin (Av-DEVD-AMC)) and the plate was sealed and incubated at 37°C for
5 hrs. The results were obtained using a fluorescent plate reader (Cytofluor Series 4000,
Perspective Biosystems) with an excitation filter set at 395nm and an emission filter set
at 490nm. The results were read in relative fluorescent units (RFU).
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2.8.5 Diff-quik® assay
The diff-quik (Dade Behring) reagents stained cells in such a way that
morphological evidence of apoptosis can be visualised by light microscopy. This assay
detects changes that occur in cell morphology during apoptosis. In cells that are healthy,
the nuclei and cytoplasm can be seen. However, in cells that are undergoing apoptosis
the cells round up and the nuclei are darkly stained.
CHO cells were cultured at a concentration of 1 x 105 cells/ml in GMEM
supplemented with 2% (v/v) FBS. The cell suspension, 200pl, (2 x 104 cells) was added
to each well of an eight well chamber slide (Lab-Tek). After 24 hrs, apoptosis was
induced using cis-platin as described in section 2.8.2.
The assay was carried out 24, 48 and 72 hrs after incubation with cis-platin.
Cells were washed once with warm (37°C) PBS. Cells were fixed by immersion in Fast
green in methanol, 0.002g/l for 10 sees. Cells were then stained by immersion in stain 1
(Eosin G in phosphate buffer ph 6.6, 1.22g/l) for 10 sees followed by immersion in stain
2 (Thiazine dye in phosphate buffer pH 6.6, 1.1 g/1) for 10 sees. The excess dye was
removed by washing slides in distilled water. The slides were air-dried and mounted
using Shandon mounting media (Shandon). The cells were examined under a light
microscope. A sample of 200 cells was counted from each well to determine whether
the cells were pyknotic or healthy.
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Chapter 3
Sequence analysis of ORF A9,




The A1HV-1 genome has been sequenced and contains eleven 'unique' genes
(Ensser et al., 1997). Many of these genes were found to have homology with cellular
counterparts, one ofwhich is contained within ORF A9. This encodes a possible
apoptosis-inhibitory protein, based on predicted amino acid comparisons. Many
herpesviruses express at least one Bcl-2 homologue that have been proven to be anti-
apoptotic.
In this study, the expression ofORF A9 in bacteria and the production ofmouse
monoclonal and rabbit polyclonal antibodies specific for A1HV-1 A9 are described.
The A9 gene was amplified by PCR and cloned into the expression vector
pGEX-3X that expresses recombinant proteins as a Glutathione S-transferase (GST)
fusion protein. Expression is repressed, under normal conditions, by the product of the
Laclq gene. Repression is removed by the addition of the inducer isopropyl P-D
thiogalactosidase (IPTG), a lactose analogue. The plasmid directs the synthesis of the
fusion protein under the control of the IPTG inducible tac promoter. This is a strong
promoter that can result in high levels of expression of the fusion protein. The plasmid
also contains the ampicillin resistance gene for the selection of plasmid-containing
colonies.
The cloned A9 gene was also inserted into the expression vector, pTrxFus that
expresses recombinant proteins as thioredoxin fusion proteins. This vector uses the PL
promoter from bacteriophage A to drive expression and has been shown to be one of the
most efficient promoters for bacterial expression (Buell et al., 1986). The bacteriophage
A cl repressor binds to the operator region in front of the Pl promoter and controls the
level of transcription from this promoter. When cells are grown in tryptophan-free
medium, the cl repressor gene is transcribed and the cl protein binds to the Pi. promoter
preventing transcription. Expression is induced by the addition of tryptophan, which
shuts down cl repressor synthesis to allow the transcription from the Pl promoter. The
vector also contains an ampicillin resistance gene to aid selection of transformed E. coli.
The thioredoxin expression system was used as it has been proven to express high levels
of soluble fusion proteins (Holmgren, 1985; La Villie et al., 1992). Both the GST and
Trx systems are useful in the identification of the recombinant proteins as (in the
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absence ofA9 specific antibodies) monoclonal antibodies for both are available
commercially.
The thioredoxin fusion protein was used as an antigen to raise specific anti-sera
in mice and rabbits. This chapter describes the purification of the thioredoxin fusion
protein by affinity chromatography and the purification of the antibodies that were
produced. These reagents were then used to detect the presence ofA9 protein in
transfected CHO cell lines and LGL cell lines.
The objectives of this part of the work were:
• To analyse ORF A9 predicted amino acid sequence for homology to the
Bcl-2 family of proteins.
• To express A9 protein and raise specific antisera.
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3.2 Materials and Methods
3.2.1 Expression of a GST-A9 fusion protein
A9 DNA was amplified by PCR from WC11 A1HV-1 DNA using PCR primers;
5 Bel Gex and 3 Bel Gex (appendix 2.1). The purified product was purified and
digested with AG/1 and Sal 1. The PCR product was ligated into pGEX-3X in frame with
GST, using the AG/1 and Sal 1 sites. The ligated DNA were transformed in E. coli strain
BL2 and streaked out onto LB agar overnight. A colony of bacteria was picked using an
inoculating loop and grown overnight in 10ml LB broth. The bacteria were pelleted by
centrifugation at 4000 x g for 10 mins. The pellet was lysed by the addition of lysis
buffer (50mM Tris, lOmg/ml lysozyme) followed by sonication using a sonication probe
(Jensons) for 30 sees. The insoluble and soluble proteins were separated by
centrifugation at 16 000 x g for 30 mins. Both the insoluble and soluble proteins were
run on a 15% SDS-PAGE gel (as described in section 2.5.1). Proteins were detected by
Coomassie blue staining.
3.2.2 Expression of a GST-truncated A9 fusion protein
PCR was used to amplify the A9 gene excluding the hydrophobic
transmembrane domain. PCR primers 5 Bel Gex and 3 Bel GexT (appendix 2.1) were
used. The PCR product was purified, digested with AG/1 and Sail and ligated into
pGEX-3X in frame with the GST as described in section 3.2.1. The fusion protein was
generated and expressed as described in section 3.2.1.
3.2.3 Solubilisation of proteins
Where indicated, the protein pellets were resuspended in 8M urea and incubated
overnight. The soluble and insoluble fractions were separated by centrifugation at 16
000 x g for 45 mins. The supernatant material was analysed by electrophoresis on a
12% SDS-PAGE gel (as described in section 2.5.1). Proteins were detected by
Coomassie blue staining.
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3.2.4 Dialysis of GST-A9 fusion protein
Samples were dialysed to remove excess urea. The dialysis tubing was prepared
by washing in running water for 3-4 hrs. The sulphur compounds were removed from
tubing by heating in a 0.3% (w/v) solution of sodium sulphide at 80°C for 1 min. The
tubing was then washed in hot water (60°C) for 2 mins, followed by an acidification step
of 0.2% (v/v) sulphuric acid then rinsed in hot water to remove the acid. Proteins were
pipetted into the dialysis tubing and dialysed overnight in PBS. The soluble and
insoluble proteins were separated by centrifugation at 16,000 x g for 45 mins. Proteins
were analysed by Coomassie blue staining of a 12% SDS-PAGE gel.
3.2.5 Expression of recombinant thioredoxin-A9 fusion protein in E. coli
DNA encoding the A9 gene excluding the hydrophobic transmembrane domain
was amplified by PCR using primers Y4233 and Y4234 (appendix 2.1). The PCR
product was purified, digested using Kpn 1 and Xba\ and ligated into the pTrxFus
expression vector. The construct was transformed into the GI724 strain ofE. coli (as
described in section 2.3.4). Bacterial colonies were analysed for the A9 sequences
inserted into pTrxFus (by mini-preps, as described in section 2.3.9) and restriction
analysis of the plasmid DNA using Kpn\ and Xbal (as described in section 2.3.1).
Positive samples were tested for the expression of thioredoxin fusion proteins. Protein
expression was induced by the addition of tryptophan to a final concentration of ImM
and then cultured for a further 3 hrs as described in section 2.6.2.2. Recombinant
thioredoxin-A9 fusion proteins were harvested from E. coli by lysis as described in
section 2.6.1. Proteins were separated by electrophoresis and detected by Coomassie
blue staining. Western blotting was also used to identify recombinant thioredoxin-A9
fusion proteins (as described in section 2.5.3). Mouse monoclonal anti-thioredoxin
(Invitrogen) was used at a concentration of 1:5000 followed by incubation with anti-
mouse-HRP (DAKO) at a concentration of 1:2000.
3.2.6 Purification of recombinant thioredoxin-A9 protein using Thiobond
Recombinant thioredoxin-A9 fusion proteins were purified using ThioBond™
resin (Invitrogen) (section 2.6.2). Thioredoxin-A9 fusion proteins were eluted using P-
mercaptoethanol and analysed by electrophoresis. Proteins were visualised by silver
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staining of SDS-PAGE gels. Eluted proteins were concentrated using lOkDa centricons
(Millipore). P-mercaptoethanol was removed from eluted proteins by dialysis with PBS
in centricons to a final volume of 500pl.
3.2.7 Purification of thioredoxin recombinant protein by electroelution
Recombinant thioredoxin-A9 proteins were separated by Serva Blue R
(Coomassie blue R) in the upper tank buffer to visualise the proteins bands in the gel
during separation. Samples in non-reducing Laemmli sample buffer were loaded into a
single large well on a Biorad Mini Protean II system using a 1.25mm comb. Up to
400pl total volume was loaded per gel. The upper tank was filled with cathode buffer
(3.08g/l Tris, 14.4g/l Glycine, 0.05% (w/v) SDS, 24mg/l Serva Blue (Sigma) and the
lower tank filled with tank buffer as for a traditional SDS-PAGE. Once identified, the
relevant protein band was excised from the gel. Gels containing the excised protein
bands were roughly chopped and placed in the cathode (-ve/upper) chamber of a Biorad
electroelution unit. Both chambers and the tank unit were filled with tank buffer (25mM
Tris, 200mM Glycine, 5mM SDS). A current of 50mA was applied for approximately
30 mins or until all the blue dye (protein) had moved from the upper to the lower
chamber. Electroeluted material was collected, washed in Vivaspin concentrators (with
a lOkDa cut-offmembrane) (Vivascience) with PBS and stored at 4°C until required.
3.2.8 Cleavage of thioredoxin-A9 fusion protein using EnterokinaseMax™
The cleavage of thioredoxin-A9 fusion protein using EnterokinaseMax™ was
carried out as described in the manufacturer's protocol (Invitrogen). The digestion was
set up as follows: 20pg of thioredoxin-A9 fusion protein, 3pl 10 x EKMax™ buffer, 4pl
EKMax™ and deionised water was added to make a final volume of 30pl. The
digestion was mixed and incubated at 4°C overnight. Samples were boiled in an equal
volume of reducing Laemmli sample buffer and electrophoresis was carried out as
described in section 2.5.1.
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3.2.9 Construction of p-Gal-A9 fusion protein
A9 DNA was amplified by PCR (see section 2.3.12) from A1HV-1 WC11 DNA
using primers 5pMSBCL and 3pMSBCL (appendix 2.1). The PCR product and pMS
plasmid DNA was digested with Hindlll and ligated together (as described in section
2.3.2).
E. coli JM109 transformed with the |3-Gal fusion constructs were inoculated into
10ml L-broth containing ampicillin (lOOmg/ml). An aliquot, 5ml, of overnight culture
was added to 100ml of L-broth containing ampicillin (lOOmg/ml) and incubated in an
orbital shaker for 3 hrs. P-gal fusion protein expression was induced by the addition of
IPTG to ImM (Sigma) and incubated for 3 hrs. Cells were centrifuged at 1080 x g for
10 mins and the bacterial pellet stored at -20°C until required. The bacterial pellets were
resuspended in 15ml of PBS containing a protease inhibitor cocktail tablet (Complete®,
Roche) and lOOpl of lysozyme (lOmg/ml, Sigma). Cells were lysed by sonicating using
a sonication probe for 1 min. Soluble and insoluble proteins were separated by
centrifugation at 13000 x g for 30 mins. Insoluble pellets were solubilised in 45pl
reducing Laemmli sample buffer (see section 2.5.1) and heated in a boiling water bath
for 5 mins. Proteins were detected by western blot analysis using mouse anti-A9 serum.
3.2.10 Production of monoclonal mouse antibodies against recombinant
A9 protein
For the preparation of monoclonal mouse antibodies, two mice were immunised
with purified thioredoxin-A9 fusion protein as described in section 2.7.4. Monoclonal
antibodies against the recombinant A9 protein were produced as described in section
2.7.5.
3.2.11 Testing of antisera by ELISA
To test the reactivity of supernatant from hybridomas that had been produced,
recombinant thioredoxin-A9 fusion protein was coated on ELISA plates (M129B,
Greiner Laborotechnik) and an ELISA was carried out as described in section 2.7.6.
Positive samples against recombinant thioredoxin-A9 protein were analysed further by
repeating the ELISA using thioredoxin protein at a concentration of 2pg/ml as described
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in section 2.7.6. Those that were positive for the recombinant thioredoxin-A9 protein
and negative for the thioredoxin protein on its own were considered positive for A9.
3.2.12 Isotyping antibodies
Antibodies 6E1 and 6G8 were isotyped with respect to immunoglobulin
class/subclass using the IsoStrip mouse monoclonal antibody isotyping kit (Roche)
according to the manufacturer's protocol. Hydridoma supernatant was diluted 1:10 and
pipetted into a development tube. The tube was incubated at room temperature for 30
sec and then agitated in order to completely resuspend the coloured latex. A strip was
inserted into the development tube and incubated for 5-10 mins to allow bands to
develop.
3.2.13 Purification of mouse anti-A9 hybridoma supernatant, 6E1 using
IgM-sepharose
Hybridoma supernatant 6E1 was purified on an anti-mouse IgM sepharose
column (Sigma) by Fast performance liquid chromatography (FPLC). The hybridoma
supernatant was filtered through a 0.45pm filter. A small column (2ml) of anti-mouse
IgM sepharose was packed and washed thoroughly with PBS. 6E1 supernatant was
loaded on to the column and unbound proteins were collected. The O.D.280 was
monitored for all fractions collected, to detect proteins. The column was washed with
PBS until the O.D.280 returned to baseline and unbound proteins were eluted. IgM
antibody was eluted from the column using elution buffer (0.5M Glycine, 0.15M NaCl
pH 2.8) at a rate of 1.5ml/min. Eluted protein samples were detected by a rise in
O.D.280, the relevant fractions collected and immediately neutralised with 1M Tris, pH
8.0. Samples were pooled together and stored at -20°C for future use. The column was
cleaned and washed with several cycles of PBS.
3.2.14 Production of polyclonal rabbit antibodies against recombinant A9
protein
For the preparation of polyclonal antibodies, two rabbits were immunised with
electroeluted thioredoxin-A9 fusion protein. The antigen was prepared as described in
section 2.7.3. Electroeluted thioredoxin-A9 fusion protein was concentrated using
107
centricons (centrifugal concentrators with a lOkDa cut-off membrane) (Millipore) to a
final volume of 1.5ml. The protein concentration was determined and this material was
divided between the two rabbits for each set of inoculations.
3.2.15 Purification of anti-A9 serum using ammonium sulphate
precipitation
Anti-A9 rabbit serum was centrifuged at 3,000 x g for 30 mins. Supernatant was
transferred to a beaker and an equal volume of saturated ammonium sulphate was added
slowly. The solution was placed on ice for 1-2 hrs and centrifuged at 3,000 x g for 30
mins. The supernatant was removed and the pellet was resuspended in 15ml of IX PBS.
The solution was dialysed in PBS overnight.
3.2.16 Transfection of CHO cells with A9 and EBV BHRF1 cDNAs
CHO cells were stably-transfected with 2pg of the plasmid constmct pEE14-A9
or pEE14-BHRFl using Lipofectamine 2000™ (4pl) (as described in section 2.2.7) to
produce A9-CHO and BHRF1-CHO cells respectively. Transfections were carried out
in 6 well plates (Nunc) with a total volume of 500pi of transfection complex being
added to each well.
3.2.17 Indirect immunofluorescence assay
CHO cells were seeded at a density of lx 105 cells/ml in 8 well chamber slides
with 200pl of cell suspension added to each well. Immunofluorescence was carried out
as described in section 2.2.9. Cells were fixed with ice-cold acetone, washed with PBS
and incubated with the positive samples in the ELISA at the following dilutions: neat,
1:5, and 1:10. This was followed by incubation with goat, anti-mouse-FITC (1:75).
Rabbit antisera, 162 and 163 were used at a dilution of 1:500. A secondary
conjugate of goat anti-rabbit-biotin was used (1:500) followed by a tertiary conjugate of
streptavidin-FITC (1:75). Cells were examined using an Olympus BX50 microscope
(Olympus) using a blue (NB) filter at 470-490nm.
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3.3 Results
3.3.1. Sequence analysis of ORF A9
Analysis of the predicted amino acid sequence ofORF A9 from C500 low
passage A1HV-1 using the blastp program revealed 33% amino acid identity with human
Bcl-w. Bcl-w is an anti-apoptotic member of the Bcl-2 family of proteins. The area of
homology between A9 and Bcl-w is concentrated in one region, the BH1 domain.
The predicted mass of the A9 protein is 19kDa. This is smaller than human Bcl-
2 which has a mass of 26kDa. The viral Bcl-2 homologues that are present in the
sequenced gammaherpesviruses are all smaller molecules than their cellular
counterparts. This is probably due to the lack of some BH domains. For example, the
Bcl-2 homologue present in HHV-8 has a molecular weight of 19kDa and contains only
BH1, BH2 and the transmembrane domain.
The A1HV-1 A9 predicted amino acid sequence was compared to viral and
cellular Bcl-2 family members by Clustal W analysis (fig. 3.1). The analysis showed
that A1HV-1 A9 has a highly conserved BH1 domain and transmembrane domain while
other Bcl-2 family domains (BH2-4) could not be identified. Within the BH1 domain of
the Bcl-2 family members there is a conserved sequence, NWGR. Part of this sequence
is present in A1HV-1 A9, where the sequence is HWGR. The A9 protein sequence
possesses the conserved glycine residue that is essential in anti-apoptotic activity (Yin et
al., 1994).
From the recent genome sequence ofOvHV-2 (Stewart & Rosbottom, personal
communication) the Bcl-2 homologue (ORF 09) also possessed a BH1 domain and
transmembrane domain but lacked the three remaining Bcl-2 family domains.
Interestingly the OvHV-2 Bcl-2 homologue does possess the conserved sequence
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ALHV-1 81 PHWGRLVAFLAYLAYLQKNSTEK LFWNDHLKKLKQIVKCHIVP-WTLGPRDPKPKQRPFD
OVHV-2 123 PNWGRWMFFAYLFYLQISSTQK VFFRDHYKKIESIIEAHIVP-WTLSQRKLK EPFPL
HHV-8 82 MNWGRALAILTFGSFVAQKLSNEP--HLRDFALAVLPVYAYEAIGPQWFRARGGWRG-LKAYCTQVLT--
MHV- 6 8 83 INSGRIVGFFDVGRYVCEEVLCPG- -SWTEDHELLNDCMTHFFIEN-NLMNHFPLE DIFLAQR
BCL-Xl 135 VNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEP-WIQENGGWDTFVELYGNNAAAES
BCL-W 91 PNWGRLVAFFVFGAALCAESVNKEMEPLVGQVQEWMVAYLETRLAD-WIHSSGGWAEFTALYGDGALEEA
BH1 Domain BH2 Domain
ALHV-1 140 -KLPSA FYFLTAAASCLTLLLLYFRTTQTK
OVHV-2 180 -KMREV VIFFTTVASLVAMLLLCRRAWG--
HHV-8 14 7 - RRRGR RMTALLGSIALLATILAAVAMSRR
MHV-6 8 1 43 -KFQTTG FTFLLHALAKVLPRIYSGNVIYV-
BCL-Xl 2 04 RKGQER FNRWFLTGMTVAG-WLLGSLFSRK
BCL-W 160 RRLREGNWASVRTVLTGAVALGALVTVGAFFASK
TM Domain
Fig. 3.1. Clustal W analysis of viral and cellular Bcl-2 proteins. The amino acid
sequences of viral and cellular Bcl-2 proteins (AIHV-1 (Ensser et al., 1997), OvHV-2
(Stewart & Rosbottom, personal communication), HHV-8 (Cheng et al., 1983), MHV-68
(Virgin et al., 1997), Bcl-xL (Boise etal., 1993), Bcl-w (Gibson et al., 1996)) were aligned
and displayed using the BOXSHADE program. Identical residues are in red while
similar residues are blue. The position of the Bel homology (BH) domains and the
transmembrane domain are also marked on the diagram.
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3.3.2 Expression of a GST-A9 fusion protein
Primers (pGex5 and pGex3 as shown in appendix 2.1) were designed to amplify
the A9 gene from WC11 A1HV-1 DNA. The amplified DNA was ligated into pGEX-3X
in frame with the GST fusion protein using the Not\ and Sal 1 sites. The construct was
transformed into E. coli bacteria and the transformants were checked for the presence of
inserted A9 DNA. Samples positive for A9 inserts were analysed for the expression of
the GST-A9 fusion protein. Expression of the GST-A9 fusion protein was induced by
the addition of IPTG. Both the cell supernatant and pellet were then analysed by
electrophoresis on a 15% SDS-PAGE gel. Recombinant proteins were detected using
Coomassie blue stain (fig. 3.2). A dominant protein that had an approximate size of
45kDa in the pelleted fraction was observed. The predicted size of the A9 protein was
19kDa and the GST protein was 26kDa, therefore the 45kDa protein band was the
correct size to be the GST-A9 fusion protein. However, since the protein was present in
the pellet and not in the supernatant, the protein was insoluble.
59kDa j GST-A9 fusion
30kDa Protein
17kDa
1 2 3 4 5
Fig. 3.2. A9-GST fusion proteins in E. coli lysates detected by Coomassie blue
staining. 1) Uninduced cell supernatant, 2) Induced cell supernatant, 3) Kaleidoscope
molecular mass markers (Bio-rad), 4) Uninduced cell pellet, 5) Induced cell pellet.
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The GST-A9 fusion protein was insoluble, possibly due to the hydrophobic
transmembrane domain present in the A9 protein. Therefore, primers were designed to
amplify a fragment of the A9 gene that excluded the hydrophobic transmembrane
domain. A 456bp A9 DNA fragment was amplified by PCR using primers 5 Bel Gex
and 3 Bel Gex T (appendix 2.1). The PCR product was ligated in pGEX-3X in frame
with the GST fusion protein using Not\ and Sal 1 sites. Fig. 3.3 shows faint bands
corresponding to the truncated GST-A9 fusion protein were detected in the supernatant.
However, the dominant band was present in the pellet, indicating that the protein was
still insoluble.
To further attempt to solublise the recombinant GST-A9 fusion protein, pellets
were resuspended in 8M urea. Fig. 3.4, shows that 8M urea solubilised the proteins in
the pellet. However, the protein could not be purified using glutathione sepharose,
possibly due to excess urea. Samples were dialysed overnight in PBS to remove the
urea. The soluble and insoluble materials were separated by centrifugation and analysed
by electrophoresis. Proteins were detected by Coomassie blue staining on a 12% SDS-
PAGE gel. Faint bands corresponding to GST-A9 were observed in supernatant
samples, however, a dominant band was observed in the pellet. Thus, removal of the
urea by dialysis led to protein becoming insoluble once more. Attempts to purify the
GST-A9 protein using glutathione beads were unsuccessful. It was decided to use an
alternative fusion protein.
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Fig. 3.3. Truncated GST-A9 fusion proteins in E. coli lysates
detected by Coomassie blue staining. 1: Truncated A9-GST
fusion protein. Cell lysate, pellet. 2: Truncated A9-GST fusion
protein. Cell lysate, supernatant.






Fig. 3.4. GST-A9 fusion insoluble protein pellets in E. coli solubilised in 8M urea
detected by Coomassie blue staining. 1: Induced truncated A9-GST. Cell lysate
supernatant. 2: Uninduced truncated A9-GST. Cell lysate supernatant. 3: Induced A9-
GST. Cell lysate supernatant. 4: Induced GST. Cell lysate supernatant.
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3.3.3 Expression of thioredoxin-A9 protein in bacteria
Primers, Y4233 and Y4234 were designed to amplify ORF A9 from WC11
A1HV-1 DNA. A9 DNA was ligated into the Kpn\ andXbal sites of the pTrxFus
plasmid. The construct was transformed into E. coli bacteria and transformants were
checked for the presence of inserted A9 DNA. Samples positive for the A9 insert were
analysed for the expression of thioredoxin fusion protein. Expression of the thioredoxin
fusion protein was induced by the addition of tryptophan. Fig. 3.5 shows a dominant
band around 30kDa. The predicted size of the A9 protein is 19kDa and the thioredoxin
protein is 1 lkDa, which is consistent with the dominant band being the thioredoxin-A9
fusion protein. The protein was present in the supernatant indicating that it is soluble.
ThioBond™ resin was used to purify the recombinant thioredoxin-A9 protein
from crude cell lysate. The fusion protein was eluted using (3-mercaptoethanol. The
SDS-PAGE gel analysis (fig. 3.6) shows that the optimum concentration to elute the
fusion protein was 100-200mM P-mercaptoethanol. Proteins were detected by Silver
staining. Western blot analysis using an anti-thioredoxin antibody confirmed the
presence of recombinant thioredoxin-A9 protein (fig. 3.7).
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Fig 3.5. Recombinant thioredoxin-A9 fusion protein in E. coli lysates detected by
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Fig. 3.6. Recombinant thioredoxin-A9 protein purified using Thiobond and various
concentrations of [3-mercaptoethanol to elute the bound protein. Detected by Silver
staining.
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Fig. 3.7. Western blot of recombinant thioredoxin-A9 fusion protein purified using
various concentrations of P-mercaptoethanol probed with anti-thioredoxin monoclonal
antibody followed by goat, anti-mouse-HRP conjugate.
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3.3.4 Polyclonal antiserum reacts with the Trx-A9 recombinant protein
Recombinant thioredoxin-A9 fusion protein was digested with
EnterokinaseMax™. This allowed the cleavage of the A9 protein from the thioredoxin
fusion protein. Western blot analysis was used to determine if there was antibody to the
A9 protein in antiserum from the tail bleed of immunised mice after the first challenge
compared with an anti-thioredoxin antibody to detect thioredoxin-A9 (fig. 3.8). A
thioredoxin-specific band was observed with the mouse serum. However, an A9 vBcl-2
specific band was also identified at the predicted molecular weight of the A9 protein
(19kDa). The mice were re-immunised to boost the anti-A9 response and to allow the










Fig. 3.8. Western blot of EnterokinaseMax™ digested thioredoxin-A9 fusion
protein. A: Antiserum from immunised mouse. B: Anti-thioredoxin antibody.
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3.3.5 A9 expression in A9-CHO cells
The expression of A9 in A9-CHO cells was investigated by Northern blot
analysis. Fig 3.9A shows the result of the Northern blot analysis with an A9 probe. A9
mRNA was detected in the transfected cells but as expected not in the UTF CHO cells.
Fig. 3.9B shows the result of the Northern blot analysis with control GAPDH labelled
probe. Both UTF and A9-CHO cells showed a GAPDF1 product. This indicated that the
RNA was intact and the gel was loaded with equivalent amounts of RNA. Northern




























Fig. 3.9. Northern blot analysis of GAPDH and ORF A9 expression in A9-
CHO cells. RNA samples were obtained from A9-CHO cells. A: Northern blot
probed with A9 probe. B: Northern blot probed with GAPDH probe.
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3.3.6 Monoclonal antibody specific for the A9 protein.
The hybridoma supemates obtained from the immunised mice were tested for
specific antibody using an ELISA. The initial ELISA was performed on 258 hybridoma
supernatants. This was originally performed using the thioredoxin-A9 protein as the
coating protein. Controls used in the ELISA were pre-immunised serum and tail bleed
from the immunised mice. Clones were selected on the basis of the OD readings being
comparable with the positive control. Tables 3.1 and 3.2 show a typical ELISA result
from one of the assays performed. From this particular assay four of the hybridomas
were used for the second round of screening, 6E1, 6G8, 6A11 and 2A1. The initial
ELISA that was earned out resulted in 26 putative anti-A9 positive clones. Samples that
were positive for the recombinant thioredoxin-A9 fusion protein were retested on ELISA
plates coated with recombinant thioredoxin. Those that were positive for thioredoxin-
A9 and negative for thioredoxin on its own were considered positive for A9. From the
hybridomas tested, six appeared to react specifically with the A9 protein. The majority
of hybridomas contained antibody against thioredoxin only. The six potential A9
antibody positive hybridoma supernates were tested by immunofluorescence assay using
A9-CHO cells. Two hybridoma supemates were positive by fluorescence, 6E1 and 6G8
(fig. 3.10). Some non-specific staining was observed in CHO cells incubated with pre-
immunised mouse serum in both untransfected (UTF) and A9-CHO cells. However the
level and intensity was very low. 6G8 was identified as an IgG: while 6E1 was
identified as an IgM antibody. Unfortunately 6G8 did not grow in subsequent cultures.
Therefore, 6E1 remained as the principle A9-specific murine monoclonal antibody for
further studies.
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6A3 6A3 5F12 5F12 4F8 4F8 2A4 2A4
B TB TB 6G8 6G8 5D11 5D11 4D8 4D8 2A1 2A1
C 1A11 1A11 6F11 6F11 5H9 5H9 4C6 4C6 1B6 1B6
D 1C12 1C12 6F12 6F12 5H7 5H7 4B4 4B4 1H4 1H4
E 1E12 1E12 6A11 6A11 5D8 5D8 3H11 3H11 1B1 1B1
F 2B6 2B6 6B8 6B8 5B8 5B8 3B10 3B10 1D6 1D6
G 5G1 5G1 6H3 6H3 5D6 5D6 3C5 3C5 1D10 1D10
H 6E1 6E1 6F3 6F3 4F11 4F11 3G3 3G3 2A1 2A1
Table 3.1: A typical ELISA using hybridoma supernates. Table shows the
orientation of the ELISA plate and which supernates were used in the assay. Pre-
immune serum was taken from pre-immunised mice and was used as a negative
control. TB= Tail-bleeds from mice after immunisation and was used as a positive
control.
1 2 3 4 5 6 7 8 9 10 11 12
A 0.010 0.021 0.029 0.062 0.057 0.042 0.007 0.012 0.022 0.073
B 2.741 2.110 2.414 1.987 0.047 0.054 0.009 0.021 0.837 0.753
C 0.039 0.020 0.062 0.054 0.006 0.010 0.054 0.065 0.037 0.021
D 0.004 0.008 0.066 0.042 0.045 0.037 0.044 0.087 0.191 0.241
E 0.06 0.068 2.023 2.132 0.050 0.045 0.024 0.021 0.070 0.039
F 0.063 0.043 0.054 0.075 0.013 0.024 0.066 0.087 0.241 0.354
G 0.028 0.045 0.108 0.154 0.004 0.010 0.005 0.012 0.014 0.031
H 1.555 1.468 0.023 0.054 0.035 0.086 0.020 0.037 0.020 0.052
Table 3.2: A typical ELISA showing the OD readings at 492nm using neat
supernatant of the samples shown in Table 3.1.
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Fig 3.10. Fluorescence images of A9-CHO and UTF CHO cells (photographs
were taken using equal time exposures, x 400 magnification). All cells were fixed
in ice-cold acetone, incubated with the appropriate primary antibody followed by
incubation with goat, anti-mouse-FITC (1:75).
A) A9-CHO cells incubated with pre-immunised mouse serum (1:200).
B) Untransfected CHO cells incubated with pre-immunised mouse serum (1:200).
C) Untransfected CHO cells incubated with 6G8 anti-A9 monoclonal antibody
supernatant (neat).
D) Untransfected CHO cells incubated with 6E1 anti-A9 monoclonal antibody
supernatant (neat).
E) A9-CHO cells incubated with 6G8 anti-A9 monoclonal antibody supernatant
(neat).
F) A9-CHO cells incubated with 6E1 anti-A9 monoclonal antibody supernatant
(neat).
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3.3.7 Purification of mouse antiserum 6E1 using an anti-mouse IgM
column
The supernatant from the 6E1 hybridoma cells was collected and fractionated on
an anti-mouse IgM column. Bound IgM proteins were eluted from the column using
low pH. However, the yield of antibody collected from the column was very poor as
shown in fig. 3.11. Consequently, the supernatant from the hybridoma cells was
partially purified using ammonium sulphate precipitation and the antibody from this was




Fig. 3.11. Antiserum to thioredoxin-A9 purified on an anti-lgM-sepharose column.
IgM fractions were eluted from the column using a Glycine elution buffer and detected
by a shift in absorbance at 280nm. (x-axis is the volume of eluted fractions, y-axis is
the absorbance units at 280nm.)
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3.3.8 Detection of AIHV-1 A9 protein in transfected CHO cells
Using 6E1 anti-A9 serum that had been partially purified by ammonium sulphate
precipitation, A9 vBcl-2 protein was detected in A9-CHO cells (Fig 3.12A).
Localisation of the antibody appeared to be in the cytoplasm. When the antibody was
incubated with untransfected CHO cells, a very low intensity of non-specific labelling




Fig 3.12. Fluorescent images of CHO cells labelled with anti-A9 and control
antibody. (All photographs were taken using equal exposure times, x 400
magnification). All cells were fixed in ice-cold acetone, incubated with the appropriate
primary antibody followed by goat anti-mouse-FITC (1:75).
A) A9-CHO cells protein labelled with ammonium sulphate enriched 6E1 antibody
(1:500).
B) UTF CHO cells labelled with ammonium sulphate enriched 6E1 antibody (1:500).
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3.3.9 Rabbit polyclonal antiserum reacts with A9 vBcl-2 recombinant
protein
Rabbits were immunised with thioredoxin-A9 purified fusion protein (as
described in section 2.7.4). The immunised rabbit serum was tested by western blot
analysis along w ith normal rabbit serum for the presence of antibodies to the
recombinant thioredoxin-A9 fusion protein and also to the (3-galactosidase-A9 fusion
protein.
The antiserum reacted with the 30kDa band of thioredoxin-A9 fusion protein and
the 1 16kDa (3-galactosidase-A9 fusion protein (fig. 3.13). From fig. 3.13 it can be seen
that the antiserum also reacts with the thioredoxin empty vector. The antibody therefore
reacted with the A9 protein because the serum reacted with (3-galactosidase-A9 fusion
protein, which does not contain any thioredoxin. Therefore, the western blot analysis
shows that the polyclonal rabbit antiserum had specificity for both A9 and thioredoxin










Fig. 3.13. Western blot analysis of rabbit antibody specific for the A9 protein.
1: p-galactosidase-A9 fusion protein.
2: P-galactosidase.
3: Thioredoxin.
4: Thioredoxin-A9 fusion protein.
5: Cleaved thioredoxin-A9 fusion protein.
A: Incubated with normal rabbit serum (1:1000), followed by goat, anti-rabbit-HRP
(1:2000).
B: Incubated with anti-A9 rabbit serum, 163 (1:1000), followed by goat, anti-rabbit-FIRP
(1:2000).
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3.3.10 Rabbit anti-A9 serum reacts with the A9 protein expressed by CHO
cells
CHO cells expressing A9 protein (A9-CHO) were incubated with antiserum from
rabbit 163. Rabbit 163 serum was used as the primary antibody (at a dilution of l :500).
The secondary conjugate was goat anti-rabbit-biotin (1:500) and finally the tertiary
conjugate was streptavidin-FITC (1:75). Normal rabbit serum was used as a control
(1:2000).
A field of 200 cells was randomly counted and determined if A9 was being
expressed or not. Positive immunofluorescence was detected in 58% of A9-CHO














Fig. 3.14. Fluorescent images of A9-CHO cells incubated with serum
from an immunised rabbit. (Pictures taken with the same exposure time, x
400 magnification). Cells were fixed in ice-cold acetone, incubated with the
appropriate primary antibody, followed by goat anti-rabbit-biotin (1:500) and
finally incubated with streptavidin-FITC (1:75)
A) A9-CHO cells incubated with 163 rabbit anti-A9 sera (1:500).
B) A9-CFIO cells incubated with normal rabbit serum (1:1000).
125
3.3.11 Expression of EBV BHRF1 vBcl-2 in CHO cell lines
EBV BHRFl vBcl-2 protects cells from apoptosis, and therefore has been used
throughout this study as a positive control. BHRFl DNA was transfected into CHO
cells (BHRFl-CHO). Immunofluorescence analysis was used to identify the percentage
of CHO cells expressing the BHRFl protein using the anti-BHRFl mouse monoclonal
antibody (clone MAB818) (Chemicon). The secondary conjugate was goat anti-mouse-
FITC.
Fig. 3.15 shows that there were no obvious differences between BHRFl-CHO
cells incubated with anti-BHRFl antibody (fig. 3.15.A) and those incubated with normal
mouse serum (fig. 3.15.B). It was decided to proceed with the BHRFl -CHO cells as
they were surviving the plasmid selectable marker selection and hence assumed a good
level of transfection had occurred. This was confirmed by apoptosis assays carried out
(discussed in chapter 5).
Fig. 3.15. Reaction of anti-BHRF1 with CHO cells expressing BHRF1 protein and
in UTF CHO cells. (All pictures taken with the same exposure time, X 400
magnification). All cells were fixed in ice-cold acetone, followed by incubation in the
appropriate primary antibody and finally incubate with goat anti-mouse-FITC (1:75).
A: BHRF1-CHO cells incubated with an anti-BHRF1 antibody (1:1000).
B: BHRF1-CHO cells incubated with normal mouse serum (1:1000).
C: Untransfected CHO cells incubated with anti-BHRF1 antibody (1:1000).
D: Untransfected CHO cells incubated with normal mouse serum (1:1000).
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3.4 Discussion
The A9 gene product predicted amino acid sequence showed limited homology
to the Bcl-2 family of apoptosis regulatory proteins. A9 vBcl-2 possessed the highly
conserved Bel homology (BH) 1 domain and the transmembrane (TM) domain. The
BH1 domain is required for the interaction between Bax and anti-apoptotic proteins Bcl-
xL and Bcl-2 (Borner et al., 1994). It has been suggested that the transmembrane
domain, which is present in some anti- and pro-apoptotic Bcl-2 family members,
localises Bcl-2 family members to membranes such as those of the mitochondria,
endoplasmic reticulum and the nucleus (Krajewski et al., 1993).
When this work was initially started, the A9 protein was unique as it was the
only Bcl-2 family member identified so far to contain only one of the four known BH
domains. However, since starting this research, work has been published on the MHV-
68 Bcl-2 homologue. Sequence analysis performed on MHV-68 vBcl-2 protein has
demonstrated that it contains only the BH1 domain and was shown to a bone-fide
functional Bcl-2 protein (Roy et al., 2000).
A9 protein shows 33% amino acid identity to human Bcl-w. Bcl-w is an anti-
apoptotic protein that co-immunoprecipitates with the pro-apoptotic Bcl-2 family
members, Bax, Bak, Bad and Bik (Holmgreen et al., 1999). The level of amino acid
identity is very low compared to other viral Bcl-2 homologues. For example, it only
shares around 10% identity to BHRF1. However, all viral Bcl-2 homologues that have
been sequenced share sequence identity within the BH1 domain and TM domain. As
would be expected for two viruses that are closely related, the A1HV-1 A9 and the
OvHV-2 09 shared the greatest sequence identity in this study.
The work performed in this section described the expression of recombinant
protein and the production of both rabbit and mouse antibodies. The production of
recombinant A9 protein by various methods was successful. The GST-A9 fusion protein
was mainly insoluble and not a useful reagent. Insolubility is often due to the presence
of strongly hydrophobic regions of the protein (Smith & Johnson, 1988). An attempt
was made to solublise the protein by deleting the hydrophobic TM. The TM domain of
Bcl-2 proteins has been shown to be involved in the import and insertion of the protein
into the mitochondrial outer membrane and can also direct the protein to other
membrane sites (Nguyen et al., 1994). Expression of the truncated A9 protein lacking
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the TM domain also resulted in a mainly insoluble protein. However, the GST-A9
fusion protein did solublise in 8M urea. This resulted in an inhibition of binding to
glutathione sepharose used for purification. Due to the insolubility of the GST-A9
protein and the inability to purify it with glutathione sepharose, an alternative expression
system was tried.
Colleagues in the laboratory had previously successfully produced soluble
thioredoxin fusion proteins. Due to problems that had been encountered with the GST
fusion protein the TM domain was removed from the A9 gene upon amplification. As
previously stated the TM domain enable the Bcl-2 family members to insert into
membranes (Hockenberry et al., 1990; Gonzalez et al., 1995). It has been demonstrated
that the TM domain is not essential in the prevention of apoptosis, as deleting this
domain does not alter the level ofprotection against apoptosis (Hockenberry et al., 1993;
Borner et al., 1994). This was acceptable for the immunisation of the animals, although
the truncated gene could not be used in localisation studies. The thioredoxin-A9 fusion
protein was successfully expressed as a soluble protein and purified using ThioBond™
affinity resin and electroelution from gels. Murine monoclonal antibodies, 6E1 and 6G8
specific for A9 protein were successfully produced in mice immunised with thioredoxin-
A9 protein. These were isotyped IgM (6E1) and IgG2 (6G8) respectively. However,
6G8 did not grow well in tissue culture. Therefore, 6E1 was chosen for the remaining
work. An attempt to purify 6E1 IgM antibody was made using an anti-IgM column.
However, the yield of IgM recovered from the column was very poor. It is possible that
the integrity of the immunoglobulin was lost in the low pH elution protocol that was
used. Due to the poor yield of purified IgM being recovered, it was decided to use a
different antibody.
The rabbit polyclonal anti-A9 antibody was shown to react with both
thioredoxin-A9 andP-galactosidase-A9 fusion proteins. It also reacted with thioredoxin
expressed from the empty pTrxFus vector. However, this reactivity to thioredoxin was
expected as the antiserum was raised against a thioredoxin-A9 fusion protein. This
rabbit polyclonal anti-A9 was used for the remaining work of this study, as it recognised
A9 vBcl-2 by fluorescence and western blot analysis.
A9-CHO cells were shown to express A9 protein through immunofluorescence
analysis. Unfortunately it was not possible to detennine the level of expression by
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BHRF1-CH0 cells. Further work needed to be carried out to develop this technique,
unfortunately this was not possible due to time constraints. It was therefore assumed
that since the transfected cells were surviving selection a proportion of the cells had
been transfected and were expressing BHRF1. BHRF1-CFIO cells were used throughout
this study as a positive control as EBV BHRF1 vBcl-2 has been shown to protect cells
from apoptosis (Khanim et al., 1997).
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Chapter 4
ORF A9 expression in AIHV-1-infected
bovine turbinate cells and LGL cell lines
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4.1 Introduction
The objective of this study was to examine the expression of A9 in various
cells during the vims life cycle. This section also examines where in the cell the A9
protein localises.
There are three strains of A1HV-1 used commonly in MCF laboratory
research. Two are based on: C500, which was first isolated from an infected ox
(Plowright et al., 1975). This has two different forms: C500 low passage, which is
cell-associated and virulent, C500 high passage, which is cell-free and attenuated
with respect to inducing disease in susceptible animals. The third strain of the virus
is WC11. This was isolated from a blue wildebeest and is cell-free and attenuated
(Plowright et al., 1960; Wright et al., 2003). To determine whether A9 was
expressed as an immediate early, early or late viral gene, the metabolic inhibitors
cycloheximide and phosphonoacetic acid were used. Early and late gene
transcription requires cle novo protein translation and can be suppressed by
cycloheximide, which inactivates host cell ribosomes. Therefore, immediate early
genes were detected in the presence of cycloheximide. Late gene expression follows
replication of the vims genome and dmgs that inhibit vims replication prevent the
expression of late genes. Phosphonoacetic acid inhibits DNA polymerase and
therefore was used to harvest early gene transcripts.
Infected cell lines can be derived from lymphoid tissues ofMCF-affected
animals. These cell lines can be maintained for months and sometimes years and
display large granular lymphocyte (LGL) characteristics. Part of this study was to
determine if the A9 gene was expressed in A1HV-1 infected LGLs, as it is unclear
which viral genes were expressed in these cell lines. Therefore, RNA was extracted
from infected rabbit LGLs and A9-specific RT-PCR was performed.
The localisation of the A9 protein in cells was determined by confocal
microscopy. Many of the Bcl-2 family members that have been characterised so far
localise at the mitochondrial membrane (Riparbelli et al., 1995). As demonstrated in
chapter 3, the A9 gene is stably-expressed in CHO cells. To identify where in the
cell the A9 protein localises the stably-transfected CHO cells were transiently
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transfected with mitochondrial green fluorescent protein (mtGFP) (Rizzuto et al.,
1995).
RNA interference (RNAi) is a mechanism of sequence-specific, post-
transcriptional gene silencing initiated by dsRNA homologous to the gene that is
being suppressed. The mechanism was first described in Caenorhabditis elegans
(Fire et al., 1998) and was shown to protect against invasion by foreign genes, but
has subsequently been described in insects, plants, fungi and vertebrates (Reviewed
in Agami, 2002).
During the RNAi process long dsRNA is degraded into 19-23 nucleotide (nt)
siRNA and then is recruited into an RNA-induced silencing complex (RISC) to
degrade corresponding mRNA (Hammond et al., 2000). In mammalian cells siRNA
molecules are capable of specifically silencing gene expressing and has become a
novel technique to probe for gene function. In this study the retroviral plasmid
pSUPER-retro (Oligoengine) was used. This vector directs the stable synthesis of
siRNA in mammalian cells and should result in the efficient long-term down
regulation of specific gene expression. The plasmid contains an ampicillin resistance
gene to aid selection of transformed E. coll and a puromycin resistance gene to aid
the selection of transfected cells. siRNA precursor molecules are transcribed from a
64-mer insert by RNA polymerase II. The transcript contains two inverted copies of
the intended siRNA target (19-mer sequences) separated by a loop to allow the
formation of a RNA duplex. After transcription this hairpin molecule is cleaved by
the DICER enzyme in vivo to produce mature siRNA (fig 4.1). A9-CHO and UTF
CHO cells were stably transfected with pSUPER-A9 and transfectants were selected
with puromycin.
Therefore, the specific objectives in this study were:
• Determine when the A9 gene was expressed in the virus life cycle.
• Determine if the A9 gene was expressed in LGL cell lines.
• Determine where in the cell the vBcl-2 localises.
• To silence the A9 gene in A9-CHO cells by siRNA.
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Fig. 4.1. siRNA production by the pSUPER system. Double stranded DNA
oligonucleotides were designed using an online design system
(www.oliqoenqine.com). (A) The annealed oligonucleotides were ligated into the
pSUPER-retro vector and then transfected into mammalian cells. (B) SiRNA
precursor molecules are transcribed by RNA polymerase II. (C) The transcript is
separated by a loop to allow the formation of a RNA duplex. (D) The hairpin
molecule is cleaved by the DICER enzyme to produce mature siRNA. (E) The
mature siRNA is recruited in a RNA-induced silencing complex (RISC) to (F)
degrade corresponding mRNA. This should result in a reduction in transcript of























4.2 Materials and Methods
4.2.1 Treatment and infection of BT cells
BT cells were seeded in 225cm2 flasks (Costar UK Ltd) and allowed to grow
until confluent.
Immediate early (IE) transcripts were detected by incubating the cells with
lOOpg of cycloheximide (Sigma) for 30 mins, virus was added and the cells were
harvested after 8hrs (Wakeling et al., 2001).
Early (E) transcripts were detected by incubating the cells with lOOpg/ml of
phosphonoacetic acid (ICN Biomedicals Inc) for 2 hrs (Seal et al., 1991) then virus
was and cells were harvested after 24 hrs.
Late (L) transcripts were detected by adding virus to the BT cells with no
treatment and the cells were harvested after 24 hrs.
Cells were harvested and the RNA was extracted as described in section
2.4.1. Virus titres used are shown in table 4.1.
Virus Titre Used (TCID50)
C500 low passage 1CU/b
C500 high passage 10"5'91
WC11 10-s.,4
Table 4.1: Virus titres used in the expression experiment. The titre of each virus
preparation used to infect BT cells is shown.
4.2.2 Northern blot analysis of A9 gene expression
The cells were harvested at the appropriate time points using RNA extraction
buffer. RNA was extracted from the BT cells as described in section 2.4.1. 10pg of
each RNA sample was loaded onto MOPS/formaldehyde gels and run at 100V for 1
hr. RNA was transferred onto nitrocellulose (section 2.4.2). A DNA probe was
labelled and the membrane was hybridised as described in section 2.4.2. The
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membrane was probed with either an A9 or GAPDH 32P labelled probe. GAPDH
was used as a control to determine if the RNA remained intact.
4.2.3 Expression of A9 gene in LGLs
RNA was extracted from LGLs as described in section 2.4.1. RT-PCR was
performed (as described in section 2.4.3.) to determine ifA9 was being expressed in
the LGLs. Primers used in this section of the study were GAPDH5, GAPDH3,
GFPBclF and GFPBclR (as described in appendix 2.1). The annealing temperature
was 55°C.
4.2.4 Localisation of the A9 proteins in transfected CHO cells
A9-CHO cells were seeded in 8 well chamber slides at a density of 1 x
105cells/ml with 200pl of cell suspension added into each well and incubated at
37°C, 5% CO2 in air atmosphere for 24 hrs. A9-CHO cells were transiently-
transfected with 0.2pg ofmtGFP (as described in section 2.2.7). After 48 hrs,
indirect immunofluorescence analysis was performed (as described in section 2.2.9).
Briefly, cells were fixed in ice-cold acetone forlO mins, blocked with normal goat
serum (1:40), incubated with anti-A9 rabbit antibody, 162 (1:500) and detected with
goat anti-rabbit-TRITC conjugate (1:75). Control incubations took place with A9-
CHO cells incubated with normal rabbit serum (1:1000).
Cells were examined by confocal analysis (as described in section 2.2.10).
4.2.5 Expression of A9 protein in LGLs
An aliquot of LGLs (2 x 105 cells) from A1HV-1 infected rabbits and
lymphoid cells grown in culture from healthy rabbits (2 x 105 cells) were
cytocentrifuged onto glass microscope slides using a cytospin 3 machine (Shandon).
Cells were fixed in ice-cold acetone for 10 mins then washed in PBS and stored at -
20°C until required. The indirect immunofluorescence test was carried out as
described in section 2.2.9. Non-specific binding sites on the LGLs were blocked
with normal goat serum (1:40), before incubating with either anti-A9 rabbit
polyclonal, 162 antibody (1:500) or normal rabbit serum (1:1000), followed by anti-
rabbit biotin conjugate (1:500) and finally streptavidin-FITC conjugate (1:75). Cells
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were examined using an Olympus BX50 microscope (Olympus) using a blue (NB)
filter at 470-490nm.
4.2.6 siRNA expression
The mammalian expression vector, pSUPER (Oligoengine) was used for the
expression of siRNA in A9-CHO cells. Target sequences were selected using the on¬
line design system for pSUPER vectors at www.oligoengine.com, which
incorporates siRNA design principles established by Elbashir et al., 2001. The gene-
specific insert specifies a 19-mer sequence corresponding to nucleotides 125857-
125875 (TGGATTTTCCTGCAGCCAC) (Ensser et al., 1997). Additional
restrictions were added to optimise the transcription and specific termination of the
transcript in pSUPER, as well as its correct folding and processing by the DICER
nuclease.
The selected sequence was produced as two complementary 64-mer DNA
oligonucleotides which carry two inverted copies of the 19-mer target sequence
separated by a 9bp loop sequence to promote correct cleavage by the DICER
nuclease and terminal overhangs to facilitate cloning between the Bglll and Hindlll
sites of the pSUPER-retro vector. The A9-specific 64-mer oligonucleotides were
annealed by heating a mixture of 3pg of each oligonucleotides to 95°C then cooling
slowly to 4°C. The annealed oligonucleotides were then 5'-phosphorylated by
treatment with Polynucleotide kinase (Promega) in the presence ofO.lmM ATP.
After heat-inactivation of the enzyme, the annealed 64-mer duplex was ligated into
Bglll and Hindlll digested pSUPER-retro and transferred into E. coli 'SURE 2' cells
(Stratagene).
Plasmid DNA from single colonies were checked for inserts by restriction
analysis with EcoRl and Hindlll and positive clones were confirmed by DNA
sequencing.
Three clones were selected for further study:
Clone 16, which had the expected sequence.
Clone 22, which had a single base substitution in the A9-specific stem.
Clone 31, which had a base substitution in the loop region.
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These three constructs, plus pSUPER-retro vector with no insert were
transfected into A9-CHO cells (as described in section 2.2.7). Stable puromycin-
resistant cell lines were established from each transfection and RNA was isolated
from these cultures (as described in section 2.4.1).
The influence of the pSUPER constructs was examined by northern blot
analysis (as described in section 2.4.2).
4.2.7 FACS analysis of rabbit cells
Cells were washed and re-suspended in FACS wash buffer (2% (v/v) FBS,
0.05% (w/v) sodium azide in PBS) to a density of 5 x 105/ml. In rounded-bottomed
96-well plates, cells were incubated with 50pl of the desired primary antibody (see
table 4.2) prepared in FACS wash buffer for 30 mins on ice. The cells were
centrifuged at 250 x g for 5 mins and the supernatant removed. The pellets were
washed twice in FACS wash buffer. The fluorescein-isothiocynate (FITC)
conjugated secondary antibody (rabbit-anti-mouse, 1:50 in FACS wash buffer)
(DAKO) was added to cells and mixed thoroughly. This mixture was incubated on
ice for 30 mins in the dark. After a further two washes the cells were fixed in 1%
(w/v) paraformaldehyde in wash buffer and transferred to FACS tubes (Falcon 2054,
Becton Dickinson).
Data acquisition and analysis was performed with a two laser four-colour
FACS Calibur flow cytometer and Cell Quest software (Becton Dickinson). 10,000
cells were acquired for each sample with linear amplification for forward (FWS) and
side (SSC) scatter and logarithmic amplification for FITC green fluorescence (FF-1).
Fymphocytes were distinguished on the basis of FWS/SSC profile. Small and large
lymphocytes were distinguished on the basis of the FWS/SSC ratio.
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Specificity mAb Specificity Ref.
CD4 KEN-4 T cells/ helper cells Kotani et a/., 1993
CD5 KEN-5 T cells & subset of B cells Kotani et at., 1993
CD8 12C7 T cells/cytotoxic cells De Smet et at., 1983
CD43 L11/135 All T cells Jackson et at., 1983
igM NRBM B cells
RLA-DR RDR34 R-DR (Class II) Spieker-Polet etal., 1990
Table 4.2. Selected markers and their use.
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4.3 Results
4.3.1 Expression of A9 gene in the lytic virus life cycle
The temporal pattern ofORF A9 expression during the infection ofBT cells
with or without cycloheximide or phosphonoacetic acid treatment was investigated
by Northern blot analysis. Chemical inhibitors were used to establish the stage of the
lytic cycle at which A9 gene expression occurred: immediate early (IE), early (E) or
late (L).
Fig. 4.2A shows the result of Northern blot analysis with control GAPDH
labelled probe. All the Northern RNA samples showed a GAPDH product. This
indicated that the RNA samples were intact and the gel was loaded with equivalent
amounts ofRNA. Fig. 4.2B shows the results ofNorthern blot analysis with the A9
probe. A9 mRNA expression was detected as an early and late virus gene in cells
infected with all three viruses. A9 is therefore expressed as an early-late gene but
not as an immediate early gene in the life cycle of both of the attenuated viruses and
the virulent C500 virus. The uninfected control cells did not show any expression at
any of the time points.
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HP LP WC11 CC
L E IE L E IE L IE E L E~TE
GAPDH
HP LP WC11 CC
L E IE L E IE L IE E L E IE
1 2 3 4 5 6 7 8 9 10 11 12
Fig. 4.2. Northern blot analysis of GAPDH and ORF A9 expression. RNA
samples were obtained from BT cells infected with high passage (HP) C500
cell-free and attenuated AIHV-1, Low passage (LP) C500 cell-associated and
virulent AIHV-1 and WC11 cell-free and attenuated AIHV-1. Cell controls (CC)
were treated with chemical inhibitors but not infected with virus. 1: HP Late. 2:
HP Early. 3: HP Immediate early. 4: LP Late. 5: LP Early. 6: LP Immediate
early. 7: WC11 Late. 8: WC11 Immediate early. 9: WC11 Early. 10: CC Late
11: CC Early. 12: CC Immediate early. A: Northern blot probed with a GAPDH
probe. B: Northern blot probed with A9 probe. Immediate early mRNA
expressed in the presence of cycloheximide. Early mRNA in presence of
phosphonoacetic acid, late mRNA no chemical inhibitors.
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4.3.2 Cellular localisation of the A9 protein
To determine the cellular localisation of the A9 protein, A9-CHO cells were
used. The A9-CHO cells were transiently transfected with mtGFP and the cells were
harvested after 24 hrs. mtGFP uses a fragment that encodes for the precursor of
subunit VIII of cytochrome c oxidase that targets the mitochondria. Therefore, once
transfected into cells, should target the mitochondria (Rizzuto et al., 1995). In this
assay mtGFP protein displayed a fluorescence signal in both the nucleus and
mitochondria (fig. 4.3). However this signal was significantly higher in the nucleus.
This pattern of distribution was not consistent with the localisation that is normally
observed with mitochondrial staining. The faint staining in the cytoplasm is possibly
consistent with mitochondrial localisation however, due to the high fluorescence
observed in the nucleus it is difficult to draw definite conclusions. The cells were
also incubated with either anti-A9 rabbit polyclonal (162) (fig 4.3 A&B) or normal
rabbit serum (Fig 4.3 C&D). Staining with the anti-A9 antibody was dispersed
throughout the cytoplasm but seemed brighter in the cytoplasm. When the A9-CHO
cells were incubated with a control normal rabbit serum, a uniform background was
observed that was less intense in comparison to the cells incubated with the anti-A9
antibody (fig. 4.3 C&D). Fig 4.3B was further analysed shown in fig 4.4.
As shown in fig. 4.4B A9 vBcl-2 (red fluorescence) is seen throughout the
cytoplasmic region of the cells and higher fluorescence in not visible in any
particular region. A proportion of the mtGFP transfected cells express mtGFP (green
fluorescence) following transient transfection (fig 4.4A). There is strong staining in
the nucleus but no staining ofmitochondria from mtGFP. Fig.4.4D shows, some co-
localisation ofmtGFP with anti-A9, however as staining with the anti-A9 antibody is
observed throughout the cell and the mtGFP localises to the nucleus, it is not possible
to conclude that A9vBcl-2 is co-localising with the mitochondrial marker. These
results indicate that further work needs to be carried out to determine whether the A9
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4.3.3 Phenotypic analysis of AIHV-1 LGL T cells
A rabbit was infected with AIHV-1 C500 HP and the LGL cell line BJ2590
was established (see section 2.2.1) and phenotyped by FACS analysis (see section
4.2.7). Lymphoid tissue was also taken from an uninfected rabbit and cells cultured
from this (referred to as uninfected lymphocyte cells (ULC)). ULC were used as
control cells and phenotyped by FACS analysis.
The results (table 4.3) show the phenotype of the cell culture at day 6, when
A9 is expressed and day 56 of culture when the cell line has been established. ULC
phenotype analyses of around the same days have also been shown.
The phenotypic analysis of the rabbit cell line was determined using a
number of anti-rabbit CD antibodies (summarised in table 4.2). Cells were
characterised with monoclonal antibodies against CD4 (thymocytes and
helper/inducer T-cell subset), CD5 (T-cells and a subset of B-cells), CD8
(thymocytes and cytotoxic/suppressor T-cell subset), CD43 (T-cells) rabbit IgM (B
cells) and D-related rabbit leukocyte antigen (RLA-DR) (rabbit MHC II DR alpha
and beta chains).
The results of the phenotype analysis are summarised in table 4.3. None of
the cells expressed surface IgM indicating that none of the cells phenotyped were B
cells. At day 6 of culture of the lymphoid tissue the cell line BJ2590 were CD4"
(98%), CD5+ (98%), CD8+ (85%) and CD43+ (99%). Cells expressed RLA-DR
(98%) indicating that these T cells were activated. Once the cell line BJ2590 had
been established in culture these cells were still CD4" (99%), CD5+ (93%), CD8+
(83%) and CD43+ (86%). Cells still expressed RLA-DR (73%) indicating that these
were activated T cells.
The ULC line at day 6 of culture was CD4" (>99%), CD5" (<1%) and CD43+
(94%). A proportion (12%) of the cells were CD8+. However the cells were RLA-
DR" indicating that these were not activated T cells. Once the ULC had been
established at day 59 these cells were CD4" (>99%), CD5" (>99%) and RLA-DR"
(>99%). A proportion of the cells were CD8+ (6%) and CD43+ (63%). The results
presented here show that the cell line BJ2590 had T cell phenotype. Some sample


















BJ2590 6 98 85 2 99 98 <1
BJ2590 56 93 83 1 86 73 <1
ULC 6 <1 12 <1 94 <1 <1
ULC 59 <1 6 <1 63 <1 <1
Table 4.3. Detection of cell surface markers on rabbit MCF cell lines. BJ2590 is
an established cell line from an AIHV-1-infected rabbit. Uninfected lymphoid cell
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Fig 4.5. FACS profile for rabbit LGL cell line BJ2590 (day 6 of culture of
lymphoid tissue).




















Fig 4.5 (continued): FACS profile for rabbit LGL cell line BJ2590 (day 56 of
culture of lymphoid tissue).
8) FITC conjugate alone. 9) anti-CD5. 10) anti-CD8. 11) anti-CD4. 12) anti-m chain.
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Fig 4.5 (continued): FACS profile for uninfected rabbit LGL cell line (day 6 of
culture of lymphoid tissue).
15) FITC conjugate alone. 16) anti-CD5. 17) anti-CD8. 18) anti-CD4. 19) anti-m
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Fig 4.5 (continued): FACS profile for uninfected rabbit LGL cell line (day 59 of
culture of lymphoid tissue).
22) FITC conjugate alone. 23) anti-CD5. 24) anti-CD8. 25) anti-CD4. 26) anti-m
chain. 27) anti-CD43. 28) anti-RLA-DR.
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4.3.4 Expression of A9 gene in LGL cell lines
To determine if the A9 gene was expressed in A1HV-1-infected LGLs
produced as a consequence of viral infection, RNA was extracted from the LGL cell
line BJ2590 and subjected to RT-PCR analysis.
Fig. 4.6 shows the results of RT-PCR analysis with GAPDH primers. All
RT-PCR samples exhibited a 950bp GAPDH product. Water was used as a negative
control and it did not show any product. This indicated that the RNA samples were
intact and that the reverse transcriptase reactions had worked.
Fig. 4.7 shows the results of RT-PCR analysis with A9 primers. A 500bp
product corresponding to the A9 gene was detected in samples from day 4, 8 and 13
of culture of lymphoid tissue but not thereafter. To determine that there was no
contaminating viral DNA present in the samples, PCR using A9 specific primers was
carried out on the RNA samples without prior RT treatment (fig 4.7, lanes 9-12).
This suggests that A9 is expressed in LGL cell lines at an early stage of LGL
establishment in culture of lymphoid tissue from MCF-affected rabbits.
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12 3 4
Fig. 4.6. RT-PCR GAPDH-specific primers. RNA was obtained from
AIHV-1-infected LGLs at various time points after initiation of cultures. 1:
Markers. 2: AIHV-1-infected LGLs day 4. 3: AIHV-1-infected LGLs, day
8. 4: AIHV-1-infected LGLs day 13.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Fig. 4.7. RT-PCR analysis using ORF A9 specific primers. RNA samples
were obtained from AIHV-1-infected LGLs. 1: 1kb marker. 2: Water. 3: ORF A9
positive DNA. 4: Uninfected lymphoid cells. 5: AIHV-1-infected LGL day 4. 6:
AIHV-1-infected LGL day 8. 7: AIHV-1-infected LGL day 13. 8: AIHV-1-infected
LGLs day 21. 9: RT-ve AIHV-1-infected LGL day 4. 10: RT-ve AIHV-1-
infected LGL day 8. 11: RT -ve AIHV-1-infected LGL day 13. 12: RT -ve AIHV-
1-infected LGLs day 21. 6: Water. 7: Negative (no primer). 8: ORF A9 DNA.
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4.3.5 Immunofluorescence analysis of A9 expression in AIHV-1-infected
LGL T cell lines.
To detect expression ofA9 protein in AIHV-1 -infected rabbit LGL T cells,
anti-A9 rabbit polyclonal antibody, 163, was used in immunofluorescence studies on
acetone-fixed cytocentrifuged preparations. Immunofluorescence analysis was
carried out on cells taken at day 6 of culture as these had been shown to express the
A9 gene by RT-PCR analysis.
Immunofluorescence analysis using the rabbit polyclonal antibody showed
positive fluorescence in a proportion of the cells (fig. 4.8A), which was brighter than
that seen in assays using AIHV-1 infected LGLs stained with normal rabbit serum
(fig. 4.8B). However, a similar level of fluorescence was observed in control
uninfected cells stained with normal rabbit serum (fig. 4.8D). These results may
indicate that the expression ofA9 is at a low level, which is difficult to detect. More
work is required to further clarify this and to show whether A9 expression could be
detected in AIHV-1 infected LGLs using the anti-A9 antibody.
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Fig. 4.8. Immunofluorescence analysis of LGL T cells. (All pictures taken
with the same exposure time, x 400 magnification). Cells were fixed using ice
cold acetone and incubated with the appropriate primary antibody followed by
incubation with anti-rabbit biotin conjugate (1:500) and finally incubated with
streptavidin-FITC (1:75).
A: AIHV-1-infected LGL incubated with anti-A9 rabbit polyclonal antibody (163)
(1:500).
B: AIHV-1 infected LGL's incubated with normal rabbit serum (1:1000).
C: Uninfected lymphoid cells incubated with anti-A9 rabbit polyclonal antibody
(163) (1:500).
D: Uninfected lymphoid cells incubated with normal rabbit serum (1:1000).
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4.3.6. Attempts to silence the A9 gene by RNA interference
In order to determine whether the expression of A9 in A9-CHO cells could be
inhibited, co-stable transfection of A9-specific siRNA was attempted.
The siRNA was produced as described in section 4.2.6. There were four
constructs used in this study. There were:
Construct 16: Correct sequence
Construct 22: Had a single base substitution in the A9-specific stem.
Construct 31: had a base substitution in the loop region.
pSUPER empty vector
Fig. 4.9 shows the results of northern blot analysis with an A9 probe on A9-
CHO cells that had been transfected with A9-specific siRNA constructs. A9 mRNA
expression was detected in all of the transfected A9-CHO cell lines indicating that
the mRNA expression has not been diminished by siRNA. A9 mRNA expression
was not reduced in the presence of the correct sequence siRNA or in any of the
mutated siRNA oligonucleotides. The blot was analysed quantatively using a
phosphor imager (Amersham) to examine if there were any differences in the signal
between any of the cell lines. However there was no obvious correlation between the
construct that had been transfected with the siRNA and A9-CHO cells.
A9-CHO UTF CHO
•H • mm mtk
12345 12345M
Fig. 4.9. Northern blot analysis of RNA interference of A9 expression.
RNA was extracted from UTF and A9-CHO cells. 1: Construct 31, mutated
loop region 2: Construct 22, mutated A9-specific stem. 3: Construct 16,
expected sequence. 4: pSUPER empty vector. 5: CHO cells not transfected
with pSuper vector. M: RNA markers.
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4.4 Discussion
ORF A9 mRNA was expressed as an early through to late viral gene but not
as an immediate early gene during the productive phase of the virus life cycle in
A1HV-1-infected BT cells. This was the case with all three virus isolates tested,
C500 low passage cell-associated and virulent, C500 high passage cell-free and
attenuated and WC11 cell-free and attenuated.
The C500 strain of the virus was first isolated from an infected ox with MCF
(Plowright et al., 1975). The virus when initially cultured is virulent and cell-
associated, however after prolonged passage in culture the virus becomes attenuated
and cell-free. This switch from cell-associated to cell free is associated with a loss of
pathogenicity for cattle and rabbits (i.e. the disease is not induced. The loss of
pathogenicity is due to genome re-arrangement (Wright et al., 2003). There are two
genes that are probably affected by the re-arrangement, these are ORF 50 and ORF
A6. Others that may also be affected are ORF 48 and A7. In OvHV-2 the 07
homologue encodes a virus glycoprotein therefore it would seem likely that A7
encodes a virus glycoprotein (Wright et al., 2003). This study has demonstrated that
although the genome is re-arranged the A9 gene is still expressed. The re¬
arrangement of the C500 genome does not bring about any changes in the position of
the A9 gene or the surrounding genes. This would therefore suggest that A9 is not
involved in the pathogenesis of the disease as it is expressed in both the cell-
associated and virulent strain and the cell-free and attenuated strain.
This result is consistent with similar studies with other gammaherpesviruses.
The MHV-68 ORFMl 1 vBcl-2 transcript was observed in mouse fibroblast cells
where expression was inhibited by cycloheximide treatment but not by
phosphonoacetic acid. Therefore it is also an early-late expressed viral gene in the
productive phase of the virus life cycle (Roy et al., 2000). The Bcl-2 homologue that
is present in KSHV is an early gene in the lytic life cycle (Sun et al., 1999). Early
genes generally encode for factors that are required for virus replication. This would
suggest that the Bcl-2 homologue is required for virus replication and the
establishment of the productive virus life cycle. The latent life cycle has not been
defined in MCF viruses therefore no study can be performed to define this at the
present time.
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A LGL cell line was established from an A1HV-1 -infected rabbit. Previous
studies have demonstrated these cells to be predominantly T cells based on the
presence of cell surface antigens CD4, CD5 and CD8 (Burrells & Reid, 1991;
Schock et al., 1998). In this study the cell line BJ2590 was CD4", CD5+, CD8+ and
CD43+. This work is in agreement with previous phenotypic work carried out on
experimentally infected rabbit LGL cell lines (Reid et al., 1983; Schock & Reid,
1996, Swa et al., 2001). The absence of surface IgM suggests that this culture did
not contain B cells.
The A1HV-1 infected LGL cell line established in this study exhibited the
morphology of large granular T lymphocytes. They are not B cells as they are IgM
negative. The cell line had a cytotoxic cell phenotype and expressed virus genes.
These aspects are common features of all LGL cell lines (Swa, 2001).
ORF A9 mRNA was found to be expressed on days 4, 8 and 13 of LGL
establishment in culture. However, it was not identified after day 13 in the cells used
in this study. This is in contrast with earlier work (carried out at the Moredun
Research Institute- Harry Wright, unpublished data), which found that ORF A9
mRNA was expressed 2-3 months after the establishment of two A1HV-1 -infected
LGL T cell lines (H. Wright, personal communication). It is possible that A9 is
required at certain stages of the virus life cycle and this differs amongst cell
populations. For example, the A9 gene product appears from the BT study to be
required for the establishment of the lytic cycle and may not be required once the
lytic phase of the virus cycle is established. The replicative state of the virus in the
LGL is unknown and the latent state of the virus is not well characterised in MCF
viruses. By examining the latent state of the virus it may lead to a better
understanding of the LGLs and their role.
The results of the immunofluorescence assay did not show conclusively
whether A9 was expressed at the protein level in A1HV-1 infected LGL cultures at
day 6. This may have been due to the level of expression in the LGL cell lines or
that the technique needed to be further optimised for the antibodies and cell lines
used. This was not possible due to time constraints. It is also possible that the
antibodies and cell lines used in this assay derived from the same species, therefore
this could lead to a higher background fluorescence being observed. The high
157
background fluorescence observed could be a reflection of this use of rabbit
antibodies with rabbit derived cell lines. Another factor to be considered is the cells
are a mixed population at this timepoint therefore the level of expression of the
virally infected LGL may be low. A possible alternative to the immunofluorescence
assay could be the use of FACS analysis using the anti-A9 antibody, this would
possibly give a quantative result of the expression ofA9 at a protein level. The
detection, by RT-PCR, ofA9 mRNA in A1HV-1-infected LGL T cells at the same
stage, supports the view that the A9 gene is likely to be expressed in LGLs. In
previous studies, LGL T cell lines have been shown to contain both viral DNA and
protein (Swa, 2001) ORF 50, A6 and A7 were found to be expressed at low levels.
These three genes encode viral transactivators and a viral glycoprotein suggesting
that replicating virus was likely to be present. More recently, OvHV-2-infected LGL
T cells from rabbits were shown to contain genome structures characteristic of both
latently-infected cells and cells with virus undergoing productive replication
(Rosbottom et al., 2002). It could therefore be possible that in A1HV-1-infected
LGL T cells, the virus may be latent in some cells and undergoing a lytic phase of
the virus life cycle in others. Thus A9 may be expressed in a small proportion of the
LGL population, especially if its expression were restricted to the lytic phase. This
remains to be determined.
The co-localisation assay carried out in this study did not conclusively reveal
the localisation of the A9 gene product. The transfection ofmtGFP into the A9-CHO
cells displayed labelling of the nucleus of some cells. The mtGFP construct uses a
fragment encoding the amino-terminal of the precursor of subunit VIII of
cytochrome c oxidase (COX) (Rizzuto et al., 1995). COX catalyses the transfer of
electrons from cytochrome c to dioxygen, which is coupled to the translocation of
protons across the inner mitochondrial membrane (Ferguson-Miller & Babcock,
1996). In mammals the enzyme consists of 13 subunits per COX monomer, ofwhich
three are mitochondrial and ten are nuclear coded (Grossman & Lomax, 1997).
When expressed in HeLa cells the mtGFP fusion protein was confined to the
mitochondria (Rizzuto et al., 1995). However, in this study CHO cells were used
and it is possible that the localisation ofmtGFP in these cells did not match that
observed in HeLa cells. Therefore, further analysis will be needed to define the
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cellular localisation ofA9. This could be carried out using another mitochondrial
marker such as Mitotracker that has been shown to localise in the mitochondria of
CHO cells (Khodjakov et al., 1998).
The vBcl-2 homologue present in EBV (BHRF1) also localised to the
mitochondria in EBV genome-positive cell lines (Elickish et al., 1994). Similarly the
adenovirus protein E1B19K, that possesses homology to Bcl-2, localised to
mitochondria (Perez & White, 2000). The fact that other viral Bcl-2 homologues
localise to the mitochondria suggests that the A9 protein may also localise in this
organelle. Localisation ofA9 may involve its association with other viral or host
proteins, either constitutively or following some stimulus. The CHO transfectant
system used here may not have provided the correct binding partners for the stimulus
to induce localisation. However, further is required to clarify this. If A9 was
associated with the mitochondria cells infected with A1HV-1 it might be bind to pro-
apoptotic Bcl-2 proteins, preventing them from inserting into the mitochondria and
allowing the virus to establish a productive life cycle by extending the life of the
target cells.
An initial experiment was carried out to silence the A9 gene in A9-CHO by
RNA interference showed no decrease in A9 expression. The reasons for this could
be that the siRNA sequence may not be optimal for significant interference with A9-
expression. This could be due to features of the siRNA duplex- its processing from
the pSUPER transcript, its sensitivity to other nuclease or its ability to activate the
silencing complex.
Alternatively the target site of the A9 RNA may not be accessible due to
secondary structure or there may be other sequence-based factors required for
efficient gene silencing.
There may also have been problems with the transfection and/or expression
of the retroviral pSUPER constructs, as the transcription of the hairpin RNA was not
assayed in these cells.
The main reason for the lack ofRNA silencing is that only a single siRNA
molecule was tested in the study. The current opinion in this field is that more than
one siRNA molecule is required. However, the design system that was used to
generate target sequences only selected one sequence.
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However, colleagues in the laboratory are currently developing this
technique.
In conclusion this study has demonstrated that A9 is expressed as an early
through to late viral gene. It has also shown that at RNA level A9 is expressed at day
6 in culture in virally infected LGLs.
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Chapter 5




In order to survive within the host, viruses often have to evade the host
immune response. Following infection with a virus, cells can enter the apoptotic
pathway as a means of limiting virus replication. In addition, one mechanism by
which cytotoxic T lymphocytes and natural killer cells kill virus-infected cells is by
inducing apoptosis via secretion of cytokines such as TNF, the release of perforin
and granzymes or the activation of Fas in the target cell (reviewed in Alcami &
Koszinowski, 2000). Many viruses inhibit apoptosis by deploying mechanisms such
as inhibiting Fas or TNF receptor pathways or expressing caspase inhibitors, IAP
proteins and anti-apoptotic Bcl-2 homologues.
In this study the main objective was to determine ifA9 vBcl-2 had anti-
apoptotic properties, by observing whether A9-CHO cells were protected after
delivery of an apoptotic stimulus (cis-platin).
CHO cells expressing EBV BFIRF1 (BHRF1-CHO) were used as a positive
control. EBV BHRF1 has been shown to protect human epithelial cells from cis-
platin induced apoptosis (Khanim et al., 1997). As a transfection control, CHO cells
containing an inactive ovine interferon gamma gene (IFNy) were used. The
transfected cell line does not express IFN-y (for the remainder of this study it will be
referred to as control CHO) (Graham et al., 1995). Finally, untransfected (UTF)
CHO cells were used as a second negative control. A9 cDNA-transfected CHO cells
(A9-CHO) were used in the apoptosis assays and immunofluorescence assays.
To determine the percentage of CHO cells expressing BHRF1 or A9,
immunofluorescence analysis was carried out using the anti-BHRFl mouse antibody
and the anti-A9 rabbit antibody respectively (as described in section 3.3.9 and
3.3.10).
There are several assays available to determine if cells are undergoing
apoptosis. These include determining the morphology of the cell, DNA
fragmentation, assays of the activity of apoptotic pathway enzymes and flow
cytometry to identify changes in cell DNA content (Chiarugi et al., 2002). The
assays that will be used in this study analyse the activity of the apoptotic enzyme
caspase-3, changes in cell morphology and DNA fragmentation.
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"Diff-quik" (Dade Behring) staining allows a quick and simple method to
identify morphological changes that arise due to apoptosis. The cells are stained
with the Diff-quik reagents. Staining allows changes in cell morphology to be
observed by light microscopy. In 'healthy' cells the nucleus has a dark appearance
with the cytoplasmic region lightly stained. However, in apoptotic cells the overall
staining of the cell is visibly darker.
DNA fragmentation occurs during apoptosis due to the activation of specific
endonucleases that cut DNA between nucleosomes. The DNA can be extracted from
the cells and its fragmentation is analysed by agarose gel electrophoresis. In
apoptotic cells typical 'DNA-laddering' is observed. This assay was chosen as it is a
simple assay that gives a clear qualitative indication of apoptosis.
The final assay chosen was the caspase-3 assay. As described in chapter 1
(section 1.5.2) caspase-3 is an executioner caspase that once cleaved and activated
initiates apoptosis. Caspase-3 is activated as a result of the cleavage of inactive pro-
caspase-3, caspase-9 or caspase-8. Caspase-9 is activated as a result of the formation
of the apoptosome complex, while caspase-8 is activated following FADD
activation.
The caspase 3 assay uses the caspase-3 fluorogenic substrate N-Acetyl-Asp-
Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC) that can be used to
identify and quantify caspase-3 activity. Caspase-3 cleaves after the tetrapeptide,
releasing the fluorescent AMC, which can be quantified in cell lysates by ultraviolet
spectrofluorometery. Apoptotic cell lysates will contain an active caspase-3 yield
with a high emission in comparison to non-apoptotic cell lysates. The assay was
chosen as it gives a quantitative indication of an early stage of apoptosis.
The cytotoxic drug cis-diamminedichloroplatinum II (cis-platin) has been
successfully used to induce apoptosis in CHO cells in other studies (Khanim et al.,
1997). Thus, cis-platin was used in this study to induce apoptosis. The specific
mechanisms that activate an apoptotic response to cis-platin are not well
characterised. However, it is thought that cis-platin damages the DNA. This in turn
leads to the induction of the p53 apoptosis system which involves mitochondrial
apoptosis and the Bcl-2 family of proteins (Jamieson & Lippard, 1999).
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5.2 Materials and Methods
5.2.1 Cells used
CHO cell lines were used throughout this study. UTF (negative control),
CHO cells transfected with an inactive ovine IFN y gene (control CFIO) (Graham et
al., 1995), CHO cells transfected with EBV BHRF1 (BHRF1-CHO, positive control)
and CHO cells transfected with A9 cDNA (A9-CHO). All cells were maintained in
GMEM supplemented with 7.5% (v/v) dFBS. Prior to the induction of apoptosis the
serum concentration was reduced to 2% (v/v). Apoptosis was induced as described
in section 2.8.2. Briefly the various CHO cell lines were incubated with 25pM of
cis-platin with for 3 hrs. The media was removed and fresh media was added. Cells
were analysed 24, 48 and 72 hrs after treatment with cis-platin.
5.2.2 Viability assay
2 • 5
The assay was set up in 35mm petri dishes; at a concentration of 3 x 10
cells/ml with 1.5ml of cell suspension being added to each petri dish. UTF CHO
cells and A9-CHO cells were used in this assay. Apoptosis was induced in cells using
cis-platin as described in section 2.8.2. The viability assay was performed as
described in section 2.2.6. A sample of cells (200) was counted; live and dead cells
were counted in a haemocytometer and the results were expressed as the percentage
of cells surviving.
5.2.3 Frequency of cells expressing proteins
To determine the numbers of cells expressing either EBV BHRF1 or A9
vBcl-2, immunostaining of the cells was performed as described in section 2.2.9.
A9-CHO cells were incubated with the anti-A9 rabbit polyclonal antibody, 163
(1:500), followed by incubation with anti-rabbit-biotin conjugate (1:500) and finally
streptavidin-FITC (1:75). BHRF1-CHO cells were incubated with an anti-BHRFl
mouse monoclonal antibody (1:1000) followed by incubation with goat anti-mouse-
FITC (1:75). A sample of cells, 200, was counted and the number expressing the
protein of interest was determined. The results were expressed as the percentage of
cells expressing the protein of interest.
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5.2.4 Caspase-3 Assay
The assay was as described in section 2.8.4. The results were analysed using
a fluorescent plate reader (CytoFluor series 4000, Perspective Biosystems) and
expressed as relative fluorescent units (RFU). Statistical analysis was performed
using the Student's t-test.
5.2.5 Diff-quik Assay
The assay was as described in section 2.8.5. Samples of cells (200) were
counted using light microscopy. The results were expressed as the number pyknotic
cells compared to healthy cells and statistical analysis was by Student's t-test.
5.2.6 DNA Fragmentation assay
The assay was performed as described in section 2.8.3. The results were
using agarose gel electrophoresis to show typical "DNA laddering".
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5.3 Results
5.3.1 Frequency of CHO cells expressing A9 and BHRF1
The frequency of CHO cells expressing A1HV-1 A9 was determined at the
start of the assays using immunofluorescence staining with an anti-A9 antibody (as
described in section 3.3.9). In A9-CHO, 58 % of the cells expressed the A9 protein.
Due to time constraints the protocol to optimise the anti-BHRFl antibody could not
be developed to the full extent however, since the BHRF1-CHO were surviving
selection it was assumed that the BHRF1-CHO cells contained the BHRF1 gene.
5.3.2 Viability Assay
UTF CHO cells and A9-CHO cells were used to investigate the optimum
concentration of cis-platin that should be used to induce apoptosis using cell viability
as a read-out. Cells were treated with various concentrations of cis-platin. From fig.
5.1 it can be observed that at higher concentrations of cis-platin (75pM and lOOpM)
both UTF CHO and A9-CHO cells were all dead at 72 hrs, indicating that cis-platin
is toxic at this concentration and that the A9 gene product could not inhibit apoptosis
induced by this dose. At the lowest concentration (25pM) of cis-platin there was a
significant difference (p=0.004) between UTF-CHO (57%) and A9-CHO (78%) cells
surviving at 72 hrs, while at 50pM an effect was also seen, although it was not
significant in this case.
Therefore, it was decided to use a concentration of 25pM of cis-platin since
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Fig. 5.1. The percentage of surviving cells after incubation with various doses of cis-
platin at various time points throughout the assay. Asterisks denote significant




All CHO cells were incubated with cis-platin and analysed 24, 48 and 72 hrs
after treatment. Fig. 5.2. shows that healthy (non-apoptotic) cells exhibited dark
staining around the nucleus and light staining around the cytoplasm. However, in
cells undergoing pyknosis, the cells rounded up and a characteristic cytoplasm was
no longer obvious. Overall the staining of the apoptotic cells was very dark/intense.
Fig. 5.3 summarises the merged to results. The assay was repeated twice with cells
set up in triplicate in each assay.
Fig 5.3. shows that at time points 24, 48 and 72 hrs after treatment with cis-
platin there were significant differences (p=0.02, 0.01 and 0.04 respectively) in the
number of pyknotic cells with more pyknotic UTF-CHO cells compared to A9-CHO
cells. When the A9-CHO cells were compared with control CHO cells at each time
point (24, 48 and 72 hrs) there were also significant differences (p=0.01, 0.01 and
0.02) with more control CHO cells undergoing pyknosis compared to A9-CHO cells.
At 24 hrs after treatment there is no significant difference (p>0.05) between
BHRF1-CHO cells and UTF-CHO cells. However at time points 48 and 72 hrs after
treatment with cis-platin there are significantly (p=0.02 and 0.04 respectively) more
pyknotic UTF-CHO cells compared to BHRF1-CHO cells. At each time point (24,
48 and 72 hrs) after treatment with cis-platin there arc significantly (p=0.003, 0.002
and 0.01 respectively) less pyknotic BHRF1-CHO cells compared to control CHO
cells.
The results of this assay show that A9 protects CHO cells from cis-platin
induced apoptosis.
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Hours after treatment with cis-platin
Fig. 5.3. The number of pyknotic cells at various time points after
incubation with 25pM cis-platin. Pyknotic cells detected with Diff-quik
assay. Asterisk shows significant differences between A9-CHO cell and
other cell lines. Where * denotes p=0.02, ** denotes p=0.01 and ***
denotes p=0.04. Number of cells counted was 400. Error bars indicated
the standard deviation.
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5.3.4 DNA Fragmentation Assay
During apoptosis, DNA is cleaved between nucleosomes to produce
fragments in multiples of around 185bp. This can be analysed using agarose gel
electrophoresis to show a typical "DNA-ladder". DNA was extracted from CHO
cells that had been incubated in the presence or absence of cis-platin.
In UTF and control CHO cells, laddering is faintly seen after 24 hrs of
treatment with cis-platin. By 48 hrs after treatment, DNA fragmentation is clearly
visible (fig. 5.4.). This contrasts with the CHO cells transfected with the Bcl-2
homologues BHRF1 and A9. Both show only very faint laddering after 48 hrs of cis-
platin treatment although this is more evident after 72 hrs (fig. 5.4.) but not as
marked as in controls. This demonstrates that A9 has anti-apoptotic activity (most
clearly seen 48 hrs after cis-platin treatment) and appears to be as qualitatively
efficient as BHRF1 in protecting cells from cis-platin induced DNA fragmentation.
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BHRF1 CHO A9CHO
Fig 5.4. Agarose gel electrophoresis showing typical "DNA laddering"
associated with apoptosis.
1: 1 kb markers.
2: DNA extracted from CHO cells without cis-platin.
3: DNA extracted from CHO cells 24 hrs after treatment with cis-platin.
4: DNA extracted from CHO cells 48 hrs after treatment with cis-platin.
5: DNA extracted from CHO cells 72 hrs after treatment with cis-platin.
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5.3.5 Caspase-3 Assay
The caspase-3 assay looks at the activation of caspase-3, an executioner
caspase, in CHO cells undergoing cis-platin-induced apoptosis. The assay was
carried out in duplicate, the results shown are the average of the two experiments.
The error bars shown on fig. 5.5 show the standard deviation.
Fig. 5.5 shows that at 72 hrs after treatment with cis-platin there was
significantly more (p=0.05) caspase-3 activity in UTF CHO cells compared to A9-
CHO cells. At each timepoint selected in this assay there is more caspase-3 activity
in UTF and control CHO cells compared to A9-CHO cells.
Fig. 5.5 shows that there is also significantly more (p=0.003) caspase-3
activity in UTF CHO cells than in BHRF1-CHO cells at 72 hrs.
The result of this assay shows that there is less caspase-3 activity in both
BHRF1 and A9-CHO cells compared to both control and UTF CHO cells, which

























Fig. 5.5. Caspase-3 apoptosis assay. Figure shows the level of caspase-3 activity
at various time points after incubation with 25/iM cis-platin. Where asterisk denotes
*p=0.05, and ** denotes p=0.003. Error bars indicate the standard deviation.
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5.4 Discussion
The A9 vBcl-2 gene product exhibited anti-apoptotic activity in CHO cells
stimulated with cis-platin, as measured in a range of apoptosis assays.
The proportion of cells expressing BHRF1 in BHRF1-CHO cells could not be
determined since the assay needed to be optimised. However, it was assumed that
the level of expression in both A9-CHO and BHRF1-CHO was comparable.
Cis-platin binds to DNA through nitrogen atoms on DNA base pairs to form
cis-platin-DNA adducts. The formation of these adducts causes the purine nitrogen
to destack and the DNA helix become kinked (Jamieson & Lippard, 1999). The
mechanism by which apoptosis is induced is largely unknown although there are two
mechanisms that have been proposed. The first is that high mobility group (HMG)
proteins that bind to the cis-platin-DNA adducts are transcription factors. This
complex may interfere with the transcription machinery, which in turns induces
apoptosis. The second proposed mechanism is that these adducts may not be
identified by the repair mechanism. Therefore, DNA repair would occur at a slower
rate and lead to the interference with normal cellular functions and induce cell death
(Jamieson & Lippard, 1999)
The assays that were chosen for this study were selected to represent different
stages of apoptosis. The early stages of apoptosis were examined through the
caspase-3 assay. The caspase-3 assay looks at the activation of caspase-3 (an
executioner caspase) in cells that have been treated with cis-platin. Once caspase-3
is activated, it cleaves key regulatory or structural proteins - in particular it activates
apoptotic nucleases such as caspase activated deoxyribonuclease (CAD) as well as
activating upstream death cascades including the release of cytochrome c from
mitochondria (Vaughan et al., 2002).
One of the biochemical hallmarks of apoptosis is the activation of specific
endonucleases that cleave the DNA between nucleosomes, which can be detected by
agarose gel electrophoresis (Wyllie, 1980). This is a relatively late indicator of
apoptosis. However, it does provide a benchmark qualitative result in comparison to
the other assays performed in this study that provide more quantative results. The
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Diff-quik assay detects morphological changes in the cells that take place during
apoptosis and is therefore also a late indicator of apoptosis (Loo & Rillema, 1998).
These assays were chosen because they were quick, simple and should be easy to
interpret.
The A1HV-1 A9 gene product and EBV BHRF1 gene product protected CHO
cells from cis-platin-induced apoptosis in all of these assays. The level of protection
was comparable in both the diff-quik and DNA extraction assay. This would suggest
that BHRF1 and A9 act at a similar level and fashion. This is similar to results
obtained previously with EBV BHRF1 (Khanim et al., 1997), where EBV BHRF1
transiently-transfected into both Cos-1 and SVK fibroblast cells protected them
against cis-platin-induced apoptosis. The BHRF1 gene product also protected
epithelial cells from apoptosis induced by a variety of stimuli such as TNF, anti-Fas
and serum deprivation (Kawanishi, 1997). Similar results have been obtained with
other gammaherpesviruses. For example, the vBcl-2s present in MHV-68 and
KSHV have anti-apoptotic activity (Sarid et al., 1997; Roy et al., 2000).
The A9 gene product, by exhibiting anti-apoptotic properties would prevent
virus-infected cells from undergoing apoptosis and this in turn would allow the virus
to replicate and establish a productive life cycle. The results presented here suggest
that A9 vBcl-2 is anti-apoptotic and could function by associating with pro-apoptotic
proteins produced as a result of infection and thereby prevent them from inducing an
apoptotic pathway for the elimination ofA1HV-1.
Many viruses, including KSHV, EHV-2, some poxviruses and some
adenoviruses have devised mechanisms to inhibit the Fas and TNFR pathways that
lead to cell death (Telford et al., 1995; Shisler et al., 1997; Shisler & Moss, 2001,
Sun et al., 2003). These viruses encode proteins that have sequence similarity with
the death effector domain (DED) motif that is found in FADD. These viral proteins
block the recruitment of cell factors to the receptor that have been induced by the
TNF and Fas pathways (Hu et al., 1997; Thome et al., 1997). Viruses including
baculoviruses and poxviruses express proteins that block the caspase cascade by
interfering with proteases such as caspase-8 (Datta et al., 1997). Many viruses are
found to possess homologues to the Bcl-2 family of protein including all
gammaherpesviruses sequenced so far and African swine fever virus. This suggests
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that the prevention of apoptosis is important to viruses and that viruses with large
genomes may employ multiple strategies to ensure the survival of infected cells.
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Chapter 6




In chapter 5, the A9 gene product was shown to protect CHO cells from cis-
platin-induced apoptosis. The mechanism by which the anti-apoptotic Bcl-2 family
members prevent apoptosis is still relatively unknown although there are some
theories (Schendel et al., 1997; Desagher et al., 1999; Tsujimoto & Shimuzu, 2000).
Many believe that the anti-apoptotic family members bind pro-apoptotic family
members and prevent them from attaching to the mitochondrial membrane to induce
apoptosis (reviewed in Harris & Thompson, 2000).
To determine if the A9 protein binds to pro-apoptotic family members (or
other binding partners) in the same way as other anti-apoptotic Bcl-2 family
members, protein-protein interactions of the A9 protein were investigated. This was
attempted first by immunoprecipitation studies using A9-CHO cells and transiently-
A9-transfected Cos-1 cells. The second method that was used in this study to
identify binding partners was tandem affinity purification (TAP). The TAP method
is a protein tag-based affinity purification that was originally designed for use in
yeast (Rigaut et al., 1999). When compared to other epitope tags such as myc- or
hemagglutinin- (HA-), TAP is reported to give better yields of affinity-purified
proteins, along with a lower background of non-specifically associated proteins
(Caspary et al., 1999; Bouveret et al., 2000) that can mask important functional
partners. The TAP tag comprises two immunoglobulin-binding domains of protein
A from Staphylococcus aureus, a cleavage site for the tobacco etch virus (TEV)
protease, and a calmodulin-binding peptide (CBP). The original method involved the
fusion of the TAP tag to the target gene and the replacement of the construct into the
correct site in the yeast genome, which leads to the tagged protein being expressed
from its natural promoter. Fusion proteins and associated components in complexes
were recovered from cell extracts by affinity purification on an IgG column (Rigaut
et al., 1999). After washing, TEV protease was added to release bound proteins.
Eluents were incubated with calmodulin-coaled agarose beads in the presence of
calcium. This second affinity-purification removed TEV protease as well as any
traces of contaminants that remained after the first purification step. Bound proteins
were released by EGTA, as this is a stronger calcium chelator than calmodulin
(Rigaut et al., 1999, Forler et al., 2003).
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In the work described here the TAP-tagged fusion constructs were made
using the pZome-C retroviral vector (Cellzome) in which the tagged protein is
expressed from the retroviral LTR promoter. The constructs were transfected into
CHO cells and stably transfected cell were selected with puromycin. TAP-tagged
transfected cells were harvested and TAP was performed. The purified eluents were
separated by electrophoresis and proteins were detected by silver staining. Any
unique protein bands detected were excised and analysed by the use ofmass
spectrometry.
Therefore, the objectives of this study were:
• Identify binding partners by immunoprecipitation.
• Generate TAP-tagged fusion proteins in E. coli.
• Identify A9 vBcl-2 binding partners through TAP.
179
6.2 Material and Methods
6.2.1 Expression of A9 mRNA analysed by Northern blot analysis
RNA was extracted from A9-CHO and control CHO cells as described in
section 2.4.1. Northern blot analysis was performed as described in section 2.4.2.
The membrane was probed with an A9 probe.
6.2.2 Immunoprecipitation of Bcl-2 proteins
Attempts to immunoprecipitate A9 protein from cell lysates using specific
antibodies at the dilutions indicated (table 6.1) were as described in section 2.6.2.
Immunoprecipitated samples were analysed by electrophoresis (as described in
section 2.5.1). Proteins were detected by Coomassie blue staining, silver staining or
western blot analysis (as described in section 2.5.2 and 2.5.3).
Antibody Dilution
Anti-A9 6E1 (mouse monoclonal) 1:500
Anti-A9 6G8(mouse monoclonal) 1:500
Anti-A9 163 (rabbit polyclonal) 1:1000
Table 6.1. Antibodies and dilution used.
6.2.3 Construction of TAP-tagged fusion in E. coli
TAP-tagged fusions were constructed in the p-Zome-C and pZome-PGK-C
vectors (Cellzome) as described in section 2.6.1.1.
6.2.4 Immunostaining of TAP-tagged fusion proteins in transfected CHO
cells
The A9-CHO cells were used in an immunofluorescence assay as described
in section 2.2.9. Briefly, the cells were washed with warm PBS, fixed in 1%
paraformaldehyde in PBS for 10 mins and then washed again with PBS, . Non¬
specific binding sites were blocked with normal goat serum (1:40) in PBS for lhr at
37°C. The primary antibody was anti-Bcl-2 rabbit polyclonal antibody 163 (1:500)
in PBS, followed by incubation the secondary with goat anti-rabbit biotin (1:500)
conjugate in PBS and detection was by streptavidin-FITC (1:75) conjugate. Cells
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were incubated for 1 hr at 37°C for each incubation. Control reactions were set up by
incubating cells with normal rabbit serum (1:100). Cells were mounted in Mowiol
and examined using a fluorescent microscope.
6.2.5 Expression of TAP-tagged fusion proteins
Cells expressing TAP-tagged fusion proteins were grown in 225cm cell
culture flasks until confluent. The cells were harvested as described in section
2.6.1.3. Supernatant material was analysed by electrophoresis (as described in
section 2.5.1). Proteins were detected by western blot analysis (as described in
section 2.5.3) using peroxidase anti-peroxidase (PAP) (1:200) (Sigma) to detect Ig-
binding protein A domain or anti-A9 rabbit polyclonal 163 (1:1000) or anti-A9
mouse monoclonal 6E1 (1:1000) followed by incubation with anti-rabbit-HRP
(DAKO, 1:2000) conjugate; or anti-mouse-HRP (DAKO, 1:2000) conjugate. Bound
HRP-antibody complexes were detected by treating blots with the enhanced
chemoluminescence (ECL) reagent (Amersham International) according to the
manufacturer's instructions, and exposure to Elyperfilm ECL (Amersham
International) for 10-60sec before development.
6.2.6 Purification of TAP-tagged fusion proteins
TAP-tagged fusion proteins were subjected to tandem affinity purification as
described in section 2.6.1.4.
6.2.7 Preparing samples for mass spectrometry analysis
Protein bands were excised from a stained polyacrylamide gel and cut up into
small pieces. The gel pieces were transferred into a clean 1.5ml micro-centrifuge
tube and covered with lOOmM Ammonium bicarbonate/50% (v/v) Acetronitrile.
This was incubated for 15 mins at room temperature with vortexing. The supernatant
was removed and discarded. This was repeated three times until the stain was
completely removed from the gel pieces. The gel pieces were dehydrated with 100%
(v/v) Acetronitrile for 10 mins, the supernatant was removed and the gel pieces
placed in a vacuum centrifuge for 20 mins to remove excess acetonitrile. To the gel
pieces, lOmM DTT in lOOmM Ammonium bicarbonate was added to cover them,
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and incubated at room temperature for 5 mins. The gel pieces were then incubated at
56°C for lhr. The supernatant was removed and 55mM Iodoacetamide in lOOmM
ammonium bicarbonate was added to cover the gel pieces. This was incubated at
room temperature in the dark for 30 mins. The supernatant was removed and the gel
pieces were incubated with lOOmM ammonium bicarbonate/50% (v/v) acetronitrile
for 15 mins with vortexing. This supernatant was removed and this wash was
repeated three times. The gel pieces were again dehydrated with 100% Acetonitrile
for lOmins. The Acetonitrile was removed and the gel pieces were dried by vacuum
centrifugation for 20mins. To the gel pieces, sequence-grade modified trypsin
(Promega) at 1Ong/pl in 25mM Ammonium bicarbonate was added and incubated for
15 mins. The gel pieces were incubated at 37°C for at least 16 hrs. Alpha cyano-4-
hydroxycinnamic acid (CHCA) was used as a matrix at lOmg/ml in 50% (v/v)
acetronitrile/0.1% (v/v) TFA and 0.5pl of the supernatant around the gel pieces was
mixed with 0.5pi ofmatrix for spotting onto a MALDI target..
6.2.8 Mass Spectrometry
The samples were analysed using an Applied Biosystems Voyager DE-PRO
Matrix Assisted Laser Desorption Ionisation-Time of Flight (MALDI-TOF) Mass
Spectrometer. Using the manufacturers guidelines a standard peptide mass
fingerprint covering the 600-5000 Daltons range was obtained in the reflectron
mode. Once a mass spectrum was obtained for the protein sample of interest, the
peptide information provided was entered into the MS-FIT database search software.
The MS-FIT software works by matching the mass spectrometry data with proteins
in a sequence database whose tryptic peptide masses best fit the data.
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6.3 Results
6.3.1 Attempting immunoprecipitation of binding proteins for A9 vBcl-2
in CHO cells
A9 protein expression was identified in A9-CHO cells (as described in
section 3.3.9). This demonstrated that 58% of A9-CHO cells expressed the A9
protein.
Fig. 6.1. Fluorescent images of A9-CHO cells incubated with serum from
rabbit (pictures taken with the same exposure time, x 400 magnification).
Cells were fixed with ice-cold acetone, incubated with the appropriate primary
antibody, then with anti-rabbit-biotin (1:500) and then finally incubated with
streptavidin-FITC (1:75).
A) A9-CHO cells incubated with 163 rabbit anti-A9 sera (1:500).
B) A9-CHO cells incubated with normal rabbit serum (1:1000).
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A9-CH0 and UTF CHO cell lysates were incubated with monoclonal
antibodies 6E1 and 6G8 to precipitate A9 and any bound proteins. The
immunoprecipitated complexes were analysed using SDS-PAGE electrophoresis on a
7-20% gradient gel. Proteins were detected by Coomassie blue staining. As shown
in fig. 6.2, no protein band was detected at the correct size of 19kDa with either
mouse monoclonal antibody. The immunoprecipitation was repeated using UTF-
CHO lysates and A9-CHO lysates with mouse monoclonal antibody 6E1 and with
the rabbit polyclonal antibody 163. The proteins were detected by Coomassie blue
staining. However, as shown in fig. 6.3. no band of the correct size was detected in
the Coomassie blue-stained gel. From these experiments it would appear that the A9
protein was not immunoprecipitated by this method using available anti-A9
antibodies.
6.3.2. Attempts to immunoprecipitate A9 vBcl-2-binding partners from
Cos-1 cells
To determine whether cell type would make a difference in identifying
binding partners Cox-1 cells were transiently transfected with pEE14-A9 construct.
Cells were harvested 48hrs after transfection. Cell lysates were incubated with the
rabbit polyclonal antibody, 163. A control immunoprecipitation experiment was also
carried out using normal rabbit serum at the same concentration. The
immunoprecipitated lysates were analysed by western blotting using 163 anti-A9
antibody. As shown in fig 6.4. there was no difference between lysates incubated
with 163 anti-A9 antibody or with normal rabbit serum. Therefore, no A9 binding
partners could be identified by immunoprecipitation.
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Fig 6.2. SDS-Page gel of immunoprecipitated CHO lysate proteins. Proteins
detected by Coomassie blue staining. 1: A9-CHO cells immunoprecipitated with
mouse monoclonal 6G8. 2: UTF CHO cells immunoprecipitated with mouse
monoclonal 6G8. 3: A9-CHO cells immunoprecipitated with mouse monoclonal
6E1. 4: UTF CHO cells immunoprecipitated with 6E1.
Fig. 6.3. Immunoprecipitated lysate proteins detected by Coomassie blue
staining. 1: A9-CHO cells incubated with 6E1 antibody. 2: UTF CHO cells
incubated with 6E1 antibody. 3: A9-CHO cells incubated with normal rabbit
serum. 4: UTF CHO cells incubated with normal rabbit serum
Fig. 6.4. Immunoprecipitated lysates detected by western blotting. 1: A9
transfected Cos-1 cells incubated with 163 antibody. 2: UTF Cos-1 cells
incubated with 163 antibody. 3: A9 transfected Cos-1 cells incubated with
























6.3.3 Generation of TAP- A9 and BHRF1 CHO cells
In this study the retroviral vector, pZome-C (Cellzome, fig.2.1) was used to
express TAP-A9 in CHO cells. Initially complete sequence was not available for this
vector and the restriction map implied that it contained a unique Ncol site. A9, with
a C-terminal Ncol site for protein fusion was cloned into this vector, but restriction
mapping and subsequent analysis revealed that a second Ncol site was present in the
SV40 promoter region of pZome-C. Therefore this pZome construct did not contain
the TAP tag or the SV40 promoter.
Therefore the entire SV40 promoter was replaced with the murine
phosphoglycerate kinase (PGK) promoter, which does not contain a Ncol site. The
cloned A9 and BHRF1 genes were then inserted into the pZome-PGK-C vector at the
Ncol site. The constructs were stably transfected into CHO cells and transfectants
were selected with puromycin.
6.3.4 Immunostaining of TAP-A9 fusion protein in CHO cells
In order to check vBcl-2 protein expression, the transfected TAP-A9 CHO
cells were analysed by immunofluorescence using the anti-Bcl-2 rabbit polyclonal
antibody 163.
Fig. 6.5. shows immunofluorescence carried out on the TAP-tagged
transfected cell lines. This figure shows that there does not seem to be differences in
the staining pattern or intensity of the staining between cells incubated with anti-A9
antibody (fig. 6.5.A) and TAP-A9 CHO cells incubated with normal rabbit serum
(fig. 6.5.B). There were also no differences noted in cell transfected with the empty
construct (fig. 6.5.C&D). This was disappointing, however, since the cells were
surviving selection media it was decided to carry on and assume that some of the
cells did contain the A9-TAP construct.
187
Fig. 6.5. Immunofluorescence analysis of TAP-tagged transfected CHO cell lines.
Cells were fixed in 1% paraformaldehyde, permeablised with ice-cold acetone,
incubated with the appropriate antibody, incubated with goat anti-rabbit-biotin (1:500)
and finally incubated with streptavidin-FITC (1:75).
A: TAP-A9 CHO cells incubated with anti-A9 antibody (163) (1:500).
B: TAP-A9 CHO cells incubated with normal rabbit serum (1:1000)
C: CHO cells transfected with the empty pZome-PGK-C plasmid, incubated with anti-
AO antibody (163) (1:500)
D: CHO cells transfected with the empty pZome-PGK-C plasmid incubated with normal
rabbit serum (1:500).
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6.3.5 Detection of TAP-A9 proteins in CHO cells
Cells expressing the TAP-A9 CHO cells were grown in 225cm2 cell culture
flasks until confluent. The cells were harvested (see section 2.6.1.3.), lysates
collected and analysed by gel electrophoresis. Proteins were detected by Western
blot using the appropriate antibody. As shown in fig. 6.6, a protein band, 30kDa, in
the empty pZome proteins was detected with the peroxidase anti-peroxidase (PAP)
antibody. However, no protein band corresponding to the expected size of A9-TAP
tagged fusion protein could be detected. Immunofluorescence analysis indicated that
cells were expressing protein. The inability to detect A9 by western blot using a
variety of antibodies was unfortunate but it was decided to proceed with the TAP





























Fig. 6.9. Western blot analysis ofTAP-tagged fusions proteins. The TAP tagged fusion proteins
were extracted from the cells, proteins were detected using anti-Bcl-2 antibodies 163 and 6Eland also
PAP.
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6.3.6 Identification of possible TAP-A9 vBcl-2 and TAP-BHRF1 vBcl-2
binding partners
Both aqueous and detergent-soluble extracts were harvested from CHO cells
and used in the TAP protocol. The lysates were analysed by electrophoresis on 12%
SDS-PAGE gels. Proteins were detected by silver staining. Fig 6.7. shows that there
are a number of bands that could correlate to Bcl-2 family members due to their
molecular weight being similar to known Bcl-2 family members. Bands 1, 3 and 4
were common to the TAP cells. Fig 6.7. shows that in lane 6 a band (5) can be
observed in the detergent-soluble lysate that has a molecular weight of approximately
30kDa. Another protein band (2) of interest was observed in lane 4. This had an
approximate molecule weight of 40kDa. All the selected bands were excised using











Fig. 6.7. Silver stained gel of TAP-purified proteins from cell lysates. Lane 1:
Purified lysates from TAP-CHO cells, detergent-soluble. 2: Purified lysate from
TAP-CHO cells, supernatant. 3: Purified lysate from TAP-tagged BHRF1-CHO
cells, detergent-soluble. 4: Purified lysate from TAP-tagged BHRF1-CHO cells,
supernatant. 5: Purified lysate from TAP-tagged A9-CHO cells, detergent-soluble.
6: Purified lysate from TAP-tagged A9-CHO cells, supernatant. Asterisks denote
bands that had been excised from the gel for MALDI mass spectrometry analysis.
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6.3.7 MALDI/Mass spectrometry analysis of protein bands
Mass spectrometry was used to determine the masses of tryptic peptides that
had been excised from the SDS-PAGE gel using MS-FIT database. Known peptide
contaminant masses e.g. from trypsin and keratin were removed before the database
search was performed. Fig. 6.8 demonstrates a typical mass spectrum that was
obtained from the purified samples. The peptide masses (denoted in red) were
entered into the database search. The peptide masses did not match well with any
known database entries.

























Fig. 6.8. Mass spectrum of purified samples. A typical mass spectrum obtained from the
purified lysates. Red denotes masses used in database search. Black denotes common
masses that were removed due to contamination (e.g. keratin and trypsin). The x-axis
represents the total mass of peptide while the y-axis represents the intensity of the peaks,
which in this case is low.
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6.4 Discussion
In this study, cellular binding partners for A9 vBcl-2 could not be identified.
This is in spite of fluorescence evidence for the expression ofA9 protein in A9-CHO
cells. Due to time constraints a full evaluation of the new TAP technology could not
be performed.
Classical immunoprecipitation did not identify any cellular binding partners
for A9 vBcl-2. This could be due to an inability of the A9 antibody to
immunoprecipitate or the conditions for immunoprecipitation not being optimal.
The TAP technique was used in preliminary experiments to look for A9
protein-cellular protein interaction. The TAP-technique has been adapted for use in
mammalian cells by a variety of groups (Cox et al., 2002; Michela et al., 2002). In
this study the retroviral plasmid pZome-C was used. Unfortunately the complete
sequence of the pZome-C plasmid was not available initially. After the A9 gene was
cloned into the pZome-C retroviral plasmid a second Ncol site was discovered in the
SV40 promoter. Therefore, the first constructs that were produced did not contain
the TAP tag or the SV40 promoter.
The problem could have been corrected by two methods: 1: re-clone the Bcl-2
genes with new flanking BamHl sites into this alternate pZome-C cloning site or 2:
alter the pZome-C vector by removing the second Ncol site. The first method was
discarded, as other genes being investigated in this study possessed internal BamHl
sites, therefore it was decided to delete the second Ncol site. Simple filling in of the
Ncol was not possible because this has been documented to cause a ten-fold reduction
in mRNA synthesis from the promoter (Khalili et al., 1986). Therefore the entire
SV40 promoter was replaced with the murine phosphoglycerate kinase (PGK)
promoter, which does not contain a Ncol site.
Immunofluorescence analysis was carried out on the TAP-tagged transfected
cell lines. However, this proved to be inconclusive with its results. No differences
could be detected between cells incubated with anti-A9 antibody and normal rabbit
serum. This is probably due to the TAP tag comprising of two immunoglobulin-
binding domains ofprotein A. Therefore, non-specific antibodies would still bind to
this domain, resulting in visible staining in immunofluorescence analysis. It was
decided to proceed with the purification of the TAP-tagged proteins with the
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assumption that if cells were surviving the selection process then most would be
transfected with the TAP-tagged construct.
From the TAP-A9 CHO and TAP-BHRF1 CHO cells a number of proteins
were isolated by the TAP procedure. Some of these were excised and analysed by
mass spectrometry. No significant peptide matches could be determined from the
database searched. However, there was very little material to work with. The bands
that were excised from the gels could be artefact since a few of the bands that were
excised were present in the empty construct. Two of the bands that were excised were
specific to A9 and BHRF1 respectively. However, these bands again showed no
specific peptide matches, this could be due to contaminating proteins or due to silver
staining being non-quantative, a band would be present but very little protein would
actually be present in the sample. The spectra from the mass spectrometry had
peptide peaks with low signal intensity. The presence of peaks for contaminating
trypsin and keratin in most of the spectra suggest that the signal/noise ratio is low.
Another factor that could influence a lack of peptide match is the lack of
database entries available for hamster proteins (CHO cells). Relatively few database
entries are available compared to mouse or human for example. Therefore, this part
of the study was slightly flawed and on hindsight, the construct should have been
transfected into cells that have a larger database such as mouse or human cells.
However, it was hoped that conserved proteins may have shared enough tryptic
peptides to hit by hamster mass spectrometry profiles.
The TAP-tag protocol was adapted by using lysis buffers with or without
detergent. The lysis buffer used can play an important role. Therefore in this
experiment, two different lysis buffers were used. While it was clear that these led to
different protein profiles after purification, neither approach identified clear A9
binding partners. The results shown in fig 6.7 suggest that both BHRF1- and A9-
specific binding partners might be identified by this system ifmore protein were
available and the TAP technique was subjected to other manipulations.
Unfortunately, a larger scale purification was not possible due to time constraints.
Another technique that could have been used was the yeast two-hybrid system.
This technique has been used to identify novel partners for proteins that have a known
function and to identify the function of a novel protein by identifying well-
characterised interacting partners. The yeast two-hybrid system is a rapid,
inexpensive technique that is simple to perform (reviewed in Toby & Golemis, 2001).
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However, false-positive and false-negative results, the lack of information about
stoichiometry and the limited set of conditions that are testable are disadvantages that
have to be considered. The TAP method allows the native purification of protein
complexes (Rigaut et al., 1999). The purified complex can then be used for protein
identification, functional or structural studies. The initial results described here
although disappointing, have encouraged further development of the technology in





In this study, the principal outcomes can be summarised as follows:
Alcelaphine herpesvirus-l A9 open reading frame was shown to have predicted
polypeptide homology to the cellular Bcl-2 family proteins involved in the regulation
of apoptosis. The A9 vBcl-2 protein was expressed and antibodies produced. In a
series of apoptosis assays, the A9 vBcl-2 was shown to be anti-apoptotic. A9 mRNA
was expressed as an early through to late viral gene in the productive phase of the
virus life cycle. In large granular lymphocytes that grow out in culture from the
tissues ofMCF-affected animals, A9 mRNA was detected. Finally, intracellular
binding partners for the A9 protein were sought but none were characterised. The
conclusion is that the A9 vBcl-2 is a functional viral anti-apoptotic molecule that
functions throughout the productive phase of the virus life cycle. This would have
the effect of prolonging the life of infected target cells to allow viral replication.
Sequence analysis ofORF A9 showed that it shared homology with the Bcl-2
family of apoptosis regulatory proteins. In particular, it shared 33% amino acid
identity to human Bcl-w. The cellular Bcl-2 family of proteins is conserved from
worms through to humans (Hengartner, 2000) however; they generally share only
around 20-45% amino acid identity to one another. The viral Bcl-2 homologues that
have been examined share 20-30% identity to one another (reviewed in Hardwick &
Bellows, 2003). For example, BHRF1 shares 38% primary sequence homology with
human Bcl-2. The KSHV Bcl-2 homologue shares 58.7% amino acid similarity to
human Bcl-2 (Sarid et al., 1997).
Bcl-w is an anti-apoptotic protein that binds to the pro-apoptotic proteins
Bax, Bak, Bad and Bik (Holmgreen et al., 1999). One proposed model for the
prevention of apoptosis by Bcl-w is that the protein, which is normally loosely
associated with the mitochondrial membrane, becomes tightly associated with the
membrane following an apoptotic stimulus. This tight association is triggered by the
heterodimerisation with pro-apoptotic BH3-only proteins such as Bik and Bid. This
would effectively neutralise apoptosis. It has also been shown that upon an apoptotic
stimulus, the C-terminal arm of Bcl-w is released and binds to Bax, preventing it
from inserting into the mitochondrial membrane (Wilson-Annan et al., 2003) thus
preventing apoptosis.
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From its predicted amino acid sequence, A9 vBcl-2 protein exhibited
homology with only one of the four known Bcl-2 homology (BH) domains of Bcl-2
family members, namely BH1. A9 vbcl2 also has a transmembrane domain. When
this work was initially started, ORF A9 product was the only Bcl-2 homologue to
have only one BH domain. However, subsequent work carried out with MHV-68 has
shown that the gene product of ORF'Mil is a vBcl-2 that possesses only the BH1
domain and that it has anti-apoptotic activity (Roy et al., 2000).
The BH1 domain is important for the function of the cellular anti-apoptotic
Bcl-2s (Borner et al., 1994b; Yin et al., 1994). Within this domain there is a
conserved sequence, NWGR. Mutational studies substituted the glycine145 residue
with alanine. This resulted in the loss of anti-apoptotic function suggesting that the
glycine residue is essential for the death-protective role of Bcl-2 (Yin et al., 1994).
185 • • ....Substitution of the glycine residue with alanine also resulted in the inability of
Bcl-2 to heterodimerise with Bax. However Bcl-2 was still able to form homodimers
(Yin etal., 1994).
The Bcl-2 homologue present in African swine fever, ORF A179L, contains
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two of the four BH domains (BH1 and BH2). When the glycine residue in the
BH1 domain was mutated to alanine, the death-protective function was abolished
(Revilla et al., 1997).
The A1HV-1 A9 protein contains a HWGR sequence that is part of the
conserved NWGR sequence. The conserved glycine residue that is essential for anti-
apoptotic activity in other Bcl-2s is also present in the A9 protein, which suggests the
A9 protein might have a death-protective role, which has been demonstrated true in
this thesis. As this is the only BH domain present in A9, it would be the site in
which heterodimerisation occurs with pro-apoptotic Bcl-2 family members such as
Bax and Bak. However, no binding partners could be found in this study to confirm
this.
The BH2 domain ofBcl-2 family members is also associated with anti-
apoptotic activity. Deletion of this domain results in the loss of anti-apoptotic
activity (Yin et al., 1994). Specifically, deletion of the GWDA sequence in the BH2
domain of Bcl-2 resulted in the elimination of anti-apoptotic activity. Deletion of the
sequence also resulted in the inability of Bcl-2 to heterodimerise with Bax (Yin et
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al., 1994). Since the BH2 domain is poorly conserved in A9 to the extent that it is
unlikely to be functional, A9 vBcl-2 would not be expected to heterodimerise with
Bax or other pro-apoptotic proteins through this domain.
The BH3 domain is essential for pro-apoptotic activity. This domain allows
protein-protein interactions between pro- and anti-apoptotic proteins (Reed, 1998).
The A9 protein does not have an identifiable BH3 domain, indicating that A9 would
be unlikely to have any role in inducing apoptosis.
The BH4 domain is anti-apoptotic and has been shown to bind proteins
outside the Bcl-2 family that are involved in apoptosis, for example, Rafl, ced4 and
calcineurin (Wang et al., 1994; Shibasaki et al., 1997; Huang et al., 1998). The BH4
domain is not conserved in A9 vBcl-2, indicating it may only bind to Bcl-2 family
members through the BH1 domain and not to non-Bcl-2 proteins involved in
apoptosis.
In summary, A1HV-1 A9 vBcl-2 has a BH1 domain that would be important
in mediating an anti-apoptotic function, but does not have any of the other BH
domains that would allow this function to be regulated by cellular Bcl-2 family or
other apoptosis regulatory proteins. This would be important in maintaining the anti-
cell death state in virus-infected cells to allow virus replication and virion
production.
The transmembrane (TM) domain is found in many Bcl-2 familymembers
and enables them to insert into cell membranes. More often than not these localise to
the mitochondrial membrane (Hockenberry et al., 1990; Gonzalez et al., 1995). The
TM domain is not involved in any of the protective functions of the protein, as
deleting this domain does not alter the level of death-protection (Hockenberry et al.,
1993; Borner et al., 1994a). However, deletion of the TM domain abolishes their
ability to localise to the mitochondrial membrane (Nguyen et al., 1993; Nguyen et
al., 1994). Many pro-apoptotic Bcl-2 family members possess the TM domain that
allows their insertion into the mitochondrial membrane after translocation from the
cytosol. The A9 protein TM domain would allow the protein to localise to
membranes within cells, particularly the mitochondrial membranes, thereby
preventing pro-apoptotic members from inserting into these membranes and effecting
apoptosis.
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The 3D structures of several Bcl-2 family members have been solved,
including those ofKaposi's sarcoma herpesvirus (KSHV) and Epstein Barr virus
(EBV) (Huang et al., 2002; Huang et al., 2003). These latter two show general
similarities to cellular Bcl-2 family members, being a-helical proteins with seven
helices. The central a-helix (a5) forms the core of the protein, and is surrounded by
a3 and a4 on one side and helices al, a2 and a6 on the other side. In KSHV Bcl-2,
a hydrophobic groove is formed on the surface of the protein from residues in a2,
a3, a4 and the N-terminal residue of a5. The EBV BHRF1 vBcl-2 structure is
similar although the hydrophobic region is less exposed as a3 crosses closer to the
middle of a5. The loop that connects al and a2 is shorter in both KSHV Bcl-2 and
EBV BHRF1 vBcl-2 compared to human Bc1-xl.
However, EBV BHRF1 protein shows several differences from other Bcl-2
family members. The protein lacks the NWGR sequence in the BH1 domain on
helix a5. The sequence SLGR is found instead. The surface of the BHRF1 differs
from other Bcl-2 proteins. The prominent groove found in Bcl-xL and the KSHV
Bcl-2 homologue is not seen in BHRF1. There are also several amino acid changes
that make the surface ofBHRF1 less hydrophobic than other anti-apoptotic proteins
(Huang et al., 2003).
In contrast, the KSHV Bcl-2 homologue does share considerable structural
similarity with related cellular Bcl-2 proteins. The sequence NWGR in the BH1
domain is conserved and it would appear to be important in maintaining the fold of
the protein (Huang et al., 2002).
Alignment of the A9 protein sequence with a range of vertebrate and viral
Bcl-2 family members showed that A9 grouped most closely with the anti-apoptotic
Bc1-xl proteins. The predicted secondary structure ofA9 is shown in fig 7.1. The
data indicates that the structure of the A9 protein could be very similar to that of both
the KSHV Bcl-2 homologue and EBV BHRF1. However, the structure does not
contain the seven helices that are seen in cellular Bcl-2 proteins. It appears that the
size and position of a4, a5 and a6 helices relative to the BH1 domain may be
conserved in the A9 protein. As previously mentioned, the NWGR sequence is
replaced with the sequence HWGR in A9. The data would suggest that the
hydrophobic groove formed by residues in al, a3, a4 and the N-terminus of a5 may
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be conserved in the A9 protein, as the contributing helices are conserved. The
alignment suggests that structural homologues of helices a2-a6 are present within
the N-terminal part of the A9 protein, being truncated and with an extended loop
between the equivalents of a3 and a4. As expected, the best region of alignment of
both sequence and structure is around the BH1 domain. This suggests that this
region is conserved for an anti-apoptotic role ofA9 vBcl-2.
3D structure modelling using Bc1-xl and BHRF1 (Swiss-model:
www.expasy.org/swissmod/SWISS-MODEL.html. Peitsch, 1995; Guex & Peitsch,
1997; Schwede et al., 2003) suggests that A9 is more like the Bc1-xl protein
structure, as the 'what-check output structure z-scores' (Hooft et al., 1996) are better
for the Bcl-xl-based model compared to that based on BHRF1. The A9 structure
models based independently on Bc1-xl and BHRF1 suggest that there is an extra loop
between a3 and a4 comprising two short P-strands. There are three major
differences between Bcl-xL and the model ofA9 (fig. 7.2A):
• The modelled A9 structure has no helix al (the white Bcl-xLal helix can
be seen running diagonally at the back of the model).
• The N-terminal part ofA9 forms a simple strand lying parallel to a5 helix
(vertical red strand). This strand may protect the BH1 domain.
• The loop between helices a3 & a4 is extended in A9, and is shown as two
short beta strands (red).
Similarly, there are three main differences between the BHRF1 and A9 structures
(fig 7.2B):
• The modelled A9 structure has no al helix
• The a6 helix is modelled in two parts for A9 (red strand in a6)
• The loop between helices a3 & a4 is extended in A9, and is shown as two




BclX-Human MSQSNRELWDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTE-E-ETPSAINGNPSWHLA 6 0
BclX-Pig MSQSNRELWDFLSYKLSQKGYSWSQF-DVEENRTEAPEGTE-EAETPSAINGNPSWHLA 60
BclX-Mouse MSQSNRELWDFLSYKLSQKGYSWSQFSDVEENRTEAPE-TEAE-ETPSAINGNPSWHLA 60






BclX-Pig DSPAVNGATGHSSSLDAREVIPMA--AVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAY 12 0
BclX-Mouse DSPAVNGATGHSSSLDAREVIPMA- -AVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAY 12 0

















AlHV- 1 A9 WT-LGPRD PKPKQRPFDKLPSAF- -YFLTjySSgCLYM^ItliTTQTK
BH2 TM
Fig 7.1. Sequence alignment based on the predicted secondary structure of
AIHV-1 A9 and the observed secondary structure of human Bcl-xL. a-Helices
for Bcl-xL are shown above the sequence. The BH domains and the
transmembrane domain (TM) are indicated below the sequence. The predicted a-





Fig 7.2A. Structure model of A9. Overlaid structural comparison of Bcl-xL (white) and the
model of the A9 structure (blue helices) with the main helices labelled. The majority of the A9
model can superimpose on the Bcl-xL structure, as seen by the blue/white patching. Small
structural variations can be seen where the blue and white structures separate. Red/green
represent the A9 model. Three major difference are demonstrated between Bcl-xL and the
model of A9. The model of A9 has no helix «1 (the white bcl-xL a1 helix can be seen running
diagonally at the back of the model). The N-terminal part of A9 form a single strand which lies
parallel to a5 helix (vertical red strand). The loop between oc3 and a.4 helices is extended in A9




Fig. 7.2B. Model of A9 structure. Overlaid structural comparison of BHRF1 (white) and the
model of the A9 structure (green/red). The majority of the A9 model can superimpose on the
BHRF1 structure, as seen by the green/white patching in most of the structure. Structural
variations can be seen where the green and white structures separate and where loops are
modelled slightly differently (red). There are three main differences between the BHRF1
structure and the model of A9. The modelled A9 structure does not contain a1 helix. The a6
helix is modelled in two parts for A9 (red strand in a6 helix). The loop between a3 and ot4
helices is extended in A9 and is shown as two short beta strands (red)
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To summarise, in spite of low overall amino acid identity to other Bcl-2
family members, A9 modelling indicates a structure similar to other Bcl-2 family
members, which would present the BH1 domain in a fully functional conformation.
Current work within the laboratory is attempting to overproduce A9 vBcl-2 for
crystallography X-ray diffraction resolution of its 3D structure.
Since this work was initiated, a second putative Bcl-2 protein has been
identified in A1HV-1, namely ORF A4.5 product. The predicted amino acid
sequence of this shares 22% sequence identity to a Bcl-2 protein in porcine
lymphotropic herpesvirus-1 and 20% amino acid identity to equine herpesvirus-2 E4
(Telford et al., 1995; Ehlers et al., 1999). The A4.5 protein has two conserved BH
domains, BEI1 and BH2. A second Bcl-2 protein has also been identified in EBV,
BamHl 'A' fragment leftward reading frame (BALF1). BALF1 is expressed as an
early through to late gene in the lytic cycle ofEBV. It also possesses two of the four
BEI domains, BEI1 and BEI2 (Marshall et al., 1999). BALF1 does not possess the
185conserved NWGR sequence present in the BH1 domain. The conserved glycine
residue present in the BH1 domain of other Bcl-2 family members is also not present.
As previously stated, this residue is essential for anti-apoptotic activity (Yin et al.,
1994). However BALF1 does contain a conserved tryptophan188 residue present in
the BH2 domain. Substitution of tryptophan 188 with alanine results in the inability
to heterodimerise with the pro-apoptotic protein Bax (Yin et al., 1994). BALF1
heterodimerises with the pro-apoptotic proteins Bak and Bax (Marshall et al., 1999).
It has been suggested that BALF1 suppresses the anti-apoptotic function ofBHRF1
in virus-infected cells at a later point during infection, when the virus no longer
requires a viable cell (Bellows et al., 2002).
The predicted A1HV-1 A4.5 amino acid sequence reveals that it also does not
contain the conserved NWGR sequence in the BH1 domain and does not contain the
highly conserved glycine residue in BH1 domain. However the sequence
demonstrates that the tryptophan188 residue is present in the BH2 domain. This
would suggest that A4.5 might act in a similar fashion to BALF1, forming
heterodimers with pro-apoptotic proteins such as Bax and Bak. This would prevent
Bax and Bak from associating with the mitochondria and therefore prevent apoptosis.
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The transmembrane domain is also missing from the BALF1 protein. BALF1
and BHRF1 do not to co-localise, BHRF1 localises to the mitochondria (Hickish et
al., 1994) while BALF1 localises in the cytoplasm, which may reflect the lack of a
TM domain in BALF1. Once apoptosis has been stimulated, BALF1 fails to localise
to mitochondria (Bellows et al., 2002). However, co-immunoprecipitation studies
demonstrated that BALF1 and BHRF1 bind to each other (Bellows et al., 2002).
BALF1 suppresses Fas-induced and topoisomerase-induced apoptosis in HeLa cells
(Marshall et al., 1999). However, BALF1 failed to suppress Sindbis-induced and
Bax-induced apoptosis in Rat-1 and B-cell lines (Bellows et al., 2002). A
transmembrane domain is not present in A4.5. In summary, the function of A1HV-1
A4.5 vBcl-2 may be similar to that ofBALF1. A4.5 may form heterodimers with
pro-apoptotic proteins such as Bax and Bak and may also bind A9 protein acting as
an antagonist protein, which alone may not be an inhibitor of apoptosis. These
hypotheses could be addressed in experiments similar to these described in chapter 6
using the TAP method, and are currently under way in the laboratory.
Apoptosis assays performed on A9-CHO cells treated with cis-platin
demonstrated that A9 vBcl-2 inhibited apoptosis. Apoptosis is often seen in response
to virus infection and is a potent cellular anti-viral innate response. Therefore,
viruses that encode anti-apoptotic Bcl-2 homologues will promote cell survival and
enhance virus production. Many of the viral Bcl-2 homologues that have been
studied so far protect virus-infected cells from apoptosis. EBV BHRF1 vBcl-2
protects both Cos-1 and SVK fibroblast cells from cis-platin-induced apoptosis
(Khanim et al., 1997). Herpesvirus papio encodes a functional Bcl-2 homologue that
protects SVK cells from cis-platin induced apoptosis (Meseda et al., 2000). The Bcl-
2 homologue present in KSHV inhibits Sindbis virus-induced apoptosis (Cheng et
al., 1997). MHV-68 encodes a functional Bcl-2 homologue (Roy et al., 2000).
Therefore A9 vBcl-2 conforms to the anti-apoptotic function of the other known
vBcl-2s.
In order to determine the mechanism by which A9 vBcl-2 inhibits apoptosis,
protein-protein binding assays were performed. A tandem affinity purification
(TAP)-fusion protein system was employed in addition to traditional immuno-
precipitation to facilitate the isolation ofmultiple protein complexes. Much time was
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spent working up this technique. Protein bands were identified that bound to TAP-A9
vBcl-2. However, protein could not be characterised, probably due to the small
quantity of protein obtained being insufficient for proteolytic degradation and mass
spectrometry analysis. The TAP method is currently being refined by colleagues in
the laboratory.
However, it is important to point out that others have carried out Bcl-2
protein-binding studies with conflicting results. Co-immuno-precipitation studies
with KSHV Bcl-2 and the cellular homologues Bcl-2, Bc1-xl, Bax and Bak failed to
demonstrate heterodimer fomiation (Cheng et al., 1997). Using the yeast two-hybrid
system, it was demonstrated that EBV BHRF1 protein interacted with Bax, Bak and
Bik (Hsu et al., 1997). However, others have failed to find interactions between
BHRF1 vBcl-2 and Bax, Bak and Bik (Hsu & Hsueh, 1998). BALF1 inhibits the
anti-apoptotic function ofBHRF1 vBcl-2 and KSHV Bcl-2 but not cellular Bcl-xL
(Bellows et al., 2002). From these results, it is possible that the affinity of binding
between Bcl-2 proteins is not strong. This suggests that conditions to identify A9
vBcl-2-binding partners will need to be optimised more carefully.
In this study, A9 vBcl-2 was expressed as an early through to late virus gene
during the productive phase of the virus life cycle in culture. Expression at this time
coupled to the ability to inhibit apoptosis confers on vBcl-2 an important role in
prolonging the life of virus-infected cells to support virus replication and virion
production. This is consistent with other viral Bcl-2s that are active during the
productive phase of the virus life cycle. For example, the Bcl-2 homologues present
in HHV-8, EBV and MHV-68 are also expressed during the productive phase of the
virus life cycle (Cheng et al., 1997; Farrell, 1989; Roy et al., 2000).
What is not clear is whether A9 vBcl-2 is active during latent infection.
Examples of vBcl-2 expression during latent infection have been described for EBV
and MHV-68. EBV infects B-lymphocytes, causes immortalisation and establishes a
latent infection. In EBV the two Bcl-2 homologues BALF1 and BHRF1 are
dispensable for efficient B-cell immortalisation when deleted individually, however,
when they are deleted as a double gene knockout the virus fails to immortalise B-
lymphocytes. This suggests that both Bcl-2 homologues are essential to establish a
latent infection (Altmann & Hammerschmidt, 2003).
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The vBcl-2 present in MHV-68 is not essential for replication during acute
infection of mice (even though it is expressed during this phase), as loss of function
vBcl-2 mutants replicated as well as wild type virus. This study also found that
vBcl-2 was not required for the establishment of latency in splenocytes. However,
the MHV-68 vBcl-2 was necessary for reactivation from latency (Gangappa et al.,
2002).
Details of the latent state in A1HV-1 and OvHV-2 infection have not yet
been defined and so this type of study is currently not possible. These studies would
be best performed in the host reservoir species (blue wildebeest for A1HV-1) where
both productive and latent states have been strongly implicated. The situation in the
MCF-susceptible host is more complex. In this study, A9 vBcl-2 was expressed in
an A1HV-1-infected rabbit LGL cell line, and although not detected after 21 days of
the development of the cells in culture, work carried out in the laboratory previously
had demonstrated that A9 vBcl-2 mRNA was expressed in established A1HV-1 +
LGL cell lines (H. Wright, personal communication). It is possible that these lines
support both the productive and latent phases of the virus life cycle and it is possible
that vBcl-2 may be expressed in one but not the other. LGL lines acquire a uniform
phenotype, the majority in cattle (OvHV-2) and rabbits (AlHv-1 and OvHV-2) being
T cells with indiscriminate cytotoxic activity. The majority (typically >90%) of the
LGLs in any given line express viral antigen detected by immunofluorescence using
virus-specific sera (Swa, 2000). Preliminary studies using Gardella gel analysis of
viral DNA in LGL cell lines from rabbits infected with A1HV-1 or OvHV-2 and
cattle infected with OvHV-2 indicate that the cell lines contain a mixture of lytic-
(productive) and latent-infected cells. Gardella analysis discriminates linear from
covalently-closed circular viral genomes, which are characteristic of either
productive or latent herpesvirus infection respectively. Gardella analysis of OvHV-2-
infected LGL cells has demonstrated that in both bovine and rabbit LGL cells, there
are both lytic and latent cycle viral genomes present (Rosbottom et al., 2002).
However, there is evidence ofmore productive, lytic infection in the rabbit cell lines
compared to the bovine cell line that predominantly contained closed circular viral
DNA (Rosbottom et al., 2002; T. Leenadevi, personal communication). These
results would suggest that the A1HV-1 -infected LGL cell cultures established from
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infected rabbits contain a mixture of lytic and latently-infected cells. It is worth
noting that in LGL lines virus is cell-associated and virions can only be obtained
with difficulty from cell lysates. This would imply that the productive phase of the
virus life cycle in these cells is inefficient, even if the cells can be used to transmit
the disease. Future studies will reveal whether A9 vBcl-2 is produced during the
latent phase of the virus life cycle or not.
Attempts during the course of this study to inhibit A9 vBcl-2 in fibroblasts
using siRNA were unsuccessful. It was hoped to express siRNA in a retroviral vector
for efficient transduction into LGLs to determine the effect of A9 mRNA knockdown
on LGL phenotype and function. For successful siRNA gene expression suppression,
several siRNAs per gene are recommended. Only one set was obtainable for A9.
However, others in the laboratory are successfully progressing this technology such
as we are now confident that we can knock down virus gene expression in LGLs. All
of the unique genes ofA1HV-1 and OvHV-2 are currently being targeted in this way.
The results of this thesis allow a speculation as to the possible role ofA9
vBcl-2 in vivo in the pathogenesis of the disease. Clearly, there is a role in
prolonging the life of infected target cells in the reservoir blue wildebeest host in
order to support virion production. This is most likely to occur in epithelial cells in
young calves. The presence of virus in nasal and ocular secretions in these animals
within 9 or so months ofbirth would support this (Mushi et al., 1981). Such animals
are thought to be the source ofMCF in pastoralists' cattle grazing areas ofwildebeest
migration in east-central Africa. In older animals, virus secretion is much reduced
although animals are persistently virus DNA positive in their blood cells. This is
most likely due to the host immune response inhibiting the productive virus cycle
(neutralising antibody and T cells) and applying pressure to maintain a latent state.
The cell reservoir for virus latency is not known for A1HV-1 in wildebeest, but is
thought to be B cells in sheep with OvHV-2 (Baxter et al., 1997).
In susceptible animals (cattle, experimentally-infected rabbits), MCF is often
acute and fatal, with a short time period between the onset of symptoms and death.
The reason why only a proportion of a herd of cattle will succumb to such a lethal
disease is one of the fascinations ofMCF. There is no horizontal spread of the
disease though, as cattle are dead-end hosts in this respect. In this scenario, the
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pathology is interesting. There is evidence of lymphoproliferation and lymphoblast
accumulation in multiple tissues (lymphoid and non-lymphoid). Tissue
damage/necrosis can be widespread. However, virus is extremely difficult to detect
in affected tissues and viral DNA is in low abundance as detected by either PCR or
in situ hybridisation (Tham, 1997). This implies that there are a few virus-infected
cells in total and only a few of the accumulating lymphoblasts are virus DNA
positive. However, infection may stimulate the accumulation and activation of non-
infected lymphocytes. When tissues are cultured from MCF-affected animal tissue,
LGLs grow out, virtually all of which contain viral antigens or viral transcripts and
are dysregulated compared to normal cell counterparts (Swa et al., 2001). One
explanation for this is that virus-infected cells exhibit a growth advantage over other
lymphocytes in these cultures. Thus LGLs represent an enriched population of the
infected, indiscriminately-cytotoxic cells found in MCF in vivo. In the absence of
any direct proof, the working hypothesis for MCF in this laboratory is that the
disease is due to the action of indiscriminately cytotoxic lymphocytes (mainly T
cells) on host tissue. Vasculitis caused by endothelial cell damage may be a major
reason for the quick demise ofMCF-affected animals.
Against this background, a role for A9 vBcl-2 may be to prolong the life of
virus-infected cells in vivo, particularly the lymphoblasts. As LGLs from MCF-
affected animals will transmit MCF into other susceptible animals when injected
intravenously, the assumption is that the productive virus life cycle occurs in the
susceptible animals and in lymphoblasts, even if virions are not apparently produced
from these cells and the infection is therefore cell-associated. The mixture of lytic
and latent virus life cycle stages that are seen in LGLs in culture needs to be
confirmed or not with infected cells in vivo. In addition, there is a need to resolve
whether vBcl-2 is expressed during latency either in maintaining the latent state or
involved in reactivation from latency into the productive virus cycle.
The work presented in this study has improved our understanding of the
biology of the Bcl-2 homologue present in A1HV-1 and shed light on an aspect of
virus pathogenesis. These results form a basis for further work. For example, does
A9 play a role in latency during establishment or reactivation? Does A9 form a
heterodimer with A4.5? What other Bcl-2 family members do these proteins bind
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